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Zusammenfassung 
Die Methylierung von CpG-Dinukleotiden in Eukaryotes ist eine epigenetische Markierung, die 
eine Unterdrückung der Transkription der Gene in den betroffenen Bereichen des Genoms zur 
Folge hat. Hierbei rekrutiert das Methyl-CpG bindende Protein MBD2 den reprimierenden 
Mi2/NuRD Komplex an methylierte Promotoren. Die Proteine p66α und p66β sind 
Bestandteile dieses Komplexes und fungieren als starke Repressoren, jedoch sind bisher keine 
Details zum Mechanismus der transkriptionellen Repression durch diese Faktoren beschrieben. 
 
Die vorliegenden Untersuchungen belegen eine Beteiligung der Deacetylierung von Histonen 
an der transkriptionellen Repression durch p66α und p66β. Zwei Repressions-Domänen in 
p66α und eine in p66β wurden charakterisiert. Weiterhin zeigte sich, dass die Aminosäure 
Lysin an Position 149 von p66α essentiell für die Interaktion mit MBD2 und die Lokalisation 
von p66α innerhalb des Zellkerns ist. Eine Analyse von p66 auf eine mögliche SUMO (small 
ubiquitin-like modifier)-Modifikation, die in zunehmenden Maße mit der Regulation der 
Aktivität von Transkriptionsfaktoren in Verbindung gebracht wird, identifiziert p66α und p66β 
als Zielproteine dieser Modifikation. Sowohl bei p66α, als auch bei p66β führt die SUMO-
Modifikation zu einer Verstärkung der transkriptionellen Repression. Die SUMO-Modifikation 
erfolgt an Lysin 30 und Lysin 487 in p66α und an Lysin 33 in p66β, wobei die Mutation der 
SUMO-Zielsequenzen verglichen mit den Wildtyp p66 Formen bei beiden Proteinen keine 
Veränderung der zellulären Lokalisation hervorruft. Darüber hinaus wird HDAC1 
(Histonedeacetylase 1) des Mi2/NuRD Komplexes an Lysin 30 von p66α, das eine TSA 
(Trichostatin A) sensitive Repression aufweist, rekrutiert. Die Mutation von Lysin 33, die keine 
Sensitivität gegenüber TSA zeigt, hebt die Interaktion zwischen p66β und RbAp46 (Rb 
Associated protein 46) in vivo auf. Zusammenfassend weisen diese Ergebnisse darauf hin, dass 
sowohl die Interaktion innerhalb des Mi2/NuRD Komplexes, als auch die optimale Repression 
durch SUMO-Modifikation vermittelt wird. 
 
Zur detaillierten Analyse von p66 enthaltenden Proteinkomplexen wurden stabile Zelllinien, 
die rekombinante p66 Proteine exprimieren etabliert. Die Isolierung der Proteinkomplexe 
erfolgte durch zweistufige chromatographischer Trennung und anschließende Reinigung über 
die mit p66 verknüpfte Affinitätsmarkierung. Western-Blot Analysen zeigten, dass die 
rekombinanten p66 Proteine mit verschiedenen bekannten Komponenten des Mi2/NuRD 
Komplexes, wie MBD2 und PRMT5, assoziiert vorliegen und belegen damit die Eignung 
dieses Systems für eine weitere Charakterisierung der p66 Komplexe. 
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Summary 
 
Methylation of CpG dinucleotides in eukaryotes is an epigenetic mark that is implicated in 
transcriptional silencing. Methyl-CpG binding protein MBD2 serves to recruit the Mi-2/NuRD 
repressive complex to a methylated promoter. Human p66α and p66β, which are components 
of Mi-2/NuRD complex, are two potent transcriptional repressors that interact with MBD2, but 
no details concerning the mechanism in hp66 proteins-mediated transcriptional repression have 
been described. 
The current work showed that transcriptional repression mediated by hp66α and hp66β is 
partially dependent on histone deacetylation. Two major repression domains in hp66α, and one 
in hp66β were characterized. In addition, the amino acid Lys-149 of hp66α was identified to be 
essential for the interaction with MBD2 and the nuclear localization of hp66α. Emerging 
evidence indicated that SUMO (small ubiquitin-like modifier) modification negatively 
regulates the transcriptional activity of transcription factors. The study gave evidence that both 
hp66α and hp66β proteins can be SUMOylated, and furthermore that SUMO modification 
enhances hp66-mediated transcriptional repression. Two major SUMO modification sites at 
Lys-30 and Lys-487 of hp66α, and one major SUMO modification site at Lys-33 of hp66β 
were identified. Mutational analysis of the SUMO modification sites in hp66α or hp66β 
revealed that there is no change in localization in comparison to wild type hp66. But 
interestingly, the Mi-2/NuRD complex component HDAC1 (histone deacetylase 1) is recruited 
to the SUMO modification site Lys-30 of hp66α which shows TSA (Trichostatin A) sensitivity, 
whereas mutation of the SUMO modification site Lys-33, which shows TSA insensitivity, 
abolishes the interaction between hp66β and RbAp46 (Rb associated protein 46) in vivo. Taken 
together, these results suggest that both, interactions within the Mi-2/NuRD complex as well as 
optimal repression are mediated by SUMOylation. 
Moreover, to gain further insights into protein complexes containing hp66 proteins, stable cell 
lines expressing individually both hp66 proteins were established. After a two-step 
chromatographic purification and a subsequent FLAG affinity purification protein complexes 
were isolated. Western blotting analysis revealed that several subunits of the Mi-2/NuRD 
complex as well as MBD2, and PRMT5 were found to be associated with FLAG-hp66 proteins. 
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1 INTRODUCTION 
 
1.1  Molecular mechanisms of gene silencing 
 
1.1.1 Basic principles of gene expression 
 
In general, histones and DNA are organized into chromatin by wrapping DNA around histone 
proteins octamers. It has long been known that structural changes in the chromatin have an 
impact on gene expression. Active gene transcription correlates with an open chromatin 
conformation, whereas inactive gene transcription relates to a closed chromatin conformation 
(Rountree et al., 2001; Wu and Grunstein, 2000). These dynamic chromatin states are 
controlled by reversible epigenetic patterns of DNA methylation and histone modifications 
(Feinberg and Tycko, 2004). Basically, active regions of chromatin have unmethylated DNA 
and hyperacetylated histones, whereas inactive regions of chromatin contain methylated DNA 
and deacetylated histones (Peterson and Laniel, 2004).  
 
1.1.2 DNA methylation 
 
The term “Epigenetics” refers to heritable changes in gene expression that occur without 
alterations in the gene nucleotide sequence (Roloff and Nuber, 2005). Epigenetic events such as 
DNA methylation play an essential part in regulating gene expression, genomic stability, X 
chromosome inactivation, and chromatin structure (Jones and Baylin, 2002). Significant 
advances have been made in elucidating mechanisms underlying DNA methylation and its 
effects on chromatin structure and gene trancription. DNA methylation occurs at the 5' position 
of the cytosine ring by covalent addition of a methyl group following production of 5-
methylcytosine (Bird, 2002). In mammalian DNA, 5-methylcytosine is primarily at 
palindromic sequence CpG. Roughly 70% of all CpG dinucleotides in the mammalian genome 
are methylated. The majority of unmethylated CpG sites locate more frequently within CpG 
islands (clusters of high-density CpG dinucleotides) found typically in or near the promoter and 
first exon regions of genes (Herman and Baylin, 2003). 
 
1.1.3 DNA methyltransferases 
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The addition of methyl groups is carried out by a family of enzymes, DNA methyltransferases 
(DNMTs). In mouse development, the maintenance methyltransferase DNMT1 appears to copy 
established methylation patterns onto the new DNA strand, whereas the de novo 
methyltransferase DNMT3a and DNMT3b seem to be responsible for mediating cytosine 
methylation at previously unmethylated CpG sites during DNA replication (Bestor, 2000; 
Okano et al., 1999; Okano et al., 1998). Recent evidences have uncovered the mechanisms by 
which DNMT enzymes are recruited to the targeted DNA sequences for de novo methylation. 
These studies have demonstrated at least three possible pathways by which de novo 
methylation might be targeted. First, DNMT3 enzymes themselves might recognize DNA or 
chromatin via specific domains. It has been shown that the conserved PWWP domain of 
DMNT3 is required to target the catalytic activity to regions of pericentromeric 
heterochromatin of the genome, and further mutation of the PWWP domain of the human 
DNMT3b protein causes ICF syndrome, a severe autosomal recessive disease in humans 
(Shirohzu et al., 2002). Second, DNMT3a and DNMT3b might be recruited through 
interactions with transcription factors. More recent evidence have shown that Myc is required 
for recruitment of DNMT3a to the p21cip1 promoter region, resulting in de novo methylation of 
the p21cip1 promoter, which indicates that DNMT3 can be recruited to the targeted DNA 
sequence via protein–protein interactions with some transcription factors (Brenner et al., 2005). 
Third, the RNA-mediated interference (RNAi) system might target de novo methylation to 
specific DNA sequences. Two independent studies have reported that the target gene is 
efficiently silenced concomitant with de novo DNA methylation of the corresponding promoter 
sequence, when double-stranded RNA corresponding to the promoter sequence of a gene is 
introduced into mammalian cells (Kawasaki and Taira, 2004; Morris et al., 2004). Although 
initial evidence supports its existence, the mechanism of the RNAi-directed DNA methylation 
during gene silencing remains poorly understood.  
 
1.1.4 DNA methylation and gene silencing 
 
It is well known that DNA methylation is assocated with a repressive chromatin state (Kass et 
al., 1997; Siegfried et al., 1999). There are several general models by which DNA methylation 
represses gene transcription (Fig.1.1): first, certain transcriptional activators are unable to bind 
to cognate DNA recognition sequences when methylated (Watt and Molloy, 1988); and second, 
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Methyl-CpG-binding proteins (MBPs) recognize methyl-CpG and recruit transcriptional co-
repressor molecules to repress transcription and to modify local chromatin architecture, 
indicating a link between DNA methylation and chromatin remodeling and modification (Jones 
et al., 1998; Nan et al., 1998; Ng et al., 1999; Sarraf and Stancheva, 2004; Wade et al., 1999; 
Zhang et al., 1999). Furthermore, another pathway of DNA methylation-mediated silencing has 
recently been discovered. As discussed above, DNMTs can be targeted to specific DNA 
sequence through interaction with some transcriptional repressors, resulting in methylation of 
DNA. Recent evidence showed that DNMTs physically interact with histone deacetylases, 
histone methyltransferases, and ATP-dependent chromatin remodeling protein hSNF2H 
independent of its catalytic domain, indicating that DNMTs mediate gene silencing through 
recruitment of transcriptional repressors such as HDAC1 (Bai et al., 2005; Fuks et al., 2000; 
Fuks et al., 2001; Fuks et al., 2003; Geiman et al., 2004; Lehnertz et al., 2003; Robertson et al., 
2000; Rountree et al., 2000). 
 
1.1.5  Methyl-CpG binding proteins (MBPs)  
 
The fact that methylated CpG islands relate to gene silencing  led  to search for transcription 
 
Figure 1.1  Mechanisms of DNA methylation-mediated repression. (a) DNA methylation in the 
cognate DNA-binding sequences of some transcription factors (TF) can result in inhibition of DNA 
binding. By blocking activators from binding targets sites, DNA methylation directly inhibits 
transcriptional activation. (b) Methyl-CpG-binding proteins (MBPs) directly recognize methylated DNA 
and recruit co-repressor molecules to silence transcription and to modify surrounding chromatin. (c) In 
addition to their DNA methyltransferase activities, DNMT enzymes are also physically linked to histone 
deacetylase (HDAC) and histone methyltransferase (HMT) activities. In this case, the addition of methyl 
groups to DNA is coupled to transcriptional repression and chromatin modification. Modified after
(Klose and Bird, 2006).
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factors that are able to recognize and interpret these epigenetic events. In the early 1990s, the 
family of proteins that specifically recognize methyl-CpG were identified. MeCP2 was the first 
such protein to be purified and characterized (Lewis et al., 1992). An additional four members, 
MBD1, MBD2, MBD3, and MBD4 have been identified based on conserved amino acid 
sequences homologous to the methyl-CpG-binding domain (MBD) of MeCP2 (Hendrich and 
Bird, 1998). Alignment of the MBPs represents that the MBD of MBD1, MBD2 and MBD3 are 
more similar to each other than to those of either MBD4 or MeCP2, while the MBD of MBD4 
is most similar to that of MeCP2 (Ballestar and Wolffe, 2001; Hendrich and Tweedie, 2003). 
The mammalian MBD proteins (MBPs) are shown in Fig.1.2. With the exception of MBD4 that 
is well defined for its role in DNA repair (Hendrich et al., 1999; Millar et al., 2002), other 
members of this family are transcriptional repressor which is associated with histone 
deacetylases in the context of chromatin remodeling (Feng and Zhang, 2001; Jones et al., 1998; 
Nan et al., 1998; Ng et al., 1999; Sarraf and Stancheva, 2004; Wade et al., 1999; Zhang et al., 
1999). However, more recent evidence suggested that MBD4 might also be a transcriptional 
repressor (Kondo et al., 2005). Four members of this family, MeCP2, MBD1, MBD2 and 
MBD4 are able to bind to methylated DNA with the exception of MBD3, which contains amino 
acid substitutions that prevent binding to methyl-CpG. A novel MBP named Kaiso lacks the 
MBD, but recognizes methylated CpG islands directly using two of three adjoining zinc-finger 
motifs near its carboxy terminus (Prokhortchouk et al., 2001). There are several potential 
mechanisms for transcriptional repression mediated by MBPs. First, as discussed earlier, MBPs 
binding to methylated DNA leads to local recruitment of histone deacetylases, which in turn 
results in transcriptional repression. Second, MBPs bind to methylated DNA and physically 
prevent access to the sequence by transcription factors. Third, MBPs bind to methylated DNA 
and locally modify chromatin structure (Wade, 2001).  
 
1.1.5.1 MeCP2 
 
MeCP2 is the first member of MBPs that specifically binds to a single, fully symmetrically 
positioned methylated CpG site (Lewis et al., 1992), however, a recent study has shown that 
enrichment for A/T base pairs, (A/T)≥4, adjacent to methyl-CpG dinucleotides is essential for 
high-affinity binding to MeCP2 target sites of its known target genes, Bdnf and Dlx6, indicating 
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the target genes of MeCP2 appear to require this additional sequence specificity (Klose et al., 
2005). This requirement for specific DNA sequences also applies to other MBPs such as MBD1, 
MBD4, and Kaiso with the exception of MBD2 that only binds specificly to methyl-CpG sites 
(Fujita et al., 2000; Klose et al., 2005; Prokhortchouk et al., 2001). MeCP2 is a chromatin 
associated nuclear protein of molecular weight approximately 55KDa (Nan et al., 1993). Two 
alternatively spliced MeCP2 transcripts have been identified: MeCP2A and the slightly longer 
MeCP2B, which differ only in their most 5' regions (Kriaucionis and Bird, 2004; Mnatzakanian 
et al., 2004). It is also the MeCP2 protein in which the MBD was first well-defined, and 
providing the molecular link between DNA methylation and histone modification(Fuks et al., 
2003; Jones et al., 1998; Nan et al., 1993; Nan et al., 1998). MeCP2 is found to localize to 
pericentromeric heterochromatin, which contains highly methylated major satellite DNA in 
mouse cells (Fujita et al., 1999). In fact, it has been shown that MeCP2 is able to bind 
nucleosomal DNA to form discrete complexes, providing a molecular mechanism by which 
MeCP2 can gain access to chromatin and recruit corepressor complexes to further modify local 
chromatin structure (Chandler et al., 1999). Considerable efforts have been put into 
understanding how MeCP2 repress transription. It has been reported that MeCP2 represses  
Figure 1.2  A family of methyl-CpG-binding proteins (MBPs). Six mammalian MBPs have 
been characterized so far. Kaiso is an atypical MBP, because it depends on a zinc-finger 
domain (ZF) to recognize methylated DNA and a POZ/BTB domain to repress transcription. 
MBD1 uses its methyl-binding domain (MBD) to bind methylated DNA sequences. In 
addition, MBD1 contains three zinc-binding domains (CxxC), one of which binds specifically 
to non-methylated CpG dinucleotides, and a C-terminal transcriptional repression domain 
(TRD). MBD2 possesses an MBD that overlaps with its TRD domain, and a GR repeat at its N 
terminus. MBD3 contains a well-conserved MBD domain that does not recognize methylated 
DNA owing to crucial amino acid changes. MBD4 binds methylated DNA through an MBD 
domain and has a C-terminal glycosylase domain that is important for is function in DNA 
repair. MeCP2 is the founding member of the MBD protein family and contains a conserved 
MBD domain and an adjacent TRD domain (Klose and Bird, 2006).  
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transcription of methylated promoters, but does not repress non-methylated promoters in vitro 
and in vivo (Kaludov and Wolffe, 2000; Nan et al., 1997). A major breakthrough is that the 
transcriptional repression domain (TRD) of MeCP2 was found to interact with a Sin3A co-
repressor complex containing HDACs, thus leads to the establishment and maintenance of 
repressive chromatin architecture (Jones et al., 1998; Nan et al., 1998). This important finding 
provided the first link between DNA methylation-mediated transcriptional repression and 
histone modifications. Histone methylation is another key epigenetic mark for the organization 
of chromatin structure and the regulation of gene expression (Kouzarides, 2002). In particular, 
methylation at lysine 9 of histone H3 (H3K9) is associated with gene silencing. MeCP2 has 
also been shown to repress transcription throuth H3K9 methylation, which is carried out by the 
histone lysine methyltransferase SUV39H1 (Fuks et al., 2003). Nevertheless, other evidence 
showed HDAC-independent transcriptional repression by MeCP2 (Yu et al., 2000), indicating 
that MeCP2 is able to repress transcription via “two layers” mechanisms.  
Lines of evidences have been indicated that MeCP2 is required in neurons for normal brain 
function. Mutations in the MeCP2 gene cause a RTT-like phenotype in mice (Chen et al., 2001; 
Guy et al., 2001), and lead to Rett syndrome (RTT) in humans (Amir et al., 1999), which is a 
progressive neurodevelopmental disorder that occurs almost exclusively in females (Kerr et al., 
2001). Take together, aberrent MeCP2 might account for more than 95% of sporadic cases of 
classical Rett syndrome in females (Archer et al., 2006). Several mouse models have advanced 
our understanding of the function of MeCP2 in the mechanisms that underlie Rett syndrome 
(Bienvenu and Chelly, 2006). Microarray-based global gene expression profiling analysis has 
revealed subtle changes between wild-type and MeCP2 knockout mice brains (Nuber et al., 
2005; Tudor et al., 2002). In addition, recent studies revealed that several imprinted genes such 
as Dlx5, Dlx6 and Ube3A, show loss of normal expression in brain tissue of MeCP2-null mice 
(Horike et al., 2005; Makedonski et al., 2005; Samaco et al., 2005), this is consistent with that 
DNA methylation is important in the regulation of imprinted gene expression. Recent results 
suggested that the function of MeCP2 might be more complicated. MeCP2 was shown to have 
a high-affinity RNA binding activity independent of the MBD, and regulate alternative splicing 
via an interaction with the RNA-binding protein YB1 (Jeffery and Nakielny, 2004; Young et al., 
2005). The finding suggested that MeCP2 regulates transcription and mRNA splicing of some 
of its targets through multiple layers of epigenetic regulation.  
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1.1.5.2 MBD1  
 
MBD1 contains, in addition to the MBD and the TRD, a cysteine-rich CXXC sequence, which 
is similar to DNA methyltransferase 1 (DNMT1) (Cross et al., 1997). Like MeCP2, MBD1 
requires only one symmetrically methylated CpG to bind DNA. So far, at least four MBD1 
isoforms were identified including MBD1v1-4, which are alternatively spliced with variations 
in the number of CXXC domains as well as differences at the C-terminus (Fujita et al., 1999; 
Hendrich and Bird, 1998). Characterization of the CXXC domains in MBD1 revealed that the 
third CXXC domain has DNA binding capacity, regardless of the methylation status (Fujita et 
al., 2000). Thus, MBD1 is unique among the MBPs in that it is able to bind both unmethylated 
promoters via a third CXXC motif and methylated promoters via the MBD domain, which in 
turn leads to repress transcription (Nakao et al., 2001). The biological significance of this dual 
DNA-binding capacity of MBD1 is currently unknown. The repression by MBD1 has been 
reported to be HDAC dependent (Ng et al., 2000). Whether HDAC-independent mechanisms of 
repression exist for MBD1 remains unclear, since MBD1 has not been placed in a known 
repressor complex. MBD1 has been demonstrated to form a transient complex with histone 
H3K9 methyltransferase enzyme SETDB1, and the chromatin assembly factor CAF-1 during S 
phase of the cell cycle when DNA replication occurs, indicating MBD1 binding to methylated 
CpG sites associates with the DNA replication machinery (Sarraf and Stancheva, 2004). Also 
similar to MeCP2, MBD1 is an abundant, chromosomal protein (Ng et al., 2000), and localizes 
to the hypermethylated regions of chromosome 1q12 (Fujita et al., 1999). As determined from 
nuclear magnetic resonance (NMR) spectroscopic analysis, the MBD is suggested to interact 
with a methyl-CpG pair in the major groove of a standard B-form DNA (Wakefield et al., 
1999). Further studies will explore the molecular basis of genome regulation by MBD1 and its 
functional relationship with other MBPs.  
 
1.1.5.3 MBD2  
 
There are two potential forms of MBD2, full-length protein (MBD2a, 43KDa) and N-terminal 
truncation (MBD2b, 29KDa), which are generated from a single gene that corresponding to 
alternative translational start codon (Hendrich et al., 1999; Hendrich and Bird, 1998). Recent 
studies  revealed  that  MBD2a  is able  to  bind  methylated  cyclic  AMP (cAMP)-responsive  
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element (CRE) and repress its transcription via recruitment of MeCP1 corepressor complex. On 
the other hand, MBD2a could activate unmethylated CRE transcription through association 
with the CBP/RNA helicase A/Pol II complex. The results indicated that MBD2a has dual 
function in gene regulation based on DNA methylation status on CRE (Fujita et al., 2003). The 
truncated MBD2b protein was originally described as a DNA demethylase (Bhattacharya et al., 
1999), however, this discovery failed to be confirmed by others, and rather suggested that it 
may also function in transcriptional repression (Boeke et al., 2000; Ng et al., 1999; Wade et al., 
1999). MBD2 has a transcriptional repression domain that overlaps with the MBD that confers 
both transcriptional repression as well as the interaction with Sin3A (Boeke et al., 2000). 
Recently, MBD2-interacting zinc finger (MIZF) was identified as a novel interaction partner of 
MBD2. MIZF can bind to a specific recognition sequence within the promoter of target gene, 
and thus repress transcription in an HDAC-dependent manner and enhance MBD2-mediated 
repression, indicating that MIZF may recruit MBD2, and potentially also the Mi-2/NuRD 
repressor complex, to mediate transcriptional repression of methylated regions (Sekimata and 
Homma, 2004; Sekimata et al., 2001). MBD2 has been reported to be a component of MeCP1 
complex that consists of additional Mi-2/NuRD chromatin remodeling complex, which 
represses transcription from methylated reporter gene in an HDAC-dependent manner (Feng 
and Zhang, 2001; Ng et al., 1999). MBD2 is able to bind a single methyl CpG dinucleotide and 
overexpression of GFP-MBD2 localizes to major satellite DNA in mouse cells (Hendrich and 
Bird, 1998). Unlike MBD2, Mbd3 knockout mice dies during early embryogenesis, whereas 
Mbd2-null mice display a normal methylation pattern and does not show any defect in genomic 
imprinting or silencing of endogenous transposable elements (Hendrich et al., 2001). Moreover, 
significantly reduced repression of methylated reporter genes is seen in Mbd2-deficient cell 
lines, further confirming that MBD2 has a role in DNA methylation-mediated gene silencing 
(Hendrich et al., 2001). 
 
1.1.5.4 MBD3 
 
MBD3, the smallest member of the MBPs family, coding for a protein of about 32KDa, shares 
extensive sequence similarity to MBD2 outside the MBD motif, differing only in the sizes of 
their introns in the vertebrates (Hendrich and Bird, 1998). This suggests a recent gene 
duplication event, which is supported by the fact that MBD2/3 protein is  encoded  by  a  single  
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gene in invertebrate genomes (Hendrich et al., 1999). Due to the point substitutions in two 
highly conserved amino acids, mammalian MBD3 lacks the ability to recognize methylated 
DNA (Hendrich and Bird, 1998), whereas Xenopus MBD3 is able to bind with high affinity to 
methylated CpG similar to that of MeCP2 (Wade et al., 1999), suggesting that the capacity to 
recognize methylated DNA by MBD3 is lost during the evolution of mammals but retained in 
amphibians. Moreover, overexpressed MBD3-GFP is shown to accumulate in many nuclear 
foci, and does not associate with the highly methylated major satellite DNA in mouse cells 
(Hendrich and Bird, 1998). In addition, MBD3 is crucial to normal mammalian development as 
MBD3 knockout mice leads to embryonic lethality immediately after implantation of the 
embryo (Hendrich et al., 2001). A recent study showed that embryonic stem cells lacking 
MBD3 are viable and undergo the initial steps of differentiation, but fail to commit to 
developmental lineages, indicating MBD3-NuRD mediated gene silencing is not absolutely 
required for embryonic stem cells differentiation, however, provides a new link between 
preservation of the undifferentiated states and the capacity to differentiation (Kaji et al., 2006). 
It is well known that MBD3 is a component of the nucleosome remodeling and histone 
deacetylation (NuRD) corepressor complex containing HDACs, a chromatin remodeling 
ATPase and other proteins (Le Guezennec et al., 2006; Wade et al., 1999; Zhang et al., 1999). 
It has not yet been proved that MBD3 represses transcription through mechanisms similar to 
those described for MeCP2, but it is likely that similar mechanism to that observed for MBD2 
and MeCP1 complex based on association of MBD3 with HDACs. Another possible 
mechanism is that MBD2 can form heterodimers with MBD3, thus results in binding 
hemimethylated DNA and recruiting HDACs as well as DNA methytransferase protein 1 
(Tatematsu et al., 2000). 
 
1.1.5.5 MBD4 
 
MBD4 is a 62-kDa protein of the MBD family that consists of two well-conserved, functional 
domains, an N-terminal MBD and a C-terminal DNA glycosylase catalytic domain with 
homology to bacterial DNA glycosylases, which appears to coordinate DNA repair with DNA 
methylation events (Hendrich et al., 1999). It has been shown to be involved in DNA repair 
rather than transcriptional repression (Bellacosa et al., 1999; Hendrich and Bird, 1998). The 
MBD of MBD4 binds preferentially to methyl-CpG/TpG mismatches, which originate from 
spontaneous  deamination  at  methyl-CpG  in  the  genome,  although  its  MBD  can  bind  
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symmetrically methylated CpG sites in vitro (Hendrich et al., 1999).  MBD4 then efficiently 
removes thymine or uracil from a mismatch CpG site with the glycosylase domain, suggesting 
that the combination of binding and catalysis of MBD4 may function to minimize mutation at 
methyl-CpG (Hendrich et al., 1999). The function was further confirmed by using transgenic 
MBD4-mutant mice. As expected, an increase in 5 methylcytosine to T mutations at CpG sites 
was found in Mbd4-mutant mice, and leads to reduced survival and an increased occurrence of 
tumour, indicating that MBD4 has a role in reducing mutation at methylated CpG sites in vivo 
(Millar et al., 2002; Wong et al., 2002). Besides G-T mismatch repair activity, MBD4 also has 
the activity of 5-methylcytosine DNA glycosylase, however, the biological significance of 
MBD4 has not yet been elucidated. Like MBD1, overexpressed GFP-MBD4 localizes at the 
foci of hypermethylated satellite DNA and this localization is impaired in DNMT-deficient 
emobryonic stem cells that have a reduced level of DNA methyltion (Hendrich and Bird, 1998). 
More recently, MBD4 appears to be involved in transcriptional repression through methyl-CpG. 
Transcriptional repression by the MBD4 is HDAC dependent, and MBD4 directly binds to 
Sin3A and HDAC1. Further evidence showed that both MBD and the glycosylase catalytic 
domain are tethered within the hypermethylated promoter in p16INK4a, suggesting that the 
glycosylase catalytic domain may be the maintenance of mCpG sites to allow preferential 
binding by MBD of MBD4 (Kondo et al., 2005). 
 
1.1.5.6 Kaiso 
 
Kaiso, is a unique methyl-DNA-binding protein, belongs to the BTB/poxvirus and zinc finger 
(POZ) protein family (Collins et al., 2001). Many evidences have shown that many members of 
this family repress gene transcription through recognition of specific DNA sequence by zinc 
finger (van Roy and McCrea, 2005). Kaiso does not have a classical methyl-DNA-binding 
domain, and is the only known member of this family that binds two distinct DNA motifs: two 
or more adjoining methylated CpG islands (Prokhortchouk et al., 2001; Yoon et al., 2003), and 
sequence-specific consensus sites with six core nucleotides (CTGCNA, where N indicates any 
nucleotide) (Daniel et al., 2002). It has been presumed, but not shown that both sites might 
work together to creat a stronger and more integrated repression complex in some gene-
regulatory context. Kaiso represses transcription of target genes by virture of its directly 
binding  to  methylated DNA using zinc finger motif, and by recruiting transcriptional  
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corepressors such as nuclear receptor co-repressor (NCoR) by its  amino-terminal POZ domain, 
which in turn recruits histone deacetylases containing NCoR complex (Daniel et al., 2002; 
Yoon et al., 2003). Furthermore, a double-point mutation in POZ domain abolishes its 
association with NCoR, indicating that co-repressor NCoR is essential for Kaiso’s repression 
function (Park et al., 2005). Moreover, Kaiso in a complex with NCoR represses the MTA2 
gene locus in a methylation-dependent manner (Yoon et al., 2003). Recently, the analysis of 
gene-array data has indicated that a number of methylated genes are upregulated following the 
depletion of Kaiso during early Xenopus embryonic stages (Ruzov et al., 2004), further 
indicating that Kaiso functions as a methylation-dependent transcriptional repressor. The 
mechanisms that regulate the functions of Kaiso seem to be complex and require to further 
investigation. 
 
1.1.6 NuRD complex and MeCP1 complex  
 
The vertebrate Mi-2/NuRD (nucleosome remodeling histone deacetylase) complex is a multi-
subunit protein complex with both chromatin remodeling and histone deacetylase activity, 
although the compostion of the complex remains controversial  (Tong et al., 1998; Tyler and 
Kadonaga, 1999; Wade et al., 1998; Xue et al., 1998; Zhang et al., 1998). It has been 
established that the two histone deacetylses HDAC1 and HDAC2, and the two histone binding 
proteins RbAp46 and RbAp48 form a core complex and exist in most of the histone deacetylase 
complexes examined to date (Guschin et al., 2000; Le Guezennec et al., 2006; Yao and Yang, 
2003). It has been reported that Mi-2, which is an autoantigen associated with human disease 
dermatomyositis (Ge et al., 1995) and a member of the SWI2/SNF2 family of ATP-dependent 
chromatin remodeling proteins (Eisen et al., 1995), is the largest subunit of the Mi-2/NuRD 
complex (Tong et al., 1998; Wade et al., 1998; Xue et al., 1998; Zhang et al., 1998). There are 
two isoforms of human Mi-2: Mi-2α and Mi-2β. However, Mi-2 isoforms seem to be present in 
the complex differently in terms of different context (Bowen et al., 2004). One possibility is 
that Mi-2β represents the sole Mi-2 isoform present in the complex  (Zhang et al., 1998), amd 
the second is that both Mi-2α and Mi-2β are present, although Mi-2β is abundant (Le 
Guezennec et al., 2006; Tong et al., 1998). Surprisingly, recent studies showed that Mi-2 is not 
present in the so called “metastasis associated protein 1 (MTA1) complex”, which also contains 
core complex and MBD3 (Yao and Yang, 2003). It might be that the above differences likely  
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result from different purification strategies employed. MTA1, which is associated with invasion 
and metastasis of tumor, was first identified as a component of Mi-2/NuRD complex (Xue et al., 
1998). Shortly after this finding, MTA2, an MTA1 homologue, was reported to be a subunit of 
Mi-2/NuRD complex (Zhang et al., 1999). Recently, the third isoform of MTA family was also 
found to be associated with the Mi-2/NuRD complex by immunoprecipitation. Interestingly, 
there was no physical interactions between MTA3 and either MTA2 or MTA1 (Fujita et al., 
2003). Other findings further revealed that MTA2 complex is remarkably similar to the Mi-
2/NuRD complex, whereas MTA1 complex does not contain Mi-2 but contains specific MTA1-
associated proteins, although both MTA1 and MTA2 complex share core complex and MBD3. 
These studies suggested that different Mi-2/NuRD complexes with distinct subunits of MTA 
family members exist. The other component of Mi-2/NuRD complex that may bring the 
complex to methylated DNA is MBD3, a member of MBPs family, suggesting a possible 
connection between methylated DNA and histone deacetylation. But due to the point 
substitutions in two highly conserved amino acids, mammalian MBD3 lacks the ability to 
recognize methylated DNA (Hendrich and Bird, 1998), although Xenopus MBD3 is able to 
bind with high affinity to methylated CpG (Wade et al., 1999). However, it was shown that the 
Mi-2/NuRD complex can be recruited to methylated DNA through interaction with MBD2 
(Zhang et al., 1999), which is known to bind methylated DNA and but is not an integral 
component of Mi-2/NuRD complex. Thus NuRD complex connects DNA methylation, 
chromatin remodeling and histone deacetylation (Bird and Wolffe, 1999).  
This MBD2 containing Mi-2/NuRD complex has been called MeCP1 complex (Feng and 
Zhang, 2001; Ng et al., 1999). MeCP1 was originally identified as a methyl-CpG binding 
activity that requires 15 or more symmetrically methylated CpG pairs  (Meehan et al., 1989). In 
a later study, MeCP1 seems to be a large multi-subunit complex, which conatins 10 major 
polypeptides including MBD2, seven characterized NuRD components and two polypeptides of 
66 and 68 KDa (Feng and Zhang, 2001; Ng et al., 1999). In addition, MeCP1 complex is able 
to repress transcription through preferentially binding, remodeling, and deacetylation of 
methylated nucleosomes (Feng and Zhang, 2001). In another independent study, HDAC1 
complex was shown to contain all known components of Mi-2/NuRD complex and MBD2. In 
contrast, HDAC2 complex contains no detectable MBD2 (Humphrey et al., 2001). The results 
seem to confirm the existence of MeCP1 complex. However, more recent study have revealed 
that MBD2 and MBD3 assemble into mutually exclusive distinct Mi-2/NuRD-like complexes,  
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termed as MBD2/NuRD complex and MBD3/NuRD. Both complexes contain an additional 
component DOC-1, which is a putative tumor repressor, besides known subunits of Mi-
2/NuRD complex. In addition, arginine methyltransferase PRMT5 and its cofactor MEP50 
were identified as specific components of MBD2/NuRD complex but not MBD3/NuRD 
complex. It is proposed that previous MeCP1 complex may in fact be a mixture of Mi-2/NuRD 
complexes, some containing MBD2 and others containing MBD3. Taken together, it seems that 
HDAC1/2, MTA1/2 or MBD2/3 may assemble into distinct protein complexes (Table 1.1). 
 
 
1.1.7 hp66 protein paralogs: hp66α and hp66β 
 
p66 protein was first identified as a component of Xenopus Mi-2/NuRD complex (Wade et al., 
1999; Wade et al., 1998). Meanwhile, as described above in the table, several groups reported 
that human p66 is also a subunit of Mammalian Mi-2/NuRD complex. It was first reported that 
two novel polypeptides of p66 and p68, are components of MeCP1 complex. Further research 
revealed that p66 and p68 represent the same protein and that p68 is a modified form of p66 
(Feng et al., 2002; Feng and Zhang, 2001). Since MBD2 has been shown to associate with Mi-2 
Mi-2βc,e MTA1d MTA2d MBD2b MBD3b HDAC1a,f HDAC2e 
Mi-2α 
Mi-2β 
MTA1c 
MTA2e 
MTA3 
p66 (?) 
p68 (?) 
HDAC1 
HDAC2 
RbAp46 
RbAp48 
 
MBD3 
 
 
 
MTA1 
 
 
p66 
p68 
HDAC1 
HDAC2 
RbAp46 
RbAp48 
 
MBD3 
MTA1 
associated 
proteins 
Mi-2 
 
 
MTA2 
 
p66 
p68 
HDAC1 
HDAC2 
RbAp46 
RbAp48 
 
MBD3 
 
 
Mi-2α 
Mi-2β 
MTA1 
MTA2 
MTA3 
p66α 
p66β 
HDAC1 
HDAC2 
RbAp46 
RbAp48 
MBD2 
 
DOC-1 
PRMT5 
MEP50 
Mi-2α 
Mi-2β 
MTA1 
MTA2 
MTA3 
p66α 
p66β 
HDAC1 
HDAC2 
RbAp46 
RbAp48 
 
MBD3 
DOC-1 
 
 
Mi-2 
 
 
MTA2 
 
p66 
 
HDAC1 
HDAC2 
RbAp46 
RbAp48 
MBD2 
MBD3 
 
mSin3A 
CoREST 
Mi-2 
 
 
MTA2 
 
p66 
 
HDAC1 
HDAC2 
RbAp46 
RbAp48 
 
MBD3 
 
Table 1.1  Difference in composition of known subunits of NuRD formed complexes 
Proteins identified as components of the various complexes as indicated. Speculative identifications 
of these proteins are indicated as query in parentheses (a, Humphrey et al., 2001; b, Le Guezennec et 
al., 2006; c, Xue et al., 1998; d, Yao and Yang, 2003; Zhang et al., 1998; e, Zhang et al., 1999). 
  
 
Introduction                                                                                                               14
 
/NuRD complex within the MeCP1 complex (Ng et al., 1999), our group identified two highly 
related 66KDa proteins in a yeast two-hybrid screen with MBD2b as a bait (Brackertz et al., 
2002). Sequence comparison of both proteins to the p66 component of Xenopus Mi-2/NuRD 
complex demonstrated that one p66 proteins is the human orthologue of the Xenopus p66 
protein (Wade et al., 1999), refered as human p66α (hp66α), another p66 protein is identical to 
the previous identified p66/68 of human MeCP1 complex (Feng et al., 2002), refered as human 
p66β (hp66β). Thus, hp66α and hp66β, also named as GATAD2A and GATAD2B, are 
encoded by two different genes comprising a novel gene family. Functional characterization of 
both hp66α and hp66β was carried out, and is summarized in the Table 1.2.  
 
 
 
 hp66α hp66β 
chromosome 19p13.11 chromosome 1q23.1 
52% homology 
conserved region 1 (CR1) 75%, conserved region 2 (CR2) 72% 
ubiquitously expressed in cell lines, fetal and adult tissues expression expression of both p66 proteins are independent from one another 
? colocalizes with MBD3 and 
dependent on CR2 
identical distribution of both proteins in a nuclear speckle pattern localization
colocalize with MBD2 and depends on CR2 and MBD2 
? CR1 is major repressive domain 
? partially dependent on histone deacetylation 
repress transcription in Gal-fusion system in a dose dependent manner 
functional interplay for the repression of both proteins  
enhance/reduce MBD2-mediated repression by overexpression/knockdown 
repression 
MBD2 is not essential for the repression of both proteins 
stronger interaction with MBD2 and 
MBD3 than hp66β 
weaker interaction with MBD2 and 
MBD3 than hp66α  
C-terminus including CR2 binds to 
MBD2 and MBD3 
C-terminus including CR2 doesnt 
bind to MBD2 and MBD3 
CR1interacts with MBD2 
interact with MeCP1 complex ? 
CR1 ineracts with components of 
MeCP1 complex 
strong affinity for all histone tails H2A, H2B, H3 and H4 
interact with PCAF and p300 
interaction 
acetylation of histone tails by PCAF or p300 specifically reduces its association 
with both hp66 proteins 
 
Table 1.2  functional characterization of hp66α and hp66β 
Functional characterization of hp66 proteins was summarized from several publications (Brackertz 
et al., 2002; Brackertz et al., 2006; Feng et al., 2002).  Modified after Brackertz’s thesis. 
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1.2 SUMO: a history of protein modification 
 
Reversible posttranslational protein modifications are acetylation, methylation, phosphorylation, 
glycosylation, carboxylation, poly(ADP-ribosyl)ation, as well as ubiquitination. The most well-
known example of posttranslational modification is ubiquitination, which was first 
characterized at 1987 (Shanklin et al., 1987)  and has been extensively studied in the 
previous years (Shcherbik and Haines, 2004). Ubiquitination is a highly conserved post-
translational protein modification process in which ubiquitin is covalently attached to lysine 
residues of the targeted substrates (Pickart, 2001). It should be noted that this process is 
reversible and is carried out by deubiquitinating enzymes (Hochstrasser, 1996). Ubiquitination 
requires three different enzymes, the ubiquitin-activating enzyme (E1), ubiquitin-conjugating 
enzyme (E2), and ubiquitin ligase (E3).  Although most of the known examples of 
ubiquitination involve proteasome-dependent degradation of transcriptional regulators, 
ubiquitin-modified proteins also perform other important functions in cell cycle progression, 
signal transduction, DNA repair, apoptosis, and transcriptional regulation (Hershko and 
Ciechanover, 1998; Hochstrasser, 1996; Pickart, 2001). In addition to ubiquitin, there are 
several ubiqutin-like polypeptides which acts as posttranslational protein modifiers have been 
identified (Schwartz and Hochstrasser, 2003; Seeler and Dejean, 2003). One member of this 
ubiquitin-like protein family is a 97 amino acid mature polypeptide, termed as small ubiquitin-
like modifier (SUMO). SUMO is covalently attached to the lysine residues of target proteins 
via a “three-enzyme-step” mechanism analogous to, but distinct from, ubiquitin (Johnson, 
2004).  The significance of SUMO was first discorved in studies on nuclear import as a 
covalent modification of RanGAP1 (Matunis et al., 1996). In recent years, a plethora of 
substrate proteins for SUMO modification have been identified. However, the consequences of 
SUMO modification seems to vary with the particular target protein. SUMO modification of 
target proteins has diverse effects on cell cycle, subcellular transport, DNA repair, regulation of 
transcription factor activity (Gill, 2005; Hay, 2005). 
 
1.2.1 The family of SUMO proteins 
 
To date, four different SUMO isoforms termed SUMO-1, SUMO-2, SUMO-3, and SUMO-4 
have been identified in mammals. Of these, SUMO-2 and SUMO-3 are closely related and  
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share about 95% amino acid sequence identity, in contrast to sharing about a 50% identity with 
SUMO-1 (Kim et al., 2002; Saitoh and Hinchey, 2000; Schwartz and Hochstrasser, 2003).  
Profiles of fractionated SUMO-1 and SUMO-2/3-modified proteins demonstrate that SUMO 
isofroms appear to modify common and also different substrates. There are examples of 
substrates such as RanGAP1  that is predominantly modified by SUMO-1, whereas 
Topoisomerase II and CAAT/enhancer-binding protein-β are specifically modified by SUMO-
2/3 (Azuma et al., 2003; Eaton and Sealy, 2003; Vertegaal et al., 2004). Recent evidence 
supported the concept of important distinctions between the SUMO-2/3 and SUMO-1 pathways, 
with SUMO-1 conjugated to proteins as a monomer, while SUMO-2 and SUMO-3 are 
conjugated to proteins as higher molecular weight polymers with SUMO-1 terminating further 
SUMO addition (Tatham et al., 2001). The fourth isoform SUMO-4 which was recently 
described a restricted expression pattern with strongest levels reported in kidney cells (Bohren 
et al., 2004). Further research will focus on establishing the expression profile of this gene in  
Fig.1.3  SUMO is highly related to ubiquitin. (A) amino acid sequence of ubiqutin and the four SUMO 
isoforms from human. Identities are indicated in bold and similarities are shaded. A consensus motif for 
SUMOylation present in SUMO-2/3/4 is boxed in yellow; the SUMO acceptor lysine (K) in this motif is 
boxed in red. Ubiquitin Lys 48 and Lys 63, which serve as common sites for ubiquitin polymerization, are 
boxed in red. The site of cleavage to produce the mature proteins with C-terminal di-glycine residues is 
also indicated. (B) Structure comparison of ubiquitin and human SUMO-1. Both proteins share a 
characteristic tightly packed ββαββαβ fold, and a C-terminal di-glycine motif. SUMO is distinguished by 
a long and flexible N-terminal extension  (Dohmen, 2004; Gill, 2004).  
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different tissues. So far, the mechanisms that determine specific SUMO isoforms for 
modification of certain protein is presently unclear, and the functional consequences of 
modification by specific SUMO isoforms also remains to be found out. The SUMO-1 protein is 
highly conserved from yeast to human, which is 18% identical to ubiquitin., but has a similar 
three-dimensional structure as shown by NMR studies (Fig.1.3). The distribution of charged 
residues on the surface of SUMO-1, however, is quite different from that of ubiquitin. 
Furthermore, SUMO-1 has a flexible N-terminal extension, which is absent in ubiquitin. These 
differences suggest that both SUMO-1 and ubiquitin interact specifically with distinct enzymes 
and substrates. Another important feature is a di-glycine motif at the C-terminus in the mature 
forms of SUMO and ubiqutin, which is very critical for SUMO conjugation.   
 
1.2.2 The SUMOylation machinery 
 
Over the past 10 years, significant progress has been made in understanding the molecular 
mechanism of the SUMOylation pathway. Similar to ubiquitination, SUMOs are conjugated to 
target substrates via a conserved enzymatic cascade requiring the E1 activating enzymes, E2 
conjugating enzymes, and in most cases, also requires an E3 ligases (Fig.1.4). SUMO is first 
activated by formation of a high energy thioester bond between its C-terminal glycine and the 
catalytic cysteine residue (C173) of the SUMO E1 activating enzyme, which is a heterodimer 
containing SAE1 and SAE2 subunits (also named Aos1/Uba2) (Desterro et al., 1999; Gong et 
al., 1999; Johnson et al., 1997; Okuma et al., 1999). This step requires ATP hydrolysis. The 
SUMO moiety is then transesterified from SAE2 to E2 conjugating enzyme Ubc9, forming the 
Ubc9-SUMO thioester complex through cysteine 93 of Ubc9, which is the only known SUMO 
E2 conjugating enzyme (Bernier-Villamor et al., 2002; Desterro et al., 1999; Johnson et al., 
1997; Lin et al., 2002). Unlike many other E2 enzymes responsible for ubiquitin conjugation, 
Ubc9 is able to recognize substrate proteins. Thus, Ubc9-SUMO thioester complex can catalyze 
formation of an isopeptide bond between glycine 97 of SUMO and the ε–amino group of the 
target lysine residue. This specific lysine residue is usually found within a SUMO modification 
consensus motif ψKXE, where ψ is a large hydrophobic residue and X is any residue 
(Rodriguez et al., 2001), which is also recognized by the Ubc9 active site  (Bernier-Villamor et 
al., 2002; Lin et al., 2002). It should be noted that certain substrates are modified on lysine 
residues where the surrounding sequence does not conform to this consensus, and not all  
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proteins containing this consensus motif are modified by SUMO. Although SUMO E1 
activating enzyme and E2 conjugating enzyme are shown to be sufficient for SUMO 
modification of various substrates in vitro, recent evidence demonstrated that additional 
components are required to increase the efficiency of transfer SUMO from Ubc9 to target 
proteins in vivo. Such proteins are known as E3 ligases (Pickart, 2001). To date, three different 
types of SUMO E3 ligases have been identified: the PIAS protein, RanBP2, and the polycomb 
group protein Pc2. These SUMO E3 ligases most likely function as adaptors rather than 
“ligases”. They bind to SUMO E2 conjugating enzyme Ubc9 and increase transfer of SUMO 
from Ubc9 to target proteins (Johnson and Gupta, 2001; Pichler et al., 2002; Takahashi et al., 
2001). The PIAS proteins contain RING-finger domain similar to ubiquitin E3 ligases, whereas 
RanBP2 and Pc2 have no sequence similarity with the ubiquitin E3 liagses. PIAS proteins were 
initially described as protein inhibitors of activated STAT, and at least five PIAS proteins 
(PIAS1, PIASxα, PIASxβ, PIASγ, and PIAS3) were characterized with the RING-finger 
domain in mammalians (Chung et al., 1997; Liu et al., 1998; Moilanen et al., 1999; Tan et al., 
2002). During the past few years, extensive studies have demonstrated that PIAS proteins  
Fig.1.4.  The SUMO cycle. The SUMO precursor is processed by a SUMO specific protease to reveal the 
C-terminal di-glycine that is activated by formation of a thioester bond with the catalytic cysteine (C173) 
of the Uba2 subunit from the E1 activating enzyme (AoS1/Uba2). This step requires ATP hydrolysis. 
SUMO is then transferred to the catalytic cysteine (C93) of the E2 conjugating enzyme Ubc9., the protein 
target is selected., and with the help of E3 ligases, the SUMO from Ubc9 is transferred to the lysine side 
chain of the substrates.  SUMO can be deconjugated from the target proteins due to the presence of 
SUMO-specific protease. Modified after (Bossis and Melchior, 2006; Hay, 2005).  
MATURATION 
ACTIVATION 
TRANSESTERIFICATION 
LIGATION 
DECONJUGATION 
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influence the activity of many transcription factors either by inhibiting their binding to DNA, 
by acting as co-repressors or co-activators, or by recruiting histone deacetylases (Jackson, 2001; 
Schwartz and Hochstrasser, 2003). Another type of SUMO E3 ligase is the nucleoporin 
RanBP2/Nup358, which is located the cytoplasmic filaments of the nuclear pore complexes, 
and was one of the first SUMO targets to be identified (Pichler et al., 2002). This distinct 
localization could contribute to functional speicificity of SUMO E3 liagses. 
SUMO modification of target proteins is dynamic and reversible. SUMO-speicific proteases 
play critical roles in both processing SUMO precursor to the mature form and deconjugating 
SUMO moiety from target proteins. Two SUMO proteases, Ulp1 and Ulp2, have been 
identified as cysteine proteases by structural analysis and sequence comparisons in yeast (Li 
and Hochstrasser, 1999; Li and Hochstrasser, 2000). So far, eight mammalian homologs of 
Ulp1 have been characterized and are referred to as SENP proteins (1-8) (Yeh et al., 2000). Of  
these proteases, SENP1 (Bailey and O'Hare, 2004), SENP2 (Best et al., 2002; Nishida et al., 
2001), SENP3 (Gong and Yeh, 2006; Nishida and Yasuda, 2002), SENP5 (Gong et al., 2006), 
and SENP6 (Kim et al., 2000) have been shown to have SUMO-specific protease activity, 
whereas, SENP8 has been found to be a NEDD8 specific protease (Mendoza et al., 2003; Wu et 
al., 2003). Very importantly, the mammalian SUMO-specific proteases have distinct 
subcellular localization that allows selection of modified substrates for deconjugation by the 
SUMO proteases in vivo. SENP1 is in nuleoplasm and nuclear bodies, SENP2 is cytoplasmic 
and nuclear pore, SENP3 is nucleolar, and SENP6 is cytoplasmic (Bailey and O'Hare, 2004; 
Gong et al., 2000; Hang and Dasso, 2002; Kim et al., 2000; Nishida et al., 2000). In general, 
most SUMO modified substrates are at very low steady state levels in vivo. Dynamic and 
reversible SUMO conjugation/deconjugation cycles could be responsible for the frequently 
observed  scenario: only a small fraction of a given target protein is SUMOylated at steady 
state, even in the presence of inhibitors of SUMO-specific proteases (Hay, 2005). 
 
1.2.3  Functions of SUMO modification 
 
The first protein be identified as a SUMO-modified substrate was RanGAP (Matunis et al., 
1996). Since this finding, the number of proteins identified as substrates of SUMO 
modification has greatly increased and new SUMO-moidified target proteins continue to be 
identified all the time. SUMO modification affects the functions of target proteins in many  
  
 
Introduction                                                                                                               20
 
ways and plays important roles in diverse processes such as subcellular transport (Lin et al., 
2003; Matunis et al., 1996; Zhong et al., 2000), inhibition of ubiquitin-mediated degradation 
(Desterro et al., 1998), and transcriptional regulation (Gomez-del Arco et al., 2005; Terui et al., 
2004; Tiefenbach et al., 2006). Furthermore, SUMOylation regulates cell cycle (Azuma et al., 
2003; Bachant et al., 2002), DNA damage repair (Hoege et al., 2002; Stelter and Ulrich, 2003; 
Ulrich, 2005), signal transduction (Lee et al., 2003; Lin et al., 2003; Lin et al., 2003), protein-
protein interactions (Yang et al., 2003), protein-DNA binding activity  (Goodson et al., 2001) 
and enzymatic activity (Hardeland et al., 2002).   
 
1.2.3.1 SUMO modification and nuclear localization 
 
SUMO modification is involved in regulating subcellular localization of many proteins, 
including the first identified SUMO substrate RanGAP1 (Matunis et al., 1996). Unmodified 
RanGAP1 resides exclusively in the cytoplasm, whereas SUMO-modified RanGAP1 is 
associated with nuclear pore complex mediated by an interaction with RanBP2/Nup358, which 
is component of nuclear pore complex and a SUMO E3 ligase (Mahajan et al., 1997; Matunis et 
al., 1998; Pichler et al., 2002). Another well-characterized example in understanding SUMO-
dependent regulation in subcellular localization comes from studies of the protein, 
promyelocytic leukaemia (PML), which is major component of PML nuclear bodies (also 
named ND10) (Zhong et al., 2000). SUMOylated forms of PML is observed predominantly in 
the PML nuclear body. Mutation of the SUMO modification sites in PML leads to nuclear body 
components such as Sp100 to relocalize in the nucleus (Best et al., 2002; Sternsdorf et al., 1999; 
Zhong et al., 2000). These observations indicated that SUMO modification of PML provides 
protein-protein interaction surface for assembly or stablility of PML nuclear body. On the other 
hand, some recent studies found that mutation of SUMO modification site of the transcriptional 
repressor CtBP leads to a cytoplasmic localization and a loss of repression activity, while wild 
type CtBP normally localizes in the nucleus (Lin et al., 2003). SUMO modification also targets 
subcellular localization of other substrates such as NF-κB (Desterro et al., 1998). Taken 
together, SUMO modification is involved in promoting subcellular localization of substrates. 
The function of SUMO modification in nuclear cytoplasmic transport remains a subject of 
further investigation.  
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1.2.3.2 SUMO modification and ubiquitination 
 
Lysine residues are not only targets for SUMOylation, but also for methylation, acetylation and 
ubiquitination. Over the past years, it has been demonstrated that several modification system 
could communicate and mutually influence the functions of common substrate proteins, and in 
some cases even involving the same lysine residue. A number of substrates have been 
identified to be modified by both SUMOylation and ubiquitination. The first example is IκBα 
inhibitor proteins in the context of transcription factor NF-κB siganling pathway (Desterro et 
al., 1998). Phosphorylation of residues Ser32/36 of IκBα leads to poly-ubiquitination, 
subsequently results in degradation of IκBα by the 26S proteasome, thus allows NF-κB to 
reenter the nucleus and to activate transcription of its target gens (Baldwin, 1996; Karin and 
Ben-Neriah, 2000). In the absence of phosphorylation, SUMO modification takes place on the 
same lysine residue 21 of IκBα, and protects IκBα from ubiquitination-mediated degradation 
by direct competition for the same modification site. In addition, SUMOyaltion of IκBα also 
indirectly leads to repression of NF-κB–dependent transcription. This paradigm was first 
reported to show the antagonistic relationship between SUMO modification and ubiquitination 
(Fig.1.5). As indicated above, other target proteins such as cAMP-reponse element binding 
protein (CREB) is also subjected to ubiquitination that leads to degradation of CREB and 
promotes expression of target genes, whereas SUMO modification of CREB results in 
stablization and nuclear localization of CREB (Comerford et al., 2003). Recent insights into 
NEMO, the kinase (IKK) regulator, demonstrated that NEMO is also modified by both SUMO 
and ubiquitin. Ubiquitin and SUMO, however, don’t counteract each other in this context. 
SUMO modification of NEMO results in retention of NEMO in the nucleus, and IKK remains 
in an inactive state. After removal of SUMO, NEMO is ubiquitinated and translocated back to 
the cytoplasm, where it activates IKK and subsequently induces NF-κB (Huang et al., 2003). 
This scenario suggests that SUMOylation and ubiquitination are successive events, and in some 
cases, need to coexist on the common substrate proteins such as NEMO and and proliferating 
cell nuclear antigen (PCNA) protein (Hoege et al., 2002; Stelter and Ulrich, 2003; Ulrich, 
2005). In conclusion, opposing effects of SUMOylation and ubiquitination on same target 
protein might be due to stablization of substrates via relocalization or sequestration of the 
substrates by SUMO modification that competes with ubiquitination-mediated degradation of  
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substrates. Nevertheless, SUMO and ubiquitin modification could cooperate to exert distinct 
functions of target proteins. Besides ubiquitination, research insights into other modifications 
such as acetylation (Bouras et al., 2005; Sapetschnig et al., 2002), phosphorylation (Bossis et 
al., 2005; Gregoire et al., 2006; Kang et al., 2006; Muller et al., 2000; Yang et al., 2003), 
indicated crosstalk between SUMO and other modifications.  
  
 
1.2.3.3 SUMO modification and transcriptional regulation 
 
Among the many known targets of SUMOylation, over half of the recently identified SUMO 
target proteins are regulators of gene expression, and in particular transcriptional activators, 
repressors, coactivators or corepressors. Thus, SUMO modification of transcription factors 
have diverse functional consequences -both activation and repression transcription. In most of 
these cases, however, SUMO modification of transcription factors results in inhibiton of 
transcription. SUMOylation of a limited number of transcription factors correlates with positive 
effects on transcriptional activity. SUMO modification of the heat-shock transcription factors 
HSF1 and HSF2 with SUMO-1 leads to increased DNA-binding activity and mutation of the 
target lysine decreases the HSF1 transcriptional activity (Goodson et al., 2001; Hong et al., 
2001). Also SUMO modification of nuclear factor of activated T (NAFT), Ikaros has been  
Fig.1.5. Opposing effects of ubiquitin and SUMO on IκBα. Signaling from cell-surface 
receptors (shown in yellow) leads to phosphorylation and subsequent ubiquitylation of IκBα. 
Proteasome-mediated degradation then releases active NF-κB, which translocates into the 
nucleus and activates its target genes. In contrast to ubiquitination, sumoylation stabilizes 
IκBα, thereby preventing the release of NF-κB. Ubiquitin are shown in gray, SUMO moieties 
are shwn in pink. Phosphate moieties are represented in red, and lysine and serine residues 
relevant to the modifications are indicated (Ulrich, 2005).
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shown to increase its transcriptional activity (Gomez-del Arco et al., 2005; Terui et al., 2004), 
although the mechanisms underlying these events remains obscure. Nevertheless, it has been 
described to date, SUMO modification of transcription factors is more often associated with 
transcriptional repression. Several evidences have been reported that the SUMO modification 
sites in many transcription factors such as Elk-1 are mapped within previously defined 
inhibitory or negative regulatory domains or the so called “synergy control” motifs, mutation of 
target lysines has been found to enhance transcriptional activity of transcription factors 
(Holmstrom et al., 2003; Iniguez-Lluhi and Pearce, 2000; Kim et al., 2002). In addition, 
overexpression of SUMO-1 or Ubc9 is able to increase SUMO subtrate mediated 
transcriptional represson (Tiefenbach et al., 2006; Verger et al., 2003). Consistent with these 
findings, blocking SUMOylation pathway by co-expression of a C93S dominant negative 
version of Ubc9  (Eloranta and Hurst, 2002; Girdwood et al., 2003; Yang et al., 2003) or 
removal of SUMO from substrates by SUMO-specific proteases (Kim et al., 2002; Long et al., 
2004; Poukka et al., 2000; Ross et al., 2002; Sapetschnig et al., 2002; Subramanian et al., 2003; 
Yang et al., 2003) has been shown to derepress SUMO-dependent transcriptional repression of 
transcription factors, therefore suggesting a mechanism for regulating transcription.  Recent 
studies provided new insights into the molecular mechanisms by which SUMO modification 
regulates transcriptional repression of transcription factors. There are several models to explain 
SUMO dependent transcriptional repression, but are not mutually exclusive. First, SUMO 
modification of transcription factors may repress transcription by recruitment of transcriptional 
co-repressors (Gill, 2004; Gill, 2005; Hay, 2005; Zhang et al., 2004). It is well known that 
acetylated histone tails correlates with active gene transcription, whereas deacetylated histone 
tails correlates with inactive gene transcription (Wu and Grunstein, 2000). Recent studies 
demonstrated that corepressor HDACs might play an important role in transcriptional 
repression mediated by SUMO modification. Consistent with this idea, Yang and coworkers 
found that SUMO modification of Elk-1 recruits HDAC2 to responsive promoters and 
decreases levels of histone acetylation at an Elk-1-regulated promoter using chromatin 
immunoprecipitation assay (Yang and Sharrocks, 2004). Similarly it was shown that SUMO 
modification of the transcriptional co-regulator p300 mediates transcriptional repression by 
recruiting HDAC6 (Girdwood et al., 2003). Moreover, SUMO modification of histone H4 was 
found to repress transcription, mediated by HDAC1 and HP1 (Shiio and Eisenman, 2003). 
These findings suggested that SUMO modified transcription factors repress transcription by  
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recruitment of HDACs, which results in deacetylation of core histones and other transcription 
factors, and in turn creates a transcriptional repressive chromatin environment. It should be 
noted that HDACs are components of several large multi-subunit repressive complexes (Yang 
and Seto, 2003). Although recent data supports the view that HDACs play an apparently broad 
role in SUMOylation-mediated transcriptional repression, this family of co-repressors is not 
likely to account for all of the observed transcriptional repression by SUMO. Other co-
repressors that function as effectors of SUMO-dependent transcriptional repression remains to 
be identified. In addition, HDACs have also been found to enhance the efficiency of SUMO 
modification of some substrates. Lysine residues of several transcription factors have been 
shown to be modified by ubiquitin, acetylation and SUMO. Thus, the hypothesis is that 
deacetylation by HDACs could increase susceptibility of substrate lysines, thereby increase 
efficiency of SUMOylation. Consistent with this hypothesis, recent studies have shown that a 
class III HDAC SIRT1 enhances p300-mediated repression depend on its deacetylase activity 
(Bouras et al., 2005). In addition, two lysine residues in p300 were found to be substrates for 
deacetylation by SIRT1 which is also modified by SUMO, suggesting that SIRT1 may 
deacetylate the SUMO acceptor lysine residues and promote SUMOylation of p300 (Bouras et 
al., 2005). Several HDACs have been reported to be substrates of SUMOylation. SUMO 
modification of HDAC1 was found to increase both deacetylase activity and transcriptional 
repression activity (Cheng et al., 2004; David et al., 2002). Taken together, HDACs serve as 
regulators, effectors and substrates of SUMO modification, indicating that crosstalk between 
 
Fig.1.6.  Complex interplay between SUMO and HDACs. As depicted here, histone 
deacetylases (HDACs) might be recruited to SUMO-modified transcription factors (TFs) to 
mediate repression. In addition, some HDACs are themselves SUMOylated, and SUMO 
modification of HDACs might alter protein–protein interactions or enzymatic activity that is 
important for repression. Furthermore, HDACs regulate SUMOylation of transcription factors 
through enzymatic removal of acetyl groups on SUMO-acceptor lysines. Moreover, SUMO 
itself can directly bind transcriptional corepressors. Modified after (Gill, 2005).  
corepressors
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deacetylation and SUMOylation might be important for regulation of gene expression (Fig.1.6). 
Second, direct evidence for transcriptional repression by SUMO modification came from the 
fact that fusion of SUMO-1 to the Gal4 DNA-binding domain represses transcription in 
reporter gene assay (Holmstrom et al., 2003; Ross et al., 2002; Yang et al., 2003), indicating 
that SUMO itself is able to directly bind to transcriptional corepressors. Third, SUMO 
modification redistributes transcription factors to the repressive environment of particular 
nuclear bodies, such as PML nuclear body. Studies on PML protein revealed that SUMO 
modification of PML is required for secondary shell-like nuclear body (NB) formation and is 
necessary for the recruitment of other PML associated components, for example homeodomain 
interactin protein kinase 2 (HIPK2), Daxx, and Sp100, into the NBs (Duprez et al., 1999; Ishov 
et al., 1999; Kamitani et al., 1998). In addition, SUMO modified HIPK2 is required for its 
localization to NBs, and represses transcriptional activity by forming a stable repressor 
complex with Groucho corepressor and HDAC1 (Choi et al., 1999; Kim et al., 1999). Similarly, 
SUMO modification of Daxx is also able to recruit HDACs into NBs, and thus mediates 
transcriptional repression by remodeling chromatin (Lehembre et al., 2001; Li et al., 2000). As 
to another NB component Sp100, SUMO-modified Sp100 enhances the interaction with 
heterochromatin protein 1 (HP1), which is well-known for the formation of repressive domain 
in chromatin (Seeler et al., 2001; Seeler et al., 1998). All these findings supported the view that 
localization of such proteins to NBs by SUMO modification is to create a local repressive 
environment within NBs. Another well-characterized example is polycomb group (PcG) 
protein. SUMO modification of C. elegans PcG protein SOP-2 results in its recruitment into 
subnuclear body, and recruitment SOP-2 into this body is required for transcriptional repression 
(Zhang et al., 2004). Further research revealed that another polycomb protein, Pc2, recruits the 
transcriptional corepressor CtBP into polycomb subnuclar domains and mediate SUMO 
modification of CtBP, which is required for its transcriptional repression (Kagey et al., 2003). 
Additional mechanisms of SUMOylation-mediated transcriptional repression are possible, but 
are not yet established.   
 
1.3 Aim of the project 
 
The goal of this project was to further understand the biological functions of hp66 proteins.  
Previous works have shown that both hp66α and hp66β are transcriptional repressors. However,  
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the mechanism by which both hp66 protein paralogs mediate transcriptional repression 
remained unclear. It has been reported that SUMO modification of transcription factors, in 
most of cases, results in inhibiton of transcription. Thus the first aim of the present study is to 
address whether both hp66α and hp66β can be SUMOylated, and how SUMO modification 
regulates hp66 mediated transcriptional repression. Interestingly, several components of Mi-
2/NuRD complex have been found in pairs. As decribed above in Table 1.2, these pairwise 
duplicated subunits form distinct complexes. Since hp66α and hp66β are homologus proteins, 
the question be answered within this work is whether both hp66 protein paralogs are within the 
same complex or form distinct complexes, and if so, what is the protein composition of the 
complexes?  
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2 MATERIALS AND METHODS 
 
2.1 Materials 
 
2.1.1 Equipment 
 
Agarose electrophoresis system   PEQLAB, Pharmacia, Stratagene 
Biometra software 
Blot apparatus                                                             Pharamcia 
Centrifuge      Eppendorf microfuge 5417R 
  Hettich Microliter 
                                                                                    Heraeus Minifuge RF, GL  
                                                                                    Heraeus Cryofuge 20/30 
       Beckman J2-MC 
       Beckman Ultracentrifuge L70, XL70 
Chromatography equipments    Pharmacia  
Cryo 1°C freezing container    NalgeneTM 
Gel drier      BioRad Geldryer Model 583 
Gel electrophoresis system    Pharmacia 
      Biorad (PAGE) (MINI PROTEAN IITM) 
Hoefer  
Microliter Pipettes (10, 20, 200, 1000µl)  Gilson, Eppendorf 
Microscope      Leica (Confocal)  
Zeiss (Fluorescence)  
Milli Q Ultra pure water system   Millipore 
Mono Q HR 5/5                           Pharmacia  
PCR cycler (Mastercycler gradient)   Eppendorf, Perkin Elmer 
                Corbett research 
Photometer                                                                  Berthold LB1210 B 
Rotator      Neolab rotator 2-1175, MAGV 
Semi-dry electroblot system                            Pharmacia 
Sonifier B21                       Branson 
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Spectrophotometer     Pharmacia 
Spectrophotometer quartz cuvette   LKB 
Superose 6 column HR 10/30    Pharmacia 
UV-transilluminator      Bachofer (366nm), UVP (254nm) 
Vacuum centrifuge                                                     Bachofer 
X-ray film processor     Eastman Kodak 
 
2.1.2 Consumables 
 
Cryotube vials (1.8ml)    NUNCTM 
Falcon centrifugation tubes (15ml/50ml)  Sarstedt, Falcon 
Filter pipet tips     Greiner  
Glassware      Schott 
Gloves                  Braun, Roth 
Microcon YM-30      Millipore 
Centricon YM-30/50/100     Millipore 
Microplates (6 well, 12 well)    Greiner  
Microscope coverslips    Marienfeld, MAGV 
Microscope slides     Marienfeld, MAGV 
Micro tubes      Eppendorf 
Parafilm      American National Can 
Pasteur pipette      Brand, Volac 
Petri dish      Greiner 
PCR soft tubes, 0.2m1    Abgene, Eppendorf 
Photometer cuvette     Ratiolab 
Pipette tips      Brand, Eppendorf 
Polyvinylidene difluoride membrane                         Millipore 
Quickseal tube (13 × 51mm)    Beckman 
Sterile filters (0.45µm/0.2µm)   Millipore, Sartorius 
Tissue culture dish     Greiner 
Whatman-3MM-paper    Whatman 
X-ray film      Kodak 
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2.1.3 Chemicals and reagents 
 
Acetate        Merck 
Acrylamide/Bisacrylamide 30, 30%, 37.5:1       Roth 
Acrylamide/Bisacrylamide 40, 40%, 19:1                  Roth 
Agar                    Difco 
Agarose ultra pure                  Roth 
6-Amino-n-caproic acid      Sigma 
Ammonium sulfate                  Merck 
Ammonium persulfate      Roth 
Ampicillin                                Serva 
Adenosine triphosphate      Sigma 
Bacto-peptone        Difco 
Bacto-tryptone                    Difco 
Bovine serum albumin        Sigma 
Bromophenol blue                  Merck 
Caesium chloride        Roth 
Calcium chloride        Merck 
Cetyl trimethyl ammonium bromide      Sigma 
Chloroform                                   Merck 
Chloramphenicol (dosage, 170µg/ml)               Roth 
Coenzym A                                   Sigma 
Coomassie brilliant blue R250     Serva 
DEPC-ddH2O                   MBI Fermentas  
Deoxynucleotidetriphosphate      MBI Fermentas 
Dulbecco modified Eagle medium      Gibco BRL  
Dimethylformamide                   Serva 
Dithiothreitol                   Amersham 
Ethanol absolute       Merck 
Ethidium bromide solution (10mg/ml)    Roth 
Ethylenediamine tetraacetic acid      Serva 
Ethylene glycol-bis(beta-aminoethyl-ether) 
-n, n, n’,n’-tetraacetic acid                  Serva 
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Fetal calf serum                  GIBCO BRL 
G-418                                    GIBCO BRL 
Glacial acetic acid                  Merck 
Glycerol                    Roth 
Glycine        Merck 
Glucose        Merck 
L-Glutamine                   Gibco BRL 
Hoechst 33342       Sigma 
Hydrochloric acid                   Merck 
n-2-Hydroxyethylpiperazine                 Roth  
Isoamyl alcohol       Merck 
Isopropanol                   Roth 
Kanamycin (dosage, 30µg/ml)     Merck 
Lysozyme                   Sigma 
D-Luciferin                   PJK GmbH 
Magnesium chloride                  Serva 
Magnesium sulphate                  Merck 
Manganese chloride                  Merck 
β-Mercaptoethanol                  Sigma 
Methanol                   Merck 
Non-fat dry milk       Roth 
Nonidet P-40                   Merck 
N-ethylmaleimide                                        Sigma 
ortho-Nitrophenyl β-D-galactopyranoside                   Sigma 
Oligonucleotide       Eurogentec, Invitroge 
Paraformaldehyde                  Sigma 
Penicillin/streptomycin solution                                GIBCO BRL 
Phenol (Roti-Phenol)                  Roth 
Phenylmethylsulfonyl fluoride     Sigma 
Piperazine-n, n’-bis (2-ethane sulfonic acid      Sigma 
Potassium chloride                  Merck 
Potassium dihydrogen phosphate               Merck 
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di-Potassium hydrogenphosphate              Merck 
Potassium hydroxide                               Merck 
Propidium iodide                   Sigma 
Roti-Load                   Roth 
Sodium acetate                       Merck 
Sodium azide                   Sigma 
Sodium chloride                         Merck 
Sodium dihydrogen phosphate dehydrate    Merck 
di-Sodium hydrogen phosphate                         Merck 
Sodium hydroxide                  Merck 
Sodium dodecyl sulphate                        Serva 
Sodium hydroxide                        Merck 
Protein A agarose/ salmon sperm DNA    Biomol 
Sucrose        Serva 
n,n,n’,n’-Tetramethylethylenediamine               Merck 
Tris base       Merck 
Triton-X-100       Merck 
Trichostatin A (TSA)                                     Biomol 
Trypsin       Gibco BRL 
Tween® 20       Roth 
Urea        Pharmacia 
Zinc chloride       Merck 
Note: All chemicals are of analytical grade. All buffers were prepared with double distilled water (ddH2O) or Milli 
Q water. Glassware, pipette tips and Eppendorf tubes were autoclaved. 
 
2.1.4 Enzymes, reaction buffers and enzyme inhibitors 
 
Calf intestine alkaline phosphatase (CIAP)  MBI Fermentas 
Complete protease inhibitor cocktail              Roche Applied Science 
DNaseI (RNase-free)                Promega 
DpnI                                          MBI Fermentas  
Klenow fragment                                            MBI Fermentas 
Lysozyme                 Boehringer  
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Mung bean nuclease                New England Biolabs 
Pfu DNA polymerase                MBI fermentas  
Protease K                                                                   MBI fermentas 
Restriction endonucleases    MBI Fermentas, New England Biolabs 
10× restriction enzymes buffer Y, R, B, G,O             MBI fermentas 
10× restriction enzymes buffer 1, 2,3, 4                     New England Biolabs  
RNase A (DNase-free)               MBI fermentas 
T4 DNA ligase                           MBI fermentas  
T4 DNA polymerase                           MBI fermentas  
Taq DNA polymerase                                                 Invitrogen 
 
2.1.5 Molecular weight markers 
 
Prestained SDS-7B protein marker   Sigma 
Prestained protein marker (broad range)  New England Biolabs 
PageRulerTM prestained protein marker  MBI Fermentas 
λ DNA/EcoRI+HindIII marker 3   MBI Fermentas 
pUC19 DNA/MspI marker 23   MBI Fermentas 
Lamda DNA/Eco130I marker 16   MBI Fermentas 
 
2.1.6 Antibodies 
 
Anti-FLAG antibody:                         Rabbit polyclonal, AbCAM 
             1:3000 in PBST for  Western blotting 
 
Anti-Gal antibody:                           Rabbit polyclonal, Covance 
1:2000 in PBST for Western blotting 
 
Anti-GST antibody:                            Mouse polyclonal, Santa Cruz 
1:1000 in PBST for Western blotting 
 
Anti-HDAC1 antibody:                Goat polyclonal, Santa Cruz 
1:1000 in PBST for Western blotting 
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Anti-HDAC2 antibody:               Mouse  monoclonal, Santa Cruz 
                             1:1000 in PBST for Western blotting 
 
Anti-MBD2 antibody:               Sheep polyclonal, Upstate 
                             1:1000 in PBST for Western blotting 
 
Anti-MBD2 antibody:               Goat polyclonal, Santa Cruz 
                             1:1000 in PBST for Western blotting 
 
Anti-MBD3 antibody:               Rabbit polyclonal, AbCAM 
1:1000 in PBST for Western blotting 
 
Anti-MBD3 antibody:               Goat polyclonal, Santa Cruz 
                             1:1000 in PBST for Western blotting 
 
Anti-Mi-2 antibody:                           Goat polyclonal, Santa Cruz 
                             1:1000 in PBST for Western blotting 
 
Anti-mSin3a antibody:               Mouse monoclonal, Santa Cruz 
                             1:1000 in PBST for Western blotting 
 
Anti-p66 antibody:                         Rabbit polyclonal, Upstate  
1:500 in 10% skim milk in PBST   
for Western blotting 
 
Anti-p66α antibody:                         Rabbit polyclonal, AbCAM  
1:1000 in PBST for Western blotting 
 
Anti-p66β antibody:                           Rabbit polyclonal, AbCAM 
                             1:1000 in PBST for Western blotting 
 
Anti-PRMT5 antibody:               Rabbit polyclonal (Dr.Uta Bauer) 
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                             1:2000 in PBST for Western blotting 
 
Anti-RbAp46 antibody:               Goat polyclonal, Santa Cruz 
                             1:1000 in PBST for Western blotting 
 
Anti-RbAp48 antibody:               Goat polyclonal, Santa Cruz 
                             1:1000 in PBST for Western blotting 
 
Anti-SUMO1 antibody:               Rabbit polyclonal, Zymed laboratories 
                             1:1000 in PBST for Western blotting 
 
Anti-SUMO1 antibody:               Rabbit polyclonal, Alexis biochemicals 
                            1:1000 in PBST for Western blotting 
 
Anti-rabbit, HRP conjugate:                         Amersham 
                             1:10,000 in PBST for Western blotting 
  
Anti-goat IgG, HRP conjugate:                         Santa cruz  
1:10,000 in PBST containing 0.5% milk  
for Western blotting 
 
Anti-mouse IgG, HRP conjugate:                         Santa cruz  
1:10,000 in PBST for Western blotting 
 
Anti-sheep IgG, HRP conjugate:                         Upstate  
1:4000 in PBST containing 0.5% milk  
for Western blotting 
 
Anti-FLAG M2 gel                                                   Sigma  
                                                                                    For binding FLAG fusion proteins 
                            
FLAG peptide                                                           Sigma  
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                                                                                   For elution of FLAG fusion proteins 
 
2.1.7 Kits 
 
TriFast™                                                                      peqLab 
TNT in vitro Translation system                                 Promega 
QIAquick® PCR purification kit                                 QIAGEN 
High purity plasmid purification system                    Marligen Biosciences  
GeneAmp® RNA PCR core kit                                  Applied Biosystems 
Platinum® SYBR Green qPCR SuperMix UDG        Invitrogen 
ECL detection system                                                Amersham/Millipore 
GENECLEAN® DNA purification kit                       Q-Biogene 
Nucleospin® DNA purification kit                             Marcherey-Nagel  
PlusOne™ Silver staining kit                                      Amersham Biosciences 
 
2.1.8 E.coli strains 
 
DH5α: genotype: F-, φ80dlacZ#M15, endA1, recA1, hsdR17 (rk-,mk+), supE44, thi-1, gyrA96, 
relA1, #(lacZYA-argF)U169, λ-, is a high transformable competent cell, which was generally 
used in DNA subcloning and production of plasmid DNA. 
 
2.1.9 Eukaryotic Cell lines 
 
CV-1: (ATCC # CCL70), the CV-1 cell line was derived from the kidney of a male 
adult African green monkey, which was cultured in DMEM with 2 mM L-
glutamine, 10% FCS at 37°C, 5% CO2. 
HeLa: (ATCC # CCL2), a human epithelial cell line derived from cervix 
adenocarcinoma, which was cultured in the same medium as CV-1 cells. 
HEK293: (ATCC # CRL1573), adenovirus 5 DNA transformed epithelial cells from 
human kidney, which was cultured in the same medium as CV-1 cells. 
HEK293T:    (ATCC # CRL-11268), a highly transfectable derivative of the 293 cell line with 
integration of the temperature sensitive gene for SV40 T-antigen, which was 
cultured in the same medium as CV-1 cells. 
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MCF7:         (ATCC # HTB-22), a human epithelial cell line derived from breast carcinoma, 
which was cultured in the same medium as CV-1 cells. 
NIH3T3: (ATCC # CRL-1658), EBV-transformed lymphoblasts with karyotype 48, 
XXXX, which was cultured in the same medium as CV-1 cells. 
 
2.1.10  Plasmids 
 
pBluescript II SK   ( Stratagene )                                 
This vector was derived from pUC19 and contains LacZ gene which provides α-
complementation for blue/white colour selection of recombination. This vector was used for 
cloning in cycle sequencing or as carrier DNA in eukaryotic cell transfections. 
 
pAB-Gal94.  ( Dr. Baniahmad ) 
This vector contains the Gal4 DNA binding domain (DBD), MCS, SV40 polyadenylation site. 
 
pAB-Gal94-hp66α.  ( Dr. Brackertz )                    
 
This vector was constructed by inserting the SalI/NdeI-linker 5’-TCGACCATATGACCGAAG 
AAGCATG-3’ in front of the SphI site of pOTB7-hp66α to generate pOTB7-hp66α and 
subcloning the SalI/XbaI fragment in-frame into the pAB-Gal94 linker. 
 
pAB-Gal94-hp66β.  ( Dr. Brackertz )                      
This vector was generated by amplification of hp66β cDNA via RT-PCR from 293 mRNA 
using the gene specific 5’ SalI-primer 5’-CACCGTCGACATGGATAGAATGACAGAAGA-
3’ and the respective 3’ BamHI-primer 5’-TCAAGGATCCGGCAGTACAAGTGGAACAG-3’. 
The RT-PCR product was cut with SalI/BamHI and cloned into the SalI/BamHI site of pAB-
Gal94 linker. 
  
pAB-Gal94-MBD2b.    ( Dr. Böke )                                                      
This vector was created by excision of the corresponding MBD2b sequences out of pGEX-2T-
MBD2b and in-frame insertion into pAB-Gal94 linker. 
 
pCMX-Gal-NCoR.    ( Dr. Baniahmad )                                                      
This vector was constructed by in-frame insertion of the corresponding NCoR sequences into  
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pCMX vector, a plasmid containing the GAL4 DNA binding domain (DBD). 
 
pEGFPC2.   ( Clontech )                               
This vector encodes a red-shift variant of the Aequorea Victoria green fluorescence protein 
(GFP) which has been optimized for brighter fluorescence and higher expression in mammalian 
cells. Genes cloned into the MCS are expressed as fusions to the C terminus of EGFP. The 
vector contains a kanamycin resistance gene and a neomycin-resistance cassette (Neor) which 
allows stably transfected eukaryotic cells to be selected using G418. 
 
pEGFPC1-hp66α. ( Dr. Brackertz )                 
This vector was cloned by ligating the SalI/BamHI fragment from pAB-Gal94-hp66α into 
pEGFP-C1 digested with SalI/BamHI . 
 
pEGFPC2-hp66β. ( Dr. Brackertz )  
This vector was created by insertion of the EcoRI/BamHI-fragment from pAB-Gal94-hp66β into 
pEGFP-C2 cut with EcoRI/BamHI. 
 
pSG5-hp66α.   ( Dr. Brackertz )                                                                 
This vector was generated by subcloning the EcoRI/XbaI fragment from pOTB7-hp66α into 
pSG5 opened with EcoRI/BamHI. 
 
pSG5-hp66β.   ( Dr. Brackertz )                                                                 
This vector was cloned by ligating the EcoRI/BamHI fragment of pAB-Gal94-hp66β into pSG5 
cut with EcoRI/BamHI. 
 
pcDNA3-FLAG-hp66α.  ( Dr. Brackertz )                                                
This vector was generated via PCR with the sense primer :5’-AGGGGATCCATATGACC 
GAAGAAGCA-3’ and the antisense primer : 5’- CCTGTCTAGAACTATTTCCACGTGGC 
TG- 3’ from vector pGBKT7-hp66α. The PCR product was digested with BamHI/XbaI, and 
ligated into vector pcDNA3-FLAG-Alien α cut with BamHI/XbaI. 
 
pcDNA3-FLAG-hp66β.    ( Dr. Brackertz )                                               
This vector was constructed by subcloning the Cfr9I/XbaI fragment from pSG5-hp66β 
followed in-frame insertion into pcDNA3-FLAG-Alien α opened with BamHI/XbaI. 
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pBS1479.   ( Euroscarf )                                                                        
A  plasmid for TAP-tagging at the C-terminus, which also contains the Kluyveromyces lactis 
TRP1 gene. 
 
pSilencer negative.   ( Ambion )                                                        
The plasmid is a circular plasmid encoding a hairpin siRNA whose sequence is not found in the 
mouse, human, or rat genome database. 
 
pN3-FLAG-SUMO1.  ( Dr. Suske )                                                      
This vector was created by excision of the corresponding SUMO1 sequences out of pHM976 
and in-frame insertion into pN3 vector digestion with XbaI/HindIII. 
 
pcDNA3-HA-Ubc9.   ( Dr. Suske )                                                        
This vector was created by in-frame insertion of the corresponding hUbc9 sequences into 
pCDNA3-HA vector. 
 
pCMV-tag-2B-PIAS1.   ( Dr. Suske )                                                   
This vector was constructed by in-frame ligation of the corresponding PIAS1 sequences into 
pCMV-tag-2B vector containing a FLAG tag. 
 
pCMV-GST.   ( Dr. Baniahmad )                                                                 
This eukaryotic expressing plasmid contains a CMV promoter, GST coding region, MCS, 
SV40 polyadenylation site, a thrombin cleavage sequence, and a PKA phosphorylation site. 
 
pCMV-GST-MBD2b.    ( Dr. Böke )                                                   
This eukaryotic expression vectors was created by excision of the BamHI/EcoRI fragment out 
of pGEX-2T-MBD2b and in frame insertion into pCMV-GST opened with BamHI/Cfr9I. 
 
pCMV-Myc-MBD3.    ( Dr. Pfeifer )                                                     
This vector was constructed by insertion of the corresponding MBD3 sequence into pCMV-
Tag1 vector digested with BamHI/HindIII. 
 
RbAp46 (pPK44).    ( Dr. Stillman )                                                         
This vector was created by in-frame ligation of the corresponding RbAp46 sequence into pET-
19b vector cut with NcoI/BamHIIII. 
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RbAp48 (pPK40).    ( Dr. Stillman )                                                        
This vector was cloned by in-frame insertion of the corresponding RbAp48 sequence into pET-
19b vector opened with NcoI/XhoI. 
 
pcDNA3-HDAC1.    ( Dr. Baniahmad )                                                        
This vector was cloned by in-frame ligation of the corresponding HDAC1 sequences into 
pCDNA3 vector. 
 
4×UAS-TK-Luciferase.   ( Dr. Baniahmad )                                                 
This vector contains four Gal binding sites upstream of the thymidine kinase promoter that 
drives the luciferase reporter gene.  
 
pCMV-LacZ.    ( Dr. Baniahmad )                                                                 
This expression plasmid encodes β-galactosidase. 
 
2.2 Methods 
 
2.2.1 Working with Escherichia coli (E.coli) 
 
2.2.1.1 Preparation of competent bacterial cells: classical CaCl2 method 
 
Preparation of DH5α competent cells was carried out as described previously (Hanahan, 1983) 
with modification. A single colony of E.coli was inoculated into 3ml of antibiotic-free LB 
medium and cultured 8 hours at 37°C. This bacterial culture was then diluted into fresh 500ml 
TB medium and cultured until an OD600nm of 0.5 was reached. Bacteria were pelleted at 
3200rpm for 10 minutes at 4°C. All the following steps were performed at 4°C. The pellet was 
carefully resuspended in 40ml of TB buffer using a pre-chilled glass pipet, and incubated for 10 
minutes, then transferred to 50ml Falcon. The suspension was then pelleted at 3200rpm at 4°C 
for 3 minutes. The pellet was resuspended and incubated with 9.3ml TB buffer and 0.7ml 
DMSO for 10 minutes.  The suspension of bacteria was then dispensed as 220µl aliquots into 
pre-chilled tubes. The aliquots were frozen immediately in liquid nitrogen and stored at -80°C. 
 
TB buffer:    10mM PIPES 
     15mM CaCl2 
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     250mM KCl 
     adjust pH to 6.7 with KOH, autoclaved. 
                                             55mM MnCl2 (sterile filtration) 
    
LB medium:    10 g/l Bacto-tryptone 
     5 g/l yeast extract 
     10 g/l NaCl 
      pH 7.5, autoclaved 
TB-Medium                        12 g/l Bactotrypton 
                                             24 g/l      Yeast extract 
                                             4 ml/l     Glycerol 
                                             autoclave 
10x  Phosphat-Puffer        170 mM  KH2PO4 
                                             720 mM  K2HPO4 
                                                                     autoclave 
 
LB-agar plate:   10 g/l Bacto-tryptone 
    5 g/l yeast extract 
    5 g/l NaCl 
    15 g/l Agar 
  pH 7.5, autoclaved and cooled to about 50°C in a waterbath. After adding 
  antibiotics, medium was poured into Petri dishes and allowed to solidify. 
  Plates were then stored at 4°C in darkness for up to 4 weeks. 
 
Antibiotic plates: contain 100μg/ml Ampicillin or 33μg/ml Kanamycin in LB-agar plates. 
 
2.2.1.2 Transformation of competent cells 
 
Frozen ompetent cells were thawed by placing on ice just before use. Plasmid DNA (100-
500ng) or 15µl of ligation mixture was mixed with 100µl of competent bacteria by stirring 
gently with a pipet tip, and then incubated on ice for 30 minutes. Competent cells were heat 
shocked at 42°C for 90 seconds, and then placed on ice for 2 minutes. For each transformation, 
900µl LB medium without antibiotics was added. After 1 hour incubation at 37°C, the mixture 
was centrifuged at 3000rpm for 3 minutes. After discarding off supernatant, the rest about 80μl 
transformation mixture was spread onto pre-warmed selective LB-agar plates. The plates were 
incubated overnight at 37°C. The colonies were then analysed for positive clones using 
restriction enzymes and further confirmed by DNA sequencing. 
  
 
Materials and methods                                                                                              41
 
2.2.2 Working with DNA 
 
2.2.2.1 Storage of DNA 
 
Basically, DNA was dissolved in TE buffer and stored at -20°C. 
 
TE buffer:   10mM Tris-HCl, pH 7.5 
    1mM EDTA, 
    sterilfilter/autoclave 
 
2.2.2.2 Small-scale preparation of plasmid DNA (Mini-prep) 
 
 
A Mini-prep of plasmid DNA was performed as described by Holmes and Del Sal. (Del Sal et 
al., 1989; Holmes and Quigley, 1981). A single bacterial colony from the antibiotics containing 
plates was inoculate 3ml sterile LB medium with appropriate antibiotics, then grown in 
incubator overnight at 37°C. An overnight 1.5ml LB culture  was spun at maximum speed in a 
microfuge for 20 seconds. The cell pellet was completely resuspended in 300µl STET buffer by 
vigorous vortexing. Then 10μl lysozyme (10mg/ml) was added to the suspension and the 
mixture was immediately placed in a boiling water bath (100°C) for 1 minute. Afterwards, the 
mixture was centrifuged at 14000rpm for 10 minutes. After taking off the bacterial pellet, 15μl 
CTAB solution was added to the supernatant and mixed by inversion. The mixture was further 
centrifuged at full speed in a microfuge for 10 minutes. After discarding off the supernatant, the 
pellet was dissolved in 500μl 1.2M NaCl on a multitube vortexer for 5-30 minutes until pellet 
dissolved. Afterwards, 1ml 100% (v/v) ethanol was added and the mixture was further 
incubated at room temperature (RT) for 10 minutes. The mixture was centrifuged at full speed 
in a microfuge for 15min and the DNA pellet was retrieved. The pellet was washed once with 
70% (v/v) ethanol, dried by placing under a vacuum for 3-5 minutes,  and finally dissolved in 
30µl TE buffer. 
 
STET-Puffer                                     50 mM  Tris-HCl (pH 7,5) 
                                                            50 mM  EDTA 
                                                            0.5% (v/v)  Triton X-100  
                                                            8%(v/v)  Saccharose  
                                                            sterilfilter  
 
5% CTAB) (W/V)                             5g CTAB in 100ml ddH2O 
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2.2.2.3 Large-scale preparation of plasmid DNA (Maxi-prep) 
 
Large-scale preparation of plasmid DNA (Maxi-prep) was performed as described previously 
(Birnboim and Doly, 1979). A single transformed bacterial colony was inoculated into 3ml LB 
medium supplemented with appropriate antibiotics and incubated overnight at 37°C. The 
overnight culture was diluted in fresh medium containing 360ml TB medium and 40ml 10× 
Phosphate buffer and the appropriate antibiotics. The bacteria were grown at 37°C with 
vigorous agitation for 8 hours and 2ml chloramphenicol solution (34mg/ml in ethanol) was 
added to enhance the amplification of plasmid in E.coli (in particular for low-copy plasmids). 
After overnight incubation (12-16 hours), cells were collected by centrifugation at 4000 rpm 
(rotor JA-10, Beckman) for 15 minutes at 4°C. The cell pellet was resuspended in 10ml Sol I 
and incubated at RT for 5 minutes. Sol II (20ml) was added and the suspension was well mixed 
by gently shaking. The mixture was kept on ice for 10min and 15ml Sol III was added. The 
mixture was gently mixed, and incubated on ice for 10 minutes. The mixture was clarified by 
centrifugation at 7000 rpm (rotor JA-10, Beckman) for 20 minutes at 4°C. The supernatant  was 
poured into 2×50ml Falcons through 3 layers of gauze, then mixed with 0.6 vol of isopropanol 
by inversion and placed at RT for 15 minutes. Centrifugation was then performed at 6000 rpm 
(Heraeus) for 20 minutes at RT to recover nucleic acids. After gently discarding the supernatant, 
the pellet was dried at 37°C and was then dissolved in 2ml TE at 37°C with agitation. The 
samples in two Falcons were combined. CsCl (4.5g) and 500µl ethidium bromide (10mg/ml)  
were added to the mixture. Then the mixture was agitated at 37°C until the salt was dissolved. 
Centrifugation was performed at 6000rpm (Heraeus) for 10 minutes at RT. The supernatant was 
transferred into a Quickseal tube and the tube was filled up with 50% (w/w) CsCl and TE 
buffer to a final weight of 9.5-9.8g. Ultracentrifugation was carried out at either 70000rpm for 
3 hours or at 55000rpm for ≥14 hours at 20°C (rotor VTi-90, Beckman). Afterwards, the tube 
was carefully removed from the ultracentrifuge. The plasmid band (the lower of the two bands) 
was recovered by inserting a 2ml syringe attached with a 20-G needle into the side of the tube 
0.5cm below the plasmid band. The recovered plasmids were transferred into another Quickseal 
tube and the tube was balanced again with a final weight of 9.5-9.8g. The second centrifugation 
either 55000rpm for ≥14 hours or 70000rpm for 3 hours was performed at  20°C (rotor VTi-90, 
Beckman). After recovering the plasmid band, 2ml of isopropanol / saturated CsCl solutions 
was added. The mixture was vortexed and the red upper phase containing ethidium bromide 
was removed. This step was repeated at least 6 times until no red colour was left. After last  
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wash, the upper phase was all discared, and 2 vol of water were added to the lower phase. The 
solution was then well mixed with 0.6 vol isopropanol and incubated on ice for 15 minutes. The 
plasmid DNA was recovered by centrifuging at 6000rpm (Heraeus) for 30 minutes at 4°C and 
was then washed once in 70% ethanol. The pellet was dried and then dissolved overnight in 
300-500μl TE at 4°C. After measuring plasmid DNA concentration, the dissolved plasmid 
DNA was stored at –20°C. Alternatively, High purity plasmid purification systems (Marligen 
Biosciences), which is a unique anion exchange resin, was available to purify plasmid DNA 
according to manufacturer’s instructions.  
 
Sol I:    50mM glucose 
25mM Tris-HCl, pH 8.0 
10mM EDTA 
autoclaved 
4g/l Lysozyme (freshly added) 
 
Sol II:    0.2N NaOH 
    1% SDS (w/v) 
    prepared freshly and kept at RT 
 
Sol III:    24.5g potassium acetate 
    35ml glacial acetic acid 
pH 4.8, adjusted with glacial acetic acid 
fill up to 100ml with ddH2O, sterilized by filtration 
 
50% (w/w) CsCl:  50g CsCl in 50g ddH2O 
 
TB-Medium                                     12 g/l Bactotrypton 
                                                          24 g/l     Yeast extract 
  4 ml/l     Glycerol 
autoclave 
10× Phosphat-Puffer                      170 mM   KH2PO4 
                                                          720 mM  K2HPO4 
autoclave 
 
2.2.2.4 Measurement of DNA concentration 
 
The concentration of DNA in a given sample was calculated based on the OD260nm and OD280nm 
measured with a spectrophotometer. Pure DNA should have an OD260nm/OD280nm ratio of  
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1.8~2.0. An OD260nm/OD280nm lower than 1.8 indicates that the DNA sample is contaminated 
with proteins and aromatic substances, whereas an OD260nm/OD280nm higher than 2.0 means a 
possible contamination with RNA. The concentration of dsDNA was calculated with the 
following formula: DNA concentration (µg/ml) = OD260nm × 50 × dilution factor. 
 
2.2.2.5 Molecular cloning 
 
2.2.2.5.1  Restriction endonuclease digestion 
Digestion with restriction endonucleases was carried out according to manufacturer’s 
instruction. Briefly, plasmid DNA or PCR product, optimal 10× reaction buffer, restriction 
endonucleases and ddH2O were mixed in an eppendorf tube in a total volume of 15-20µl. The 
reaction mixture was incubated at different temperature as recommended by the manufacturer. 
Restriction endonucleases were inactivated by either heating at 65°C or 80°C or the digestion 
was terminated by phenol/chloroform extraction. 
 
2.2.2.5.2  Filling-in of recessed 3’-termini of DNA with Klenow Fragment  
The Klenow Fragment is the Large Fragment of DNA polymerase 1, E.coli, which exhibits a 
5’-3’ polymerase activity, and is used to fill-in of recessed 3’-termini ends with 
deoxynucleotides(dNTPs) (Tabor and Richardson, 1987). The reaction mixture was prepared 
mixing digested DNA (0.1-4µg), 2µl of 10× Reaction buffer, 0.5µl 2mM dNTPs (50µM final 
concentration) and Klenow Fragment (1-5U) with ddH2O up to final volume of 20µl. The 
reaction was performed at 37°C for 10 minutes and was terminated by heating at 75°C for 10 
minutes.  
 
2.2.2.5.3  Removing of 3’ and 5’ protruding ends with Mung Bean Nuclease 
The properties of Mung Bean Nuclease (McCutchan et al., 1984) is removal of 3’ and 5’ 
protruding ends of DNA creating ligatable blunt ends. Standard assay was prepared by mixing 
digested DNA, Mung Bean Nuclease, 10× Reaction buffer and ddH2O and was incubated at 
30°C for half an hour. The reaction was stopped by phenol/chloroform extraction. 
 
2.2.2.5.4  Dephosphorylation of DNA ends 
To avoid re-circulization and self-ligation of the linearized vector DNA during subcloning, calf 
intestinal alkaline phosphatase (CIAP) was employed to dephosphorylate the terminal 5’- 
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phosphate of the vector DNA (Ausubel, 1989). The reaction mixture was prepared by mixing 
DNA, CIAP, 10× Reaction buffer and ddH2O and was incubated at 37°C for half an hour. 
Alternatively, CIAP was added directly to the restriction endonuclease mixture after DNA 
cleavage when the reaction buffer is compatible to CIAP. CIAP was inactivated either by 
heating at 85°C for 15 minutes or phenol/chloroform extraction. 
 
2.2.2.5.5  Phenol/chloroform extraction and ethanol precipitation of DNA 
Phenol/chloroform extraction was routinely employed to purify and concentrate the DNA 
preparation. The volume of DNA mixture was adjusted to ≥ 200µl. An equal volume of phenol 
and chloroform were added to the DNA containing solution followed by vortexing  vigorously. 
After centrifugation at maximum speed for 5 minutes at RT, the upper aqueous phase was 
transferred to a new tube and precipitated with 1/10 vol 3M NaAc (pH 5.2) and 2.5 vol of ice-
cold 100% ethanol. After incubation for 20 minutes at -20°C, DNA was recovered by 
centrifugation at 14000rpm for 15 minutes at 4°C. Pellet was washed once with 70% ethanol, 
air-dried and then dissolved in an appropriate volume of ddH2O or TE buffer. 
 
2.2.2.5.6  PCR cloning 
This strategy was used to amplify DNA of interest with desired restriction enzyme by 
polymerase chain reaction (PCR) for subcloning. For PCR cloning, the high-fidelity Pfu 
polymerase was used. PCR primers were designed with 1-5 extra nucleotide at their 5’-end 
adjacent to the recognition site for the desired restriction enzyme. The standard PCR reaction 
was prepared (Table 2.1). 
                            
 
dsDNA template (50ng/μl) 1.0µl 
sense primer (10μM)    1.0µl 
antisense primer (10μM) 1.0µl  
dNTP mix (10mM)   1.0µl 
10×Pfu polymerase reaction buffer 5.0µl 
Pfu polymerase (2.5U/μl) 1.0µl 
ddH2O 40.0µl 
Total volume 50.0µl 
 
The reaction mixture was prepared in a thin-wall tube, and placed in a thermal cycler. The  
Table 2.1 standard PCR reaction composition 
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mixture was first denatured for 2 minutes at 95°C followed by cycles as shown in Table 2.2. 
 
 
denaturation 30 second 95°C 
annealing 30 second 60-65°C 
extension 2 minutes/kb 68°C 
cycles 30  
final extension 10 minutes 68°C 
 
The PCR product was loaded on an agarose gel and the DNA band was excised and purifed by 
GENECLEAN® or Nucleospin® DNA purification Kit. Then the PCR product was digested 
with specific restriction enzyme, and ligated into corresponding linear vector DNA. Then 
transformation was carried out with competent cells, and the correct clones were confirmed by 
digestion and further DNA sequencing. 
 
2.2.2.5.7 Agarose gel electrophoresis 
Agarose powder was melted in 1×TAE buffer using a microwave oven and the solution was 
cooled to about 55°C, and 0.5μg/ml ethidium bromide was added. The solution was then 
poured into a casting platform and allowed to solidify. 0.8-2% agarose gels were routinely 
employed for analyzing DNA. DNA samples were mixed with a final volume of 1× loading 
buffer before loading into the slots. The voltage of electrophoresis was set to ~10V/cm gel 
length. DNA was visualized by illuminating the gel with a UV light source and was 
photographed directly. For subcloning, the desired bands were excised with a clean scalpel. 
 
50× TAE:   2M Tris-HCl, pH7.8 
    150mM NaAc 
    50mM EDTA 
 
6× loading buffer:  0.025% (w/v) bromophenol blue 
30% (v/v) glycerol 
 
2.2.2.5.8 Extraction of DNA fragments from agarose gel 
The desired DNA bands were cut from ethidium bromide stained agarose gel under the UV 
light. DNA fragments were extracted from agarose gel slices with a Nucleospin DNA 
purification kit   (Marcherey-Nagel) or GENECLEAN® II KIT (Q- Biogene) according to the 
manufacturer’s instructions.  
Table 2.2 standard protocol for PCR  
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2.2.2.5.9  Ligation  
The T4 DNA ligase catalyzes the formation of phosphodiester bonds between adjacent 3’-
hydroxyl and 5’-phosphate termini in duplex DNA with blunt or sticky end termini (Ausubel, 
1989). A ligation reaction mixture was mixed with 1µl T4 DNA ligase, 1.5µl of 10× Ligation 
buffer, an appropriate molar ratio of linearized vector DNA and purified insert DNA fragment 
(1:5 for blunt ends and 1:3 for sticky ends) in a total volume of 15µl. The reaction was 
incubated at 22°C overnight for blunt-end ligation or for 4-6 hours for sticky-end ligation. 
Ligated DNA was transformed into competent cells after the ligation reaction. 
 
2.2.2.6 Site-directed mutagenesis 
 
This protocol is based on Quickchange® Site-Directed Mutagenesis Kit (Stratagene) with 
modifications.  The strategy is used to make point mutations, switch amino acids, and delete or 
insert single or multiple amino acids. The general procedure utilizes a supercoiled double-
stranded DNA vector with insert of interest and two synthetic primers containing the desired 
mutation. The mutagenic oligonucleotide primers were designed according to recommended 
instructions. The mutagenesis PCR reaction was prepared as indicated above (see section 
2.2.2.5.6). The cycling parameters for the mutagenesis PCR was shown in Table 2.3. The cycle 
number was adjusted based on the type of desired mutation (Table 2.4). To each amplification 
reaction 1μl of DpnI restriction enzyme (10U/μl) was added, which is used to disgest the 
parental DNA template, and then incubate overnight at 37°C. For each sample, an aliquot of 
100μl DH5α competent cells was added to a prechilled tube with 1μl of the DpnI treated DNA.  
 
 
Segment  Cycles Temperature Time 
1 
2 
1 
12-18 
95 
95 
55 
68 
30 sec 
30 sec 
1 min 
1 min/kb of plamid length 
 
 
 
 
Type of mutation desired Number of cycles 
Point mutations 12 
Single amino acid changes 16 
Multiple amino acid deletions or inserions 18 
 
Table 2.3 The cycling parameters for the mutagenesis PCR 
Table 2.4 The cycle number was adjusted based on the type 
of desired mutation 
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The transformation reaction was carried out (see section 2.2.1.2). The colonies were further 
confirmed by nucleic acid sequencing. 
 
2.2.3 Working with RNA 
 
2.2.3.1 Isolation of total RNA from mammalian cells 
 
To prevent contamination of RNase, gloves were worn and RNase-free tubes, filter pipette tips, 
glassware and solutions were used. Eukaryotic HEK293 cells with or without transfection were 
washed twice with PBS. Cells from one 10cm2 dish were directly lysed in 1ml TriFastTM 
solution for 5 minutes by gently pipetting up and down. The lysate was transferred to a new 
tube, and kept at RT for 5 minutes. The lysate was shaken by hand vigorously after addition of 
0.2ml of chloroform for 15 seconds and kept at RT for 5-10 minutes.  Then the samples were 
clarified at 11,000rpm for 5 minutes at RT. The colorless upper aqueous phase was transferred 
to a new tube. The RNA was precipitated with 0.5ml isopropanol and kept on ice for 10 
minutes. The RNA pellet was formed by centrifugation at 11,000rpm for 10 minutes at 4°C. 
The pellet was then washed twice with 1ml 75% ethanol by centrifugation at 9,000rpm for 8 
minutes at 4°C and air-dried  about 10-15 minutes in a clean space. The dried pellet was 
dissolved in 40µl DEPC-H2O. 
 
2.2.3.2 Measurement of RNA concentration 
 
The concentration of RNA of a given sample was calculated depending on the ratio of  
OD260nm/OD280nm measured with a spectrophotometer. Pure RNA should have an 
OD260nm/OD280nm ratio of approximately 2.0. An OD260nm/OD280nm smaller than 2.0 indicated 
that the samples is contaminated with proteins and aromatic substances. The concentration of 
RNA was calculated based on the OD260nm with the following formula: RNA concentration 
(µg/ml) = OD260nm × 40 ×dilution factor 
 
2.2.3.3 cDNA synthesis from total RNA by reverse transcription 
 
Reverse transcription was employed to convert mRNAs into cDNAs by using reverse 
transcriptase and random hexamers. The components of reverse transcription reaction were  
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mixed (Table 2.5). The mixture was first incubated at RT for 10 minutes for extension of the 
hexameric primers by reverse transcriptase, and then incubated at 42°C for 15 minutes and the 
reaction was terminated by incubation at 99°C for 5 minutes. Finally, the mixture was kept at 
5°C. 
 
10× Reaction buffer 2.0µl 
MgCl2  (25mM) 4.0µl 
dNTPs (25mM) 2.0µl each 
Random Hexamers (50µM) 1.0µl 
RNase Inhibitor (20U/µl) 1.0µl 
DEPC-ddH2O 2.0µl 
Total RNA (1µg/µl) 1.0µl 
MuLV reverse transcriptase (50U/µl) 1.0µl 
Total volume 20µl 
 
 
2.2.3.4  PCR amplification 
 
PCR was used to amplify a segment of DNA of a known sequence with gene-specific primers. 
A repetitive series of cycles involving template denaturation, primer annealing, and extension 
of the annealed primers by the polymerase leads to exponential accumulation of a specific 
DNA fragment. The ends of the fragment are defined by the 5’ ends of the primers. Basically, 
PCR reaction mixture contains 1.0μl cDNA from reverse transcription, dNTPs, two appropriate 
synthesized primers, Taq polymerase (instead of Pfu polymerase), and reaction buffer (see 
2.2.2.5.6). The mixture was first denatured for 2 minutes at 95°C followed by cycles (Table 
2.6). The PCR reaction was loaded on an agarose gel, and visualized under the UV light 
resourse. 
 
 
denaturation 30 second 95°C 
annealing 20 second 55-65°C 
extension 30 second 72°C 
cycles 25-35  
final extension 10 minutes 72°C 
cool to 4°C   
 
Table 2.5 standard reverse transcription reaction mixture 
Table 2.6 standard protocol for PCR reaction 
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2.2.4 Working with eukaryotic cells  
 
2.2.4.1 Cell culture 
 
Cells were cultured in the complete culture medium containing Dulbecco modified Eagle 
medium (DMEM) supplemented with 10% FCS, penicillin (100U/ml), and streptomycin 
(100µg/ml) at 37°C, 5% CO2. Adherent cells were passaged by trypsinization. The medium in 
culture dishes was aspirated and discarded. Cells were washed twice with PBS by pipetting 
onto the side of the plate. Afterwards, 1-2ml Trypsin/EDTA solution was added and swirled to 
cover the whole dish. Cells were incubated at 37°C until they were fully trypsinized. Cells were 
detached from the bottom of dishes by flicking the plate. DMEM culture medium was then 
added and cell clumps were dispersed into single cells by gently pipetting. The cell number was 
counted using a blood cell counting chamber. Afterwards, cells were diluted to a desired 
density and split into new dishes. 
 
10× PBS:   100mM Na2HPO4· 2H2O 
17mM KH2PO4 
1.37M NaCl 
27mM KCl 
pH 7.4, autoclaved 
 
Trypsin/EDTA: 
 
A    6mM Na2HPO4· 2H2O 
    1mM KH2PO4 
    137mM NaCl 
    2.7mM KCl 
    3mM EDTA 
    0.125% (w/v) trypsin (Bovine Pancreas) 
    pH 7.0, prepared in 3/4 of the final volume  
 
B    0.6mM CaCl2 
    0.4mM MgSO4 
    prepared in 1/5 of the final volume 
mix A and B and fill up to the final volume with ddH2O, sterilized by filtration and stored at -20°C 
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2.2.4.2. Freezing, thawing and storage of eukaryotic cells 
 
Cells grow at least to 80% confluence for freezing preservation. Adherent cells were suspended 
by trypsinization and were collected by centrifugation at 500-1000g for 5 minutes. The cell 
pellet was resuspended in 2ml fresh DMEM medium and dispensed as 0.8ml aliquots into 
Cryotube vials. To each tube, 0.8ml DMSO frozen medium was slowly added. The cell 
suspension was gently mixed by inversion of tubes. The cell aliquots were then placed into a 
Cryo 1°C freezing container and were placed in -80°C overnight. The next day, the cells were 
stored in liquid nitrogen. For thawing cells, frozen aliquots were removed from liquid nitrogen 
and thawed immediately at 37°C water bath. The cell suspension was then transferred into 
tissue culture dishes containing 20ml of fresh complete DMEM medium at an appropriate cell 
density. The next day, the medium had to be refreshed with pre-warmed DMEM medium. 
 
Frozen medium:   15% DMSO 
40% FCS 
45% DMEM medium 
 
2.2.4.3. Transfection of DNA into mammalian cells 
 
2.2.4.3.1 Calcium phosphate transfection 
Cells were seeded out in 6-well or 10cm tissue culture dishes at a density such that 50-70% 
confluence could be reached for transfection. Calcium phosphate precipitation of plasmid DNA 
(Wigler et al., 1978) was prepared in Eppendorf tubes (Table 2.7).  
  
 
 
Components 6-well 10 cm 
DNA (1μg/μl) 5.4μl 20-30μl 
10×HEBS 21.6μl 125μl 
ddH2O 178.2μl 1042.5/1032.5μl 
2M CaCl2 
Total volume 
10.8μl 
216μl 
62.5μl 
1250μl 
 
 
DNA was well mixed with 10× HEBS and ddH2O. 2M CaCl2 was then added and the whole 
mixture was immediately vortexed for 10secs and incubated at RT for 10-15 minutes. Finally,  
 
Table 2.7 standard transfection reaction mixture 
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the mixture was dropped onto the cells. 24 hours after transfection, cells were washed twice 
with PBS and fresh culture medium was added. 
 
10× HEBS:   1.37M NaCl 
0.06M glucose 
0.05M KCl 
0.007M Na2HPO4 
0.2M HEPES 
pH 7.2 adjusted with NaOH, sterilized by filtration and  
aliquots were stored at -20°C 
 
2.2.4.3.2  jetPEI transfection 
jetPEITM (Polyplus) is a cationic polymer transfection reagent that ensures effective and 
reproducible transfection with low toxicity. jetPEITM was employed according to 
manufacturer’s instructions. 
 
2.2.4.3.3 Luciferase reporter assay 
For luciferase reporter assay, about 2×105 cells were seeded into each well of a 6-well plates 24 
hours prior to transfection and then transfected using the CaPO4 method as described above. 
Each transfection contained 5.4µg of total plasmid DNA, includuing 0.25µg of 4×UAS-TK-
luciferase reporter plasmid, 0.05µg of pCMV-lacZ encoding β-galactosidase and varying 
amounts of expression plasmids Gal, Gal-hp66α, Gal-hp66β. Cells were harvested 48 hours 
after transfection by addition of 200μl lysis buffer after removal of old medium and washing 
with 1×PBS buffer twice in each well. The reaction was incubated at RT for 15 minutes. The 
cell lysate was then transferred to a new tube, and kept on ice. 5-20μl of cell lysate was taken 
together with 100μl luciferin buffer for assay on luminometer. The luciferase activity was 
expressed as relative light units per second (RLU/s). In addition, transfection efficiency was 
normalized to β–galactosidase activity. 5-10μl of cell lysate was taken together with 0.8ml Z-
buffer and 0.2ml ONPG solution (4mg/ml in Z-buffer) and the mixture was incubated at 30°C 
until the color of mixture turned out light yellow. The β–galactosidase activity was measured 
on spectrophotometer with absorbance at 420nm. The results are the average of at least two 
independent transfection experiments. 
 
Lysis buffer:                     50mM Tris/Ac, pH 7.8 
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10mM MgAc 
0.1mM EDTA 
10% Triton X-100 
15% glycerol 
sotered at -20°C, freshly added 0.1mM PMSF and 1mM DTT 
 
Luciferin buffer:  360μM Luciferin (5mg) 
1mM ATP  
50mM Tris/Ac, pH 7.8 
400μM Coenzyme A 
 fill up to 50ml, stored at -20°C 
 
Z-buffer:   60mM Na2HPO4.2H2O 
40mM NaH2PO4.H2O 
10mM KCl 
1mM MgSO4.7H2O 
 pH 7.0 adjust with HCl, autoclaved, stored at -20°C 
 
2.2.4.4. Establishment of stably transfected HEK293 cell lines 
 
Basically, the stable cell lines is that the transfected DNA is integrated into chromosomal  DNA, 
and can be distinguished by using selectable markers (usually an eukaryotic antibiotic-resistance 
gene). Several expression plasmids were created for generation of stable cell lines, such as 
pcDNA3-FLAG-hp66α/β-CBP which contain FLAG tag, CBP tag and neomycin-resistance gene. 
In addition, pcDNA3-FLAG-CBP was used to generate control stable cell lines. Prior to selection 
with G418, it is important to titrate with selection antibiotics, for example G418, to determine the 
optimal concentration for selection with particular cell line being tested. For selecting the optimal 
concentration of antibiotics, it is recommended to use the minimum concentration that starts to 
give maximum cell death in 5 days and kills all the cells within two weeks. In this study, we 
found that the optimal concentration of G418 is 1.5mg/ml in HEK293 cells. HEK293 cells were 
grown in 6-well plates, and transfected with 1.0µg pcDNA3-FLAG-CBP, pcDNA3-FLAG-
hp66α-CBP or pcDNA3-FLAG-hp66β-CBP constructs by using calcium phosphate transfection. 
Cells were transferred to DMEM medium containing 1.5mg/ml G418 48 hours after transfection. 
The DMEM medium containing 1.5mg/ml G418 was refreshed every 3 days until individual 
colonies appeared. Cell colonies were then picked and expanded individually. The stable cell 
colonies were identified by RT-PCR using specific primers (see section 2.2.3) and by Western  
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blotting using FLAG antibody (see section 2.2.5.2), and were prepared frozen aliquots to be a 
reusable source of cells.  
 
2.2.4.5. Cellular fractionations 
 
2.2.4.5.1  Preparation of whole cell extract 
Whole cell extract was prepared by lysing cells in lysis buffer. Cells were washed twice with 
PBS. Lysis buffer (106-107 cells/ml) was then added, and the cells were incubated at 4°C for 
15-30 minutes on a shaker. The cells were scraped and collected. The cell suspension was 
centrifuged at 12,000rpm for 15 minutes at 4°C. The supernatant was transferred to a prechilled 
tube. 10% glycerol was added and aliquots of the whole cell extract  were stored at -70°C, if the 
supernatant was not to be used immediately. For immediate use, the whole cell extract was kept 
on ice, and Roti-Load 1 solution (Roth) was added. The samples were then boiled for 5 minutes 
to denature proteins and were ready for Western blotting analysis.  
 
Lysis buffer:   50mM Tris HCl, pH 7.4 
150mM NaCl 
1mM EDTA 
1% Triton X-100 
 
2.2.4.5.2  Nuclear protein extraction 
Nuclear extracts were prepared as described previously with modification (Standke et al., 1994). 
Briefly, the cells with or without transfection were washed twice with PBS, and trypsinized 
with trypsin. The cells were then harvested after adding DMEM medium, and centrifuged at 
3000rpm for 3 minutes at 4°C. Afterwards, the cell pellet was resuspended in 3 volumes of 
buffer A, and incubated on ice for 7 minutes. After centrifugation at 5600rpm for 10 minutes at 
4°C, the supernatant (cytoplasmic fraction) was transferred into a new tube for later use. The 
remaining nuclear pellet were resuspended in 2 volumes buffer B, followed by incubation for 
40  minutes at 4°C on a rotator. The lysate was centrifuged at 14000rpm for 10 minutes at 4°C 
and the supernatant that is nuclear extract was transferred into a new tube. The nuclear extract 
was diluted with 2 volumes of Buffer C, and kept at -20 °C. 
 
Buffer A:   20mM HEPES, pH 7.9 
10% glycerol 
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1mM EDTA 
10mM KCl 
0.2% Nonidet P-40 
freshly added 0.1mM PMSF and 1mM DTT 
 
Buffer B:   20mM HEPES, pH 7.9 
420mM NaCl 
1mM EDTA 
10mM KCl 
freshly added 0.1mM PMSF 
          
Buffer C:   20mM HEPES, pH 7.9 
10mM KCl 
1mM EDTA 
 
2.2.4.5.3  Measurement of protein concentrantion 
Bradford Assay (Bradford, 1976) is a rapid and accurate method commonly used to determine 
the total protein concentration of a sample. The method is based on the observation that the 
absorbance maximum for an acidic solution of Coomassie Brilliant Blue G-250 shifts from 
465nm to 595 nm when binding to protein occurs. Within the linear range of the assay (~5-25 
mg/ml), the more protein present, the more Coomassie bind.  The concentration of given 
samples were measured by mixing 1-5 µl proteins extract with 800 µl 0.25 M Tris/HCl (pH 7.8) 
and 200 µl Roti-Quant (Roth). Then the mixture was incubated for 5 minutes at RT. The 
absorbance was read in the photometer at 595nm, and the concentration was caculated with the 
following formula: protein concentration (µg/μl) = OD595nm × 19.89 (μg) / volume of protein 
extract (μl). 
 
2.2.5 Preparation and analysis of proteins 
 
2.2.5.1. Protein precipitation with TCA 
 
The whole procedure was carried out at 4°C. 100μg samples were diluted to 300μl volume with 
water, and 100μl ice-cold 80% TCA was added. The mixture was vortexed briefly, and 
incubated on ice for 20 minutes.  The mixture was spun at 14000 rpm for 5 minutes in a 
microfuge and the protein pellet at the bottom was generally visible. The supernatant was 
carefully removed without disturbing the pellet. Afterwards, 500µl ice-cold aceton was added  
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and the protein pellet was recovered by centrifugation at 14000rpm for 5 minutes. This step 
was repeated two times. The pellet was air-dried for 10-15 minutes and dissolved in the 
appropriate buffer. If the color of sample turns into yellow, add 1-5 drops of 1M NaOH until 
the color of sample turns into blue again.  
 
2.2.5.2. SDS polyacrylamide gel electrophoresis and Western blotting analysis 
 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) was carried out as described from 
Laemmli (Laemmli, 1970)on acrylamide slab gels. The glass plate sandwich mold were 
assembled according to the manufacturer’s instruction using 1mm thick spacers. Acrylamide 
gels was prepared (Table 2.8).  
 
 
Separating gel  7.5% 10% 12% 
ddH2O 5.0ml 4.1ml 3.5ml 
1.5M Tris-HCl, pH 8.8 2.5ml 2.5ml 2.5ml 
Acrylamide/Bis (30/0.8, 37.5:1) 2.5ml 3.4ml 4.0ml 
10% (w/v) SDS 100µl 
40% (w/v) APS 30µl 
TEMED 20µl 
 
Stacking gel 5% 
ddH2O 6.2ml 
0.5 M Tris-HCl, pH 6.8 2.5ml 
Acrylamide/Bis (30/0.8, 37.5:1) 1.3ml 
10% (w/v) SDS 100µl 
40% (w/v) APS 30µl 
TEMED 20µl 
 
Ingredients were mixed gently, and APS and TEMED were added just before pouring the gels. 
The separating gel was poured to an appropriate level and the top of gel was slowly covered 
with a layer of ethanol to ensure a flat surface and to exclude air. After the gel was polymerized, 
the ethanol was poured off. The stacking gel was then poured above the separating gel with a 
comb inserted. After the stacking gel was polymerized, the comb was carefully removed and 
the gel slots were rinsed with ddH2O and excessive gel debris were removed. The gel slabs  
Table 2.8 compositions of separating gel and stacking gel  
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were assembled into the electrophoresis chamber and the chamber was filled with Laemmli 
buffer. Protein samlpes were denatured by boiling in SDS-loading buffer or Roti-Load 1 (Roth) 
for 5 minutes. Samples and prestained protein molecular mass markers were loaded and empty 
slots were filled with equal volume loading buffer to prevent spreading of adjoining lanes. For 
electrophoresis, a constant current of 20-25mA/gel was used for stacking gels and 30-35mA/gel 
for separating gels. 
After SDS-PAGE, proteins on the gel were transferred to PVDF membrane using a semi-dry 
blotting system. The transfer sandwich was assembled on the bottom of anode electrode by 
laying, one after the other, 6 pieces of whatman paper (soaked in anode buffer I), 3 pieces of 
whatman paper (soaked in anode buffer II), a piece of PVDF membrane, the gel and 6 pieces of 
whatman paper (soaked in cathode buffer III). Air bubbles were extruded by gentle rolling with 
a glass pipet. Finally, the cathode electrode was placed on top of the transfer sandwich. The 
transfer was performed at a constant current of 1mA/cm2 for 1-2 hours. 
After transfering, membranes were blocked in PBST containing 5-10% non-fat milk at RT for 
at least 2 hours or at 4°C overnight with regular shaking and then incubated with the 
corresponding primary antibodies overnight at 4°C or at RT for 1.5 hour. After 3×10 minutes 
washing with PBST, membranes were incubated with secondary antibodies at RT for 1 hour. 
All the secondary antibodies are coupled to horseradish peroxidase and can be visualized by 
enhanced chemoluminescence (ECL). Membranes were washed 3×10 minutes with PBST after 
the incubation with the secondary antibodies, and ECL solution (Amersham/Millipore) was 
added to membranes according to manufacturer’s instructions. The membranes were then 
sealed in plastic bags. X-ray films were laid over the membrane and different exposure time 
was chosen. Films were finally developed in an X-ray film processor.  
Membranes were stripped in a stripping buffer I at 65°C for 40 minutes or a stripping buffer II 
for 30 minutes at RT with frequently shaking. This strips the bound antibodies from the 
membrane so that it can be re-immunoblotted with different antibodies. After stripping, 
membranes were washed 3× 10 minutes with PBST and were blocked and immunoblotted as 
described above. 
 
SDS-loading buffer:  62.5 mM Tris, pH 6.8 
3% SDS 
2% 2-mercaptoethanol 
0.01% bromophenol blue 
15% glycerol 
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Laemmli buffer:   192mM glycine 
    25mM Tris-base 
    0.1% (w/v) SDS 
    Do not adjust the pH with acid or base 
 
Anode buffer I:   0.3M Tris, pH 10.4 
    10% methanol 
 
Anode buffer II:   25mM Tris, pH 10.4 
    10% methanol 
 
Cathode buffer:   40mM 6-amino-n-caproic acid 
    pH is not adjusted 
 
PBST:    1× PBS 
    0.1% (v/v) Tween® 20 
 
Stripping buffer I:  62.5mM Tris-HCl, pH 6.7 
2% (w/v) SDS 
100mM 2-mercaptoethanol 
 
Stripping buffer II:  25mM glycine, pH 2.0 
1% (w/v) SDS 
 
2.2.5.3. Detection of proteins on the PVDF membrane by Coomassie blue staining 
 
The membranes were incubated in Coomassie staining buffer for 2 minutes and were then 
destained in destaining buffer I for 10 minutes. Afterwards, the membranes were washed in 
destaining buffer II until no background was left. The membranes were then kept in ddH2O or 
air-dried between two pieces of Whatman paper. 
 
Coomassie staining buffer: 0.1% Coomassie brilliant blue R250 
    50% methanol 
    7% acetic acid 
 
Destaining buffer I:  50% methanol 
    7% acetic acid 
 
Destaining buffer II:  90% methanol 
    10% acetic acid 
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2.2.5.4  Mammalian pulldown 
 
HEK293 cells were transiently cotransfected with mammalian expression vectors pCMV-GST, 
pCMV-GST-MBD2/MBD3, pCMV-GST-HDAC1 or pCMV-GST-RbAp46/RbAp48 with Gal, 
Gal-hp66α, four single mutant forms of Gal-hp66α (K30R, K149R, K451R, K487R), Gal-
hp66β or two single mutant forms of Gal-hp66β (K33R, K454R). Cells were collected 48 hours 
after transfection and nuclear extracts were prepared as described above. 400μg of nuclear 
extract was incubated with 40μl glutathione-Sepharose 4B beads (Amersham Biosciences) for 
30 minutes at room temperature. The beads were washed six times with washing buffer NTEN-
100. Bound proteins were eluted with SDS sample buffer, fractionated together with the 
corresponding input fractions on SDS-PAGE and subsequently detected by Western blotting 
using the anti-Gal4 polyclonal IgG antibody. The membranes were stripped as described above. 
Blots were subsequently reprobed with mouse anti-GST polyclonal IgG at a dilution of 1:3000 
and subsequently with horseradish peroxidase-conjugated goat anti-mouse IgG  at a dilution of 
1:10000. The ECLTM kit was used to visualize the proteins on the membrane following the 
manufacturer’s protocol. 
 
NTEN-100:   20mM Tris, pH 8.0 
100mM NaCl 
1mM EDTA 
0.5% Nonidet P-40 
freshly added 1mM DTT 
 
2.2.6 Fluorescence microscopy analysis 
 
2.2.6.1 Cleaning of coverslips 
 
For cleaning, coverslips were immerged in 40% HCl in a glass beaker and were agitated at RT 
for 1 hour. Afterwards, coverslips were washed 15-20 times with distilled water followed by 
acetone. After air-drying on Whatman paper, coverslips were used immediately or stored at RT 
in a sterile tissue culture dish. 
 
2.2.6.2  Fluorescence assay 
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Fluorescence assay was carried out on cells growing on coverslips or microscope slides. 
NIH3T3 cells were cultured to subconfluency on coverslips and transfected with pEGFP-C2, 
pEGFP-hp66α, pEGFP-hp66αK30R, pEGFP-hp66αK487R, pEGFP-hp66β or pEGFP-
hp66βK33R. Transfection of NIH 3T3 cells was performed using jetPEI (Polyplus) according 
to manufacturer’s protocol. Cells (80-90% confluence) were washed with PBS twice 24-48 
hours after transfection. DNA was counter stained with Hoechst 33342 for 10min at 37°C. 
Coverlips were mounted on slides and sealed with nail polish. Images were taken by 
fluorescence microscopy using a 1000-fold magnification. 
 
Hoechst 33342 stock:  5mg/ml Hoechst 33342 in PBS 
0.2µm filter filtration and stored at -20°C 
use 1-5µg/ml as the final concentration. 
 
2.2.6.3  Fluorescence microscopy and image-editing 
 
Fluorescence microscopy was performed with a Zeiss Axiophot fluorescence microscope. 
Filters were selected according to the excitation/emission of the fluorescence dyes used which 
are listed below. Images were edited with Adobe Photoshop software. 
 
GFP    488nm/507nm 
Hoechst 33342   352nm/461nm 
 
2.2.7 Purification of the hp66 proteins complexes  
 
2.2.7.1 Preparation of whole cell extract 
 
The whole cell extract was prepared as described above (see section 2.2.4.5.1), thawn on ice, 
and was ultracentrifuged at 50,000rpm for 2 hours at 4°C. The supernatant was filtered through 
0.22μm filter, and concentrated using Centricon® Ultracel YM-30 membrane (Millipore). The 
total amount of protein is about 20-50mg. The samples were ready for ion-exchange 
chromatography. 
 
2.2.7.2 Ion-exchange chromatography (Mono Q column) 
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Ion-exchange chromatography separates molecules on the basis of their net charge. Mono Q 
column purification was used during this study. Mono Q is a strong anion exchanger based on a 
beaded hydrophilic resin with a particle size of 10μm. Practical protein loading capacity is 
around 20-50mg/column. Large volumes of sample can be applied by a Superloop. A gradient 
volume of 20ml is basically sufficient. A Mono Q HR5/5 (1ml) column was equilibrated with 
anion-exchange solution A and then allowed for the proteins to bind to resin. Non-specifically 
bound proteins were washed with equilibrated solution A (100mM KCl) and the resin bound 
proteins were eluted using salt gradient (from 100mM KCl to 1M KCl)with Buffer B which 
was similar to Buffer A but had 1M KCl. SDS-PAGE analysis of Mono Q eluted fractions  was 
detected with FLAG antibody. 
Briefly, a typical conditions for a separation on a Mono Q HR 5/5 column are as follows:  
 
Column: Mono Q HR 5/5 
Sample volume: 10ml (Superloop) 
Buffer A: anion-exchange solution Acontaining 100mM KCl 
Buffer B: anion-exchange solution A containing 1.0M KCl 
Flow rate: 0.5ml/min 
Gradient: 0-100%B in 20ml 
Detector: UV-M, 280nm 
Chart speed: 0.5cm/min 
 
The method should contain the following steps:  a. The extract was filled in Superloop. b. The 
column was equilibrated with 5 column volumes buffer A. c. The valve was changed to 
 
 
 Volume (ml) Function Value 
0 %B 0 
0 ml/min 1.0 
0 cm/min 0.5 
0 valve position 1.1 
5 port set 6.1 
5 %B 0 
25 %B  100 
30 %B 100 
30 port set 6.0 
Table 2.9 standard program of ion-exchange chromatography 
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 “INJECT” position and sample was applied to column with 5ml buffer A. d. The valve was 
changed to “LOAD” position. e. The linear gradient was run from buffer A to 100% buffer B in 
20ml. f. The column was washed with 5ml buffer B. The general program can be composed 
(Table 2.9). 
 
Anion-exchange solution A: 100mM KCl 
20mM Tris/HCl, pH 7.9 
0.2mM EDTA 
10mM  2-mercaptoethanol  
0.2mM PMSF 
10% glycerol 
Filtered and degas, store at 4°C 
 
Anion-exchange solution B: 1M KCl 
20mM Tris/HCl, pH 7.9 
0.2mM EDTA 
10mM  2-mercaptoethanol  
0.2mM PMSF 
10% glycerol 
Filtered and degas, store at 4°C 
 
2.2.7.3 Gel filtration chromatography (superpose 6) 
 
Further purification was carried out with gel filtration chromatography, which separates 
molecules according to their size. In gel filtration chromatography, fractionation is based on the 
diffusion of molecules into the pores of the resin. Large proteins do not enter the pores of the 
resin as readily, but pass through the fluid volume of a column faster than smaller proteins.  
Proteins that are small enough can fit inside all the pores in the beads and therefore elute last in 
a gel filtration separation. Molecular weight determination of unknown proteins is made by 
comparing the ratio of Ve/Vo for the protein to the Ve/Vo of protein standards of known 
molecular weight (Ve is the elution volume and Vo is the void volume). The Vo of a given 
column is based on the volume of effluent required for the elution of a large molecule such as 
blue dextran. The standard curve was made by separation of a mixture of alcohol 
dehydrogenase (150KDa), apoferritin (443KDa), thyroglobulin (669KDa) on a gel filtration 
column (Superose 6 HR10/30). The Void was determined according to manufactures’s 
guidelines (1/3 of column volume or 7ml). Estimation of the relative molecular weight of  
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protein complexes was based on the elution profile of the standard curve. The running buffer 
was used in this study as follows: 
 
Running buffer:                 200mM KCl 
10mM Hepes, pH 7.5 
1.5mM MgCl2 
10μM ZnCl2  
10% glycerol 
Filtered and degas, store at 4°C 
 
2.2.7.4 Affinity purification with anti-FLAG M2 affinity gel 
 
The anti-FLAG M2 affinity gel was thoroughly suspended in the vial to make a uniform 
suspension of the resin, and 40-60μl of suspension was transferred to a new tube immediately 
using a clean, cut pipette tip. The resin was centrifuged at 6900rpm for 30 seconds at 4°C. The 
supernatant was removed with a narrow-end pipette tip. The packed gel was washed twice with 
0.5-0.8ml TBS buffer, and most of the wash buffer was removed. Then 200-400μl fractions 
from gel filtration was added to the washed resin. If necessary, the final volume was filled up to 
1ml by adding running buffer of gel filtration. The mixture was incubated for 2 hours or 
extended overnight on a roller shaker at 4°C. The next day, the mixture was centrifuged at 
6900rpm for 30 seconds at 4°C and the supernatant was removed. The resin was incubated with 
1ml buffer A for 30 minutes at 4°C on a roller shaker, and then centrifuged at 6900rpm for 30 
seconds. This step was repeated 3 times. Afterwards, the resin was incubated with 1ml buffer B 
for 30 minutes at 4°C on a roller shaker and then centrifuged at 6900rpm for 30 seconds. This 
step was repeated 3 times. Finally, the resin was incubated with 100μl buffer B containing 
200μg/ml 3×FLAG peptide for 3hours at 4°C on a roller shaker and then centrifuged at 
6900rpm for 30 seconds. The supernatant is the eluted fraction, and transferred to a fresh tube. 
Then the eluted fraction was pooled and precipitated with TCA as described above (see section 
2.2.5.1). Finally, these fractions were ready to load on 10% SDS-PAGE. 
 
TBS Buffer:                              50mM Tris/HCl, pH 7.4 
150mM NaCl 
 
Buffer A:                              400mM NaCl 
20mM Hepes, pH 7.9 
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0.2mM EDTA 
0.3% NP-40  
20% glycerol 
freshly added 0.4mM PMSF and protease inhibitor complex 
 
Buffer B:                              500mM NaCl 
20mM Tris/HCl, pH 7.4 
0.1% NP-40  
5% glycerol 
freshly added protease inhibitor complex 
 
FLAG peptide stock solution: 150mM NaCl 
10mM Tris/HCl, pH 7.4 
FLAG peptide was dissolved in stock solution  
to a final concentration of 5mg/ml 
 
2.2.8 Mammalian GST purification 
 
HEK293 cells were transiently transfected with mammalian expression vectors pCMV-GST, 
pCMV-GST-hp66α, pCMV-GST-hp66β, respectively. Cells were collected 48 hours after 
transfection and nuclear extract was prepared as described above. 400μg of nuclear extract was 
incubated with 60μl glutathione-Sepharose 4B beads, which had been equilibrated with NTEN-
200 buffer, for 2 hours at 4°C. The beads were washed six times with washing buffer NTEN-
200. Bound proteins were eluted with Roti Load 1 sample buffer, fractionated together with the 
corresponding input fractions on SDS-PAGE and subsequently analysed by Western blotting 
using the anti-Mi2 antibody. The membranes were stripped as described above. Blots were 
subsequently reprobed with anti-HDAC1/HDAC2, RbAp46/RbAp48, MBD2/MBD3, PRMT5 
antibodies. The ECLTM kit was used to visualize the proteins on the membrane following the 
manufacturer’s protocol. 
 
NTEN-200:   20mM Tris, pH 8.0 
200mM NaCl 
1mM EDTA 
0.5% Nonidet P-40 
freshly added 1mM DTT 
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3  RESULTS 
 
3.1 hp66 mediates repression and interacts with HDAC and MBD2 
 
3.1.1 The transcriptional repression activity of hp66α is stronger than that of hp66β  
 
Previously, two proteins termed hp66α and hp66β were detected as interaction partners of 
MBD2 in a yeast two-hybrid screen and it was shown that hp66β is the p66 components of the 
MeCP1 complex. In addition, both hp66 proteins were identified as transcriptional repressors 
(Brackertz et al., 2002; Feng et al., 2002). The high homology in the amino acid sequences of 
hp66α and hp66β (Brackertz et al., 2002) rises the question whether the transcriptional 
repression activity mediated by hp66α or hp66β proteins is similar as well. In order to asses 
this, the reporter plasmid 4×UAS-TK-Luc, which contains four Gal binding sites upstream of 
the thymidine kinase promoter that drives the luciferase reporter gene, was used in transient 
transfection assay. Cotransfection with the Gal-DNA binding domain fusion constructs Gal-
hp66α and Gal-hp66β resulted in a strong transcriptional repression of the reporter gene in a 
dose dependent manner (Fig.3.1A). More importantly, the transcriptional repression activity of 
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Fig.3.1 The transcriptional repression activity of hp66α is stronger than that of hp66β.
HEK293 cells were cotransfected with a 4×UAS-TK-luciferase reporter together with constructs 
coding for the Gal-DNA binding domain or the indicated Gal fusions hp66α and hp66β. (A) Cell 
extracts were analyzed for reporter gene activity and protein expression 48 hours after transfection. 
Transfection efficiency was normalized with the β–galactosidase assay. Fold repression was 
determined relative to the Gal-DNA binding domain alone. Error bars represent variations within 
duplicate transfections. (B) The relative expression levels of each of the constructs were detected 
by Western blotting using anti-Gal4 antibodies. 
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Gal-hp66β is significantly lower than that of Gal-hp66α. Analysis of the protein expression of 
hp66 proteins was analyzed with anti-Gal antibody by Western blotting demonstrated a relative 
expression similar for both fusion proteins (Fig.3.1B) confirming, that indeed the 
transcriptional repression activity of hp66α is much stronger than that of hp66β.  
 
3.1.2 Identification of  potent repression domains  in hp66α  
 
Based on the protein aligment, deletion constructs representing corresponding domains in both 
hp66 proteins were generated in order to identify possible domains responsible for the 
difference in transcriptional repression activity of hp66α and hp66β. Fusions of these deletion 
constructs to the Gal-DBD and transfection into HEK293 cells together with the Gal-dependent 
luciferase reporter gene identified several domains that mediate gene repression (Fig.3.2A and 
3.2B). The protein expression of both hp66α and hp66β derived proteins was analyzed by 
Western blotting using an anti-Gal antibody, demonstrating that similar amounts of the 
fusionproteins are expressed in all of the transfections (Fig.3.2C). Four domains were 
distinguished in both proteins, the N-terminal region including CR1, a central region between 
CR1 and CR2, the CR2 region, and the C-terminal domain outside of CR2. In general, each 
corresponding domain contributes to the transcriptional repression activity of the full length 
protein. Comparison of hp66α with hp66β revealed that the N-terminal domain including CR1 
as well as the central region mediate similar repression activity. In contrast, the CR2 region as 
well as the C-terminal region differ in repression, with the hp66α domains being about 5-fold 
stronger than the corresponding hp66β domains. For p66α in details, the central region between 
CR1 and CR2 has only little effect on transcriptional repression activity of hp66α, whereas the 
N-terminal region, the CR2 domain and the C-terminal part outside of CR2 contributed to 
about 20%, 35%, 30% transcriptional repression activity of full length hp66α, respectively. 
Further results showed that the transcriptional repression activity of C-terminal region 
including CR2 possesses about half of the transcriptional repression activity of full length 
hp66α. In the case of hp66β, the N-terminal region including CR1 domain contributes to 70% 
transcriptional repression activity of full length hp66β. In summary, the major repression 
domains of hp66α are within the C-terminus including CR2, and within the N-terminus 
including CR1, which together mediate the full transcriptional repression activity of hp66α. In 
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Fig.3.2 Identification of potent repression domains in hp66 proteins. HEK293 cells were 
cotransfected with a 4×UAS-TK-luciferase reporter together with vectors coding for the Gal-DNA 
binding domain or the indicated Gal-hp66α/Gal-hp66β fusion constructs. Cell extracts were 
analyzed for reporter gene activity and protein expression. (A and B) Schematic overview of the 
Gal-hp66α/Gal-p66β deletion constructs and reporter gene activity expressed as fold repression as 
in Fig.1. (C) The relative expression levels of each of the constructs were detected by Western 
blotting using anti-Gal4 antibodies. 
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contrast, only the N-terminus in hp66β shows a comparable activity to the corresponding 
region of hp66α, whereas the C-terminus of hp66β is about 5-fold less active as compared to 
this region of hp66α. The data indicated that the N-terminal part is major repression domain of 
hp66β, which is consistent with previous data (Feng et al., 2002) and shows, that the region 
responsible for the increased repression by hp66α is located in the C-terminus of the protein. 
 
3.1.3 The transcriptional repression activity of hp66α is partially dependent on histone 
deacetylase activity 
 
It has previously been shown that p66β-mediated transcriptional repression is partially 
dependent on histone deacetylation (Feng et al., 2002). Therefore, possibly the transcriptional 
repression mediated by hp66α involves histone deacetylase activity as well. To test this 
assumption the transcriptional activity of wild type Gal-hp66α and Gal-hp66β as well as 
comparable deletion constructs of both Gal-hp66α and Gal-hp66β was analyzed in the presence 
and absence of the histone deacetylase inhibitor TSA. Gal-NCoR and Gal-hp66β was used as a 
positive control (Feng et al., 2002; Polly et al., 2000). As shown in Fig.3.3, the transcriptional 
repression of both Gal-NCoR and Gal-hp66β is partially released by TSA, especially, N-
terminal part of Gal-hp66β shows strong TSA sensitiviy. More importantly, the strong 
transcriptional repression mediated by Gal-hp66α is sensitive to TSA as well, in particular, the 
transcriptional repression of C-terminal part of hp66α is partially released in the presence of 
TSA. This results indicated that histone deacetylase activity contributes to the repressive 
function of the hp66α C-terminus. 
 
3.1.4 Enhancement of MBD2-mediated transcriptional repression is dependent on 
interaction between MBD2 and hp66α 
 
Recent results clearly demonstrated that both hp66α and hp66β are able to enhance MBD2-
mediated transcriptional repression, with the enhancement by hp66α being stronger than that by 
hp66β (Brackertz et al., 2006). Therefore it showed be tested whether this effect is directly 
mediated by the interaction of the both hp66 proteins with MBD2. Previously, a critical amino 
acid sequence (minimal overlapping region) was identified within conserved region 1 (CR1) by  
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GST pulldwon, which is required for the interaction between hp66α protein and MBD2 
(Brackertz et al., 2002).  SUMO (small ubiquitin-like modifiers) has been shown to affect many 
biological processes such as transcription regulation (Hay, 2005). hp66α and hp66β were first  
 
Fig.3.3 The transcriptional repression activity of hp66α is partially dependent on histone 
deacetylase activity. HEK293T cells were cotransfected with a 4×UAS-TK-luciferase reporter 
together with constructs coding for the Gal-DNA binding domain or the indicated Gal fusions in 
the presence or absence of TSA. Cell extracts were analyzed for reporter gene activity. Gal-NCoR 
is a positive control for TSA sensitive repression (Polly et al., 2000). Fold repression was 
determined relative to the Gal-DNA binding domain alone. Error bars represent variations within 
duplicate transfections. 
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examined for the SUMOylation consensus sequence ψKXE, where ψ represents a large 
hydrophobic amino acid, most frequently isoleucine or valine, K (lysine) is the SUMO acceptor 
site, and X represents any amino acid (Rodriguez et al., 2001). Inspection of the amino acid 
sequence of hp66α and hp66β revealed four potential SUMO modification sites at Lys-30, Lys-
149, Lys-451 and Lys-487 in case of hp66α, and two potential SUMO modification sites at 
Lys-33 and Lys-454 in   case of hp66β (Table 3.1).  
 
The SUMOylation consensus site Lys-149 (K149) can not be SUMOylated in hp66α (see 
section 3.2.1), and K149 is not present in hp66β. To further investigate the interation of hp66α 
and MBD2, the eukaryotic expression vector pCMV-GST or pCMV-GST-MBD2 was 
cotransfected with Gal, Gal-hp66α, Gal-hp66β or their respective mutants (lysine mutated into 
arginine) (Fig.3.4A and 3.4B) into HEK293 cells and nuclear extract was bound to glutathione-
Sepharose beads. Coprecipitated proteins were detected via western blotting using an antibody 
directed against Gal-DBD. The results clearly revealed that GST-MBD2 retains wild type Gal- 
hp66α and most of the mutant forms with one exception: Gal-hp66αK149R. Since all mutant 
forms as well as wild type Gal-hp66α are similarly expressed in these cells, this indicates that 
the interaction of MBD2 with hp66α requires an intact site K149 within hp66α. In addition, the 
GST-MBD2 containing sample retains Gal-hp66β and all single mutant forms (Fig.3.4B), 
which indicated that mutation of the SUMO modification sites (see section 3.2.1) does not 
influence MBD2 binding to hp66β. Since hp66α is able to enhance MBD2-meidiated 
transcription repression, the consequence of point mutant hp66αK149R (lysine mutated into 
arginine) in MBD2-mediated transcriptional repression was further investigated. Hela cells  
No. Pos. Group Score 
1 K33 VLAKR LKME GHEAM 0.94 
2 K454 NQKKA LKAE HTNRL 0.91 
3 K432 DFTPH WKQE KNGKIL 0.64 
No. Pos. Group Score 
1 K30 VESKK IKME RGLLA 0.94 
2 K149 RMIKQ LKEE LRLEE 0.91 
3 K451 NQKKA LKVE HTSRL 0.91 
4 K487 TAPAQ AKAE PTAAP 0.80 
5 K367 LEIPP PKPP APEMN 0.50 
  hp66α SUMOylation prediction sites 
hp66β SUMOylation prediction sites  
  Table 3.1 Potential SUMOylation sites of both hp66 proteins 
Red value indicates motifs with high probability for SUMOylation  
(SUMOplot™ Prediction program)
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were cotransfected with the Gal-DNA binding domain, or Gal-MBD2b and increasing amounts 
of hp66α or hp66αK149R and an appropriate luciferase reporter.  The mutant hp66αK149R  
 
        
 
         
 
 
pCMV-GST + – + – – – 
pCMV-GST-MBD2b – + – + + + 
Gal + + – – – – 
Gal-hp66β – – + + – – 
Gal-hp66β-K33R – – – – + – 
Gal-hp66β-K454R – – – – – + 
αGST 
αGal 
purified
input
Fig.3.4B SUMO modification sites does not influence hp66β binding to MBD2. HEK293 cells 
were harvested 48hours after transfection with various combinations of DNA constructs, as 
indicated above the figure. Nuclear protein fraction was prepared and purified with glutathione-
Sepharose beads. Bound protein (purified) together with the input fractions were analyzed via 
western blotting using the anti-Gal antibody compared to input, which was analyzed with the anti-
GST antibody as well. 
B 
pCMV-GST + – + – – – – – 
pCMV-GST-MBD2b – + – + + + + + 
Gal + + – – – – – – 
Gal-hp66α – – + + – – – – 
Gal-hp66α-K30R – – – – + – – – 
Gal-hp66α-K149R – – – – – + – – 
Gal-hp66α-K451R – – – – – – + – 
Gal-hp66α-K487R – – – – – – – + 
αGST 
αGal 
purified
input 
Fig.3.4A K149 of hp66α is required for the MBD2 interaction. HEK293 cells were harvested 
48hours after transfection with various combinations of DNA constructs, as indicated above the 
figure. Nuclear protein extract was prepared (input) and purified with glutathione-Sepharose beads. 
The bound protein together with the input fractions were analyzed by western blotting using the 
anti-Gal antibody compared to input, which was analyzed with the anti-GST antibody as well. 
A 
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protein is not able to enhance MBD2-mediated transcriptional repression as observed by the the 
wild type site (Fig.3.4C). Thus the interaction of MBD2 and hp66α, in particular via K149, is 
essential for the functional enhancement of MBD2-mediated transcriptional repression.  
However, by using wild type MBD2+/+ mouse fibroblast cells or MBD2-/- mouse fibroblast cells 
which MBD2 has been knocked out, both hp66 proteins still maintain their ability to repress 
transcription, even in an MBD2-/- environment (Brackertz et al., 2006). To further investigate 
the influence of MBD2 on hp66 paralogs-mediated transcriptional repression, endogenous 
MBD2 was knocked down by using RNAi, and the effect on hp66 paralogs-mediated 
transcriptional repression was subsequently analyzed. pSilencer vector such as pSil-MBD2X 
was generated, which can drive shRNA procedure with targeting sequences identified in target 
genes in this study. Hela cells were either transfected with pSil-MBD2X or a non-targeting 
control (pSil-neg) and MBD2 protein expression was analyzed by Western blotting using 
MBD2 antibody. As shown in Fig.3.4D, the expression of MBD2 protein was significantly 
reduced 96hours after RNAi treatment. Since suitable condition for MBD2 knockdown was 
established, Hela cells were cotransfected with vectors expressing the Gal-DNA binding 
domain, Gal fusions of hp66 proteins, and pSil-MBD2X, pSil-neg. Fig.3.4E demonstrated that 
both Gal-hp66β and Gal-hp66α are still able to repress transcription after knockdown of MBD2, 
with hp66β-mediated transcriptional repression also being about 2-fold lower as compared with 
hp66α-mediated transcriptional repression. MBD2 is therefore not essential for the repression  
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Fig.3.4C K149R mutant of hp66α decreases MBD2-mediated repression. Hela cells were 
cotransfected with a 4×UAS tk luciferase reporter together with vectors expressing the Gal-DNA 
binding domain, or Gal-MBD2b and increasing amount of pSG5-hp66α or pSG5-hp66αK149R. 
Fold repression was determined relative to the Gal-DNA binding domain.  
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by either Gal-hp66α or Gal-hp66β, and thus does not function as a downstream factor for hp66 
paralogs-mediated transcriptional repression. Rather, in case of wildtype hp66, MBD2 may act 
to target p66 to DNA. 
        
 
3.1.5 Nuclear distribution of hp66α depends on MBD2 
 
Previously, hp66α and hp66β were identified as interaction partners with MBD2, which is 
thought to recruit the Mi-2/NuRD complex to methylated DNA (Brackertz et al., 2002). Further 
results revealed that nuclear distribution of both hp66 proteins is dependent on MBD2 and 
conserved region 2 (CR2) (Brackertz et al., 2006). The CR1 domain of hp66α and hp66β have 
already been shown to interact with MBD2 and a point mutation within the CR1 domain of  
Fig.3.4 Knockdown of endogenous MBD2 does not affect hp66α or hp66β-mediated 
transcriptional repression. (D) Endogenous expression of MBD2 is reduced 96hours after RNAi 
treatment. Hela cells were transfected with either pSil-MBD2X or a non-targeting control (pSil-
neg). Nuclear extract was prepared and detected by Western blotting using the MBD2 antibody. (E) 
Both hp66 paralogs-mediated transcriptional repression are independent of MBD2. Hela cells were 
transfected with the pSilencer constructs together with the Gal or Gal-hp66 paralogs constructs 
with a 4×UAS-TK-luciferase reporter. Cell extracts were analyzed for reporter gene activity. 
Transfection efficiency was normalized with the β–galactosidase assay. Fold repression was 
determined relative to the Gal-DBD alone. Error bars represent variations within duplicate 
transfections.
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hp66α (hp66α K149R) disrupts MBD2-binding (see above). Therefore, the mutant 
hp66αK149R fused to EGFP was used to analyze the MBD2-dependent nuclear distribution of 
the protein. The nuclear localization of EGFP-hp66α and EGFP-hp66αK149R was tested in 
NIH 3T3 cells. EGFP-hp66α shows a speckled distribution in the nucleus, whereas 
EGFP-hp66αK149R leads to overall loss of the speckled pattern and displays a diffuse nuclear 
localization (Fig.3.5). Taken together, the results suggest that the interaction with MBD2 via 
the K149 site of the CR1 domain determins the nuclear distribution of hp66α. 
 
 
3.2 SUMO modification enhances hp66-mediated transcriptional repression of 
the Mi-2/NuRD complex 
 
3.2.1 hp66α and hp66β can be SUMOylated in vivo 
 
SUMO (small ubiquitin like modifier) has been shown to modify the function of target proteins 
upon covalent binding. Here, I tested whether both hp66 proteins could be SUMOylated. As 
described in Table 3.1, there are four potential SUMO modification sites at K30, K149, K451 
and K487 within hp66α, and two potential SUMO modification sites at K33 and K454 within 
hp66β.  
To examine whether hp66α and hp66β can be SUMOylated in vivo, HEK293T cells were 
cotransfected with Gal-hp66α or Gal-hp66β in the presence or absence of pcDNA3-FLAG-
SUMO1 and pcDNA3-HA-Ubc9 (expressing the E2 conjugating enzyme). Expression of either  
EGFP 
EGFP-hp66α 
EGFP-hp66αK149R 
Fig.3.5 Nuclear distribution of hp66α depends on K149 site of CR1 domain. NIH3T3 cells 
were transfected with the indicated EGFP-fused hp66 proteins. Phase contrast (left column) and 
fluorescent images were taken 24-48 hours post transfection after incubation with “Hoechst DNA 
stain” (center column). pEGFP-hp66α revealed similar nuclear speckle patterns, whereas 
pEGFP-hp66αK149R lead to diffuse pattern(right column). EGFP control expression resulted in 
a diffuse whole cell distribution. 
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or both proteins has been used in several cases to detect SUMOylated proteins in vivo. Gal 
fused hp66 was used in order to to generate mutants which can be distinguished functionally 
from endogenous wild type hp66. SDS-PAGE separation and Western blotting using anti-Gal 
antibody detected SUMOylation of hp66α and hp66β. Various bands of presumably 
SUMOylated proteins in whole cell extract are seen (Fig.3.6A, arrow). Therefore, all future 
experiments were performed with nuclear extract. Again, Western blotting using anti-Gal 
antibody detected Gal-hp66 proteins as well as a higher band presumably corresponding to 
SUMO-modified hp66α or hp66β when FLAG-SUMO1 and HA-Ubc9 were overexpressed 
(Fig.3.6B and 3.6C, arrow).  
 
         
 
To verify the involvement of SUMO1 Gly-97, the essential amino acid of SUMO1 required to  
  G
al
 
G
al
 
G
al
-h
p6
6α
 
G
al
-h
p6
6α
 
G
al
-h
p6
6α
K
 
30
R
K
14
9R
 
G
al
-h
p6
6α
K
 
14
9R
K
45
1R
 
G
al
-h
p6
6α
K
 
30
R
k1
49
R
K
45
1R
K
48
7R
 
FLAG-SUMO1 – – + – + + + + 
HA-Ubc9 – – + – + + + + 
  G
al
 
G
al
 
G
al
-h
p6
6β
 
G
al
-h
p6
6β
 
G
al
-h
p6
6β
 
K
 3
3R
 
G
al
-h
p6
6β
 
K
45
4R
 
G
al
-h
p6
6β
K
 
33
R
k4
54
R
 
FLAG-SUMO1 – – + – + + + + 
HA-Ubc9 – – + – + + + + 
Fig.3.6 hp66α and hp66β can be SUMOylated in vivo. HEK293T cells were cotransfected with
vectors expressing the indicated Gal fusions together with vectors for FLAG-SUMO1, HA-Ubc9. 
After 48h, equal amounts of whole cell extracts were separated by SDS-PAGE and analyzed by 
Western blotting using an anti-Gal antibody. The position of the non-SUMOylated (dot) and of the
SUMOylated form (arrow) of hp66α or hp66β is indicated. 
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conjugate to substrates (Kim et al., 2000; Schwienhorst et al., 2000), was mutated to alanine (A)  
via mutagenesis PCR. HEK293T cells were cotransfected with FLAG-SUMO1G97A and Gal- 
hp66α or Gal-hp66β in the presence of HA-Ubc9. As expected, no higher band was 
detected(Fig.3.6B and 3.6E), confirming that hp66α and hp66β are specifically conjugated by 
SUMO-1. To further confirm the SUMOylation pathway, I generated a dominant negative-
Ubc9 (DN-Ubc9) by mutating Cys-93 of Ubc9, that has previously been shown to efficiently 
inhibit SUMO1 conjugation (Bernier-Villamor et al., 2002; Lin et al., 2002). Cotransfection of 
DN-Ubc9 with Gal-hp66α or Gal-hp66β in the presence of FLAG-SUMO1 resulted in the loss 
of the higher band (Fig. 3.6B and 3.6C). To identify one or several target sites for 
SUMOylation I mutated all SUMO consensus sites individually or in combination. In case of 
hp66α, the mutant form K30R or K487R or any combination including one of these two sites 
reduces SUMOylation to below detectable levels (Fig.3.6D). Thus K30 and K487 are the major 
SUMOylation target sites within hp66α. Apparently both sites synergize in SUMOylation since 
mutation of a single site alone reduces SUMOylation dramatically. Analysis of the two 
consensus sites of hp66β by testing the K33R or K451R mutants individually clearly showed 
that a single SUMOylation site at Lys-33 could be detected (Fig.3.6E). Despite the presence of 
two SUMOylation sites in hp66α and a single site in hp66β, migration of the SUMOylated 
wild type forms seems to be similar, suggesting that only a single site is modified at a time.  
 
To test SUMOylation in the absence of overexpressed components one has to purify hp66 to 
visualize any small SUMOylated fraction. It has been shown in many cases that only a fraction 
of the substrate is modified although the bulk of the substrate is functionally changed (Hay, 
2005). Since there was no commercially hp66 antibodies for immunoprecipitation, I generated 
stable cell lines which stably express low amounts of FLAG tagged hp66 proteins. Several 
colonies such as clone 54 (pcDNA3-FLAG-CBP), clone 29 (pcDNA3-FLAG-hp66α-CBP), or 
clone 87 (pcDNA3-FLAG-hp66β-CBP), were identified by RT-PCR and Western blotting (see 
section 3.3.2). There is no significant difference in the amount of hp66 proteins (Fig.3.6F, input) 
as compared to endogenous hp66 proteins (Ctrl). Despite the fact that clones C29 and C87 
clearly express FLAG-hp66α or FLAG- hp66β. Nuclear extracts were immunoprecipitated 
with the FLAG M2 agarose gel, and the resulting elution fractions were subjected to Western 
blotting with anti-FLAG anitibody and anti-SUMO1 antibody (Fig.3.6F, IP). As shown in 
Figure 3F, the FLAG antibody detected in addition to the major FLAG-hp66 protein a small 
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fraction with a higher molecular weight in case of the C29 and C87 clones. Using the SUMO1 
antibody the higher molecular weight band was identified to represent the SUMOylated form. 
These results indicated that endogenous hp66α and hp66β are modified by SUMO1 in vivo. 
86 
Fig.3.6 hp66α and hp66β can be SUMOylated in vivo. (B-E) HEK293T cells were cotransfected 
with vectors expressing the indicated Gal fusions together with vectors for FLAG-SUMO1, FLAG-
SUMO1G97A, HA-Ubc9 or HA-DN-Ubc9. After 48h, equal amounts of nuclear extracts were 
separated by SDS-PAGE and analyzed by Western blotting using an anti-Gal antibody. The 
position of the non-SUMOylated (dot) and of the SUMOylated form (arrow) of hp66α or hp66β is
indicated.  
Gal – + – – – 
Gal-hp66β – – + + + 
FLAG-SUMO1 – + – + + 
HA-Ubc9 – + – + – 
HA-DN-Ubc9 – – – – + 
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B C 
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Gal – + – – – – 
Gal-hp66α – – + + + + 
FLAG-SUMO1 – + – + – + 
FLAG-SUMO1G97A – – – – + – 
HA-Ubc9 – + – + + – 
HA-DN-Ubc9 – – – – – + 
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It is generally known that a E3 ligase, for example PIAS1 protein, is able to enhance the 
efficiency of SUMO conjugation to target substrates in vivo (Johnson and Gupta, 2001; Kahyo 
et al., 2001). Therefore I tested Whether SUMO modification of both hp66α and hp66β could 
be enhanced by co-expressing PIAS1 protein. PIAS1 was co-expressed with Gal-hp66α and 
Gal-hp66β constructs in the presence of FLAG-SUMO1 and HA-Ubc9. The results revealed 
that, in the case of hp66α, there are two extra bands in the presence of PIAS1 protein, referred 
to as mono-SUMOylated form and bi-SUMOylated form of hp66α. The data further confirmed 
two major SUMO modification sites within hp66α. However, in the case of hp66β, there is still 
one extra band by co-expressing PIAS1 protein, indicating one major SUMO modification site 
within hp66β (Fig.3.6G and 3.6H).  
 
3.2.2 SUMO modification sites of hp66 proteins are required for maximal repression  
 
Ctrl          C54          C29      C87 
Input 
Ctrl          C54          C29      C87 
IP:α FLAG 
WB: α hp66 
WB: α FLAG 
WB: α SUMO1 
WB: α FLAG 
Fig.3.6 hp66α and hp66β can be SUMOylated in vivo. Nuclear extract was prepared from 293 
cells (Ctrl) and stable cell clones C54 (expressing pcDNA3-FLAG-CBP), C29 (expressing 
pcDNA3-FLAG-hp66α-CBP), and C87 (expressing pcDNA3-FLAG-hp66β-CBP). Extracts (input) 
were analyzed by Western blotting with an antibody against both hp66 paralogous (α hp66) 
showing no major changes in overall p66 amounts even upon expression of the FLAG tagged hp66 
as detected with an antibody against FLAG (α FLAG). After purification with FLAG M2 gel and 
elution with FLAG peptide (IP: α FLAG), the eluted fractions were analyzed by Western blotting 
using the antibody against FLAG and against SUMO1. The position of the non-SUMOylated (dot) 
and of the SUMOylated form (arrow) of hp66α or hp66β is indicated.  
SUMOylated hp66 
SUMOylated hp66 
hp66 •
F 
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Next, Gal-hp66 paralogs fusions were employed in reporter gene repression assays in order to 
test for possible functional differences of hp66 mutants which cannot be SUMOylated. The 
transcriptional repression activity of wild-type Gal-hp66α and Gal-hp66β and various 
SUMOylation-deficient mutants were compared. HEK293 cells were cotransfected with the 
reporter plasmid4×UAS-TK-Luc together with Gal-hp66 fusion constructs. Expression levels 
of wild type and mutant Gal-hp66α and Gal-hp66β proteins were normalized using Western 
blotting analysis with anti-Gal antibody. The results demonstrated the relative expression of 
Gal-fusion proteins to be similar (Fig.3.7A and 3.7B). In addition, the results show that all 
SUMOylation deficient mutants, Gal-hp66αK30R, Gal-hp66αK487R or Gal-hp66βK33R, are 
severely impaired in their transcriptional repression activity. Moreover, Gal-hp66αK149R, 
which has no effect on SUMOylation (see section 3.1.4), but rather abolishes binding to MBD2 
(see section 3.1.6), reduces transcriptional repression as well. Furthermore, double mutants,  
86 
62 • 
•62 
86 
G 
Gal + – – – – – 
Gal-hp66α – + + + + + 
FLAG-SUMO1 – – – + + + 
FLAG-SUMO1G97A – – + – – – 
HA-Ubc9 – – + + – + 
HA-DN-Ubc9 – – – – + – 
PIAS1 – – – – – + 
 
*
Gal – + – – – – 
Gal-hp66β – – + + + + 
FLAG-SUMO1 – + – + + + 
HA-Ubc9 – + – + – + 
HA-DN-Ubc9 – – – – + – 
PIAS1 – – – – – + 
 
H 
Fig.3.6 E3 ligase PIAS1 enhances the SUMOylation efficiency of hp66 proteins  in vivo. (G-H) 
Human 293T cells were cotransfected with indicated Gal fusions together with FLAG-SUMO1, 
FLAG-SUMO1G97A, HA-Ubc9, HA-DN-Ubc9 or PIAS. After 48h, equal amounts of nuclear 
extracts were separated by SDS-PAGE and analyzed by Western blotting using an anti-Gal antibody. 
The position of the non-SUMOylated (dot), of the mono-SUMOylated form (arrow) and of the bi-
SUMOylated form (star) of hp66α or hp66β is indicated.  
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triple mutants as well the quadruple mutants of Gal-hp66 fusions were also examined. In 
general, any combination of individual mutations that impair SUMOylation also show a strong 
reduction of transcriptional repression. This is dramatically demonstrated by the quadruple 
mutation of hp66α that results in a 20-fold reduction of transcriptional repression as compared 
to wild type hp66α (Fig. 3.7A). This mutant can not be SUMOylated (sites K30 and K487 are 
mutated, see section 3.1.4). In contrast, there is almost no difference in transcriptional 
repression activity in the case of Gal-hp66αK451R or Gal-hp66βK454R, the wild-type sites of 
which are not SUMOylated (see section 3.1.4). These results indicate that SUMOylation 
influences transcriptional repression of hp66α and hp66β.  
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αGal 
Fig.3.7. Loss of SUMO modification impairs hp66α mediated repression. 293 cells were 
cotransfected with a 4×UAS-TK-luciferase reporter together with vectors coding for Gal-
constructs. Shown is the transcriptional repression of the indicated Gal-hp66α variants. Fold 
repression was determined relative to the Gal-DNA binding domain. Error bars represent 
variations within duplicate transfections. Anti-Gal4 Western blotting shows expression levels 
of wild type Gal-hp66α or mutant forms.  
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Fig.3.7 Blocking SUMO conjugation pathway impairs hp66 mediated repression. 293 cells 
were cotransfected with a 4×UAS-TK-luciferase reporter together with vectors coding for Gal-
constructs in the presence of FLAG-SUMO1, FLAG-SUMO1G97A, HA-Ubc9, or HA-DN-Ubc9. 
Shown is the transcriptional repression of the Gal fusion hp66 paralogs. Fold repression was 
determined relative to the Gal-DNA binding domain. Error bars represent variations within 
duplicate transfections.  
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Fig.3.7 Loss of SUMO modification impairs hp66β mediated repression. 293 cells were 
cotransfected with a 4×UAS-TK-luciferase reporter together with vectors coding for Gal-
constructs. Shown is the transcriptional repression of the indicated Gal-hp66β variants. Fold 
repression was determined relative to the Gal-DNA binding domain. Error bars represent variations 
within duplicate transfections. Anti-Gal4 Western blotting shows expression levels of wild type 
Gal-hp66β or mutant forms.  
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To further confirm the effect of SUMOylation on transcriptional repression, the SUMO mutant 
FLAG-SUMO1G97A as well as the dominant negative mutation of the E2 ligase HA-DN-Ubc9 
were utilized in the transcriptional repression assay (Fig.3.7C). Both transcriptional repression 
mediated by hp66α or by hp66β can be increased by the wild type FLAG-SUMO1 and Ubc9, 
and this repression can be relieved by about two fold by the FLAG-SUMO1 mutant and the 
Ubc9 mutant. Thus, mutation of the two SUMOylation sites of hp66α and the single site of 
hp66β, and expression of defective SUMO1 and Ubc9 impair the transcriptional repression 
activity of both hp66 factors. 
 
3.2.3 SUMO modification does not affect hp66α and hp66β nuclear localization 
 
It has been shown that SUMO modification can regulate the subcellular localization of target 
proteins. To test whether SUMO modification affects nuclear localization of hp66α and hp66β, 
the subcellular localization of wild-type pEGFP-hp66α and pEGFP-hp66β was compared to the 
localization of the corresponding SUMOylation defective forms pEGFP-hp66αK30R, pEGFP-        
        
 
EGFP 
EGFP-hp66α 
EGFP-hp66αK30R 
EGFP-hp66αK487R 
EGFP-hp66β 
EGFP-hp66βK33R 
Fig.3.8 Subnuclear distribution of EGFP-hp66α and EGFP-hp66β is not changed in the 
SUMOylation mutants. NIH3T3 cells were transfected with the indicated EGFP-fused hp66 
proteins. Phase contrast (left column) and fluorescent images were taken 24-48 hours post 
transfection after incubation with “Hoechst DNA stain” (center column). Mutant forms of pEGFP-
hp66α and pEGFP-hp66β revealed similar nuclear speckle patterns as observed with wild type 
pEGFP-hp66α and pEGFP-hp66β (right column). EGFP control expression resulted in a diffuse 
whole cell distribution. 
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hp66αK487R and pEGFP-hp66βK33R by fluorescence microscopy. All mutant forms of 
pEGFP-hp66α and pEGFP-hp66β show a similar speckled nuclear pattern as is observed with 
wild-type pEGFP-hp66α or pEGFP-hp66β (Fig.3.8). These results suggested that SUMO 
modification or loss of modification of hp66α and hp66β does not lead to a change in the 
subcellular or subnuclear localization. Another mechanistic role for SUMO modification of 
hp66 proteins might be in the protein/protein interaction within the Mi-2/NuRD complex. 
Therefore, four of the known components of the Mi-2/NuRD complex were tested in their 
binding to hp66α or hp66β and for a possible effect of the SUMO-defective hp66 mutants.  
 
3.2.4 HDAC1 is recruited to the N-terminal SUMO modification site of hp66α, but not 
hp66β in  vivo  
 
Previous study showed that HDAC1 is the component of the Mi-2/NuRD complex (Le 
Guezennec et al., 2006; Zhang et al., 1999). As showed in above results, hp66 mediated 
transcriptional repression is at least partially due to histone deacetylation. Furthermore, most of 
the mutant forms of Gal-hp66α and Gal-hp66β retain a TSA sensitivity except for Gal- 
        
Fig.3.9 The transcriptional repression activity of hp66α is partially released upon TSA 
treatment. HEK293T cells were cotransfected with a 4×UAS-TK-luciferase reporter together with 
constructs coding for the Gal-DNA binding domain or the indicated Gal fusions in the presence or
absence of TSA. Cell extracts were analyzed for reporter gene activity. Gal-NCoR is a positive
control for TSA sensitive repression (Polly et al., 2000). Fold repression was determined relative to 
the Gal-DNA binding domain alone. Error bars represent variations within duplicate transfections. 
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p66αK30R and Gal-p66βK33R (Fig.3.9A). Both sites might be required for interaction with 
HDAC1 or other NuRD components. To test this assumption, HEK293 cells were cotransfected 
with mammalian vector pCMV-GST or pCMV-GST-HDAC1 together with Gal, Gal-hp66α, 
Gal-hp66β or corresponding four single mutant forms of Gal-hp66α and two single mutant 
forms of Gal-hp66β. After purification of nuclear extract with glutathione beads, GST-HDAC1  
pCMV-GST + – + – – – 
pCMV-GST-HDAC1 – + – + + + 
Gal + + – – – – 
Gal-hp66β – – + + – – 
Gal-hp66β-K33R – – – – + – 
Gal-hp66β-K454R – – – – – + 
αGST 
αGal 
purified
input
Fig.3.9 Mutation of the N-terminal SUMO modification site does not influence HDAC1 
binding to hp66β in vivo. HEK293 cells were harvested 48h after transfection with various 
combinations of DNA constructs as indicated above the figure. Nuclear protein fractions were
prepared and purified using glutathione Sepharose beads. Bound proteins (purified) were analyzed 
by Western blotting using an anti-Gal antibody as compared to input, which was analyzed with the 
anti-GST antibody as well.  
C 
pCMV-GST + – + – – – – – 
pCMV-GST-HDAC1 – + – + + + + + 
Gal + + – – – – – – 
Gal-hp66α – – + + – – – – 
Gal-hp66α-K30R – – – – + – – – 
Gal-hp66α-K149R – – – – – + – – 
Gal-hp66α-K451R – – – – – – + – 
Gal-hp66α-K487R – – – – – – – + 
αGST 
αGal 
purified
input 
Fig.3.9 Mutation of the N-terminal SUMO modification site inhibits HDAC1 binding to
hp66α in vivo. HEK293 cells were harvested 48h after transfection with various combinations of 
DNA constructs as indicated above the figure. Nuclear protein fractions were prepared and purified
using glutathione Sepharose beads. Bound proteins (purified) were analyzed by Western blotting
using an anti-Gal antibody as compared to input, which was analyzed with the anti-GST antibody 
as well.  
B 
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containing sample retains wild type Gal-hp66α, Gal-hp66β, and most of the mutant forms with 
one exception: Gal-hp66αK30R, which destroys the major SUMO modification site of hp66α  
and which is insensitive to TSA treatment, is not bound to GST-HDAC1 (Fig.3.9B and 3.9C). 
The results indicated that HDAC1 binding to hp66α and TSA sensitivity of transcriptional 
repression require an intact SUMJO modification site at K30 of hp66α. In contrast, mutation of 
a paralogs site in p66β, K33R, does not interfere with HDAC1 binding (Fig. 3.6D). 
Nevertheless, this mutant is resistant to TSA, indicating that other components of the HDAC 
complexes are bound at this site (see below). 
 
3.2.5 Mutation of the SUMO modification sites does not affect MBD3 binding to 
hp66α and hp66β 
 
MBD3 has previously been shown to be part of the Mi-2/NuRD complex (Feng et al., 2002; 
Hendrich and Bird, 1998; Le Guezennec et al., 2006) and to interact with hp66α and hp66β in 
vitro (Brackertz et al., 2002). In this work, expressing pCMV-GST or pCMV-GST-MBD3 was 
cotransfected together with Gal, Gal-hp66α, Gal-hp66β or the corresponding point mutant forms 
in HEK293 cells. After nuclear extract preparation, the input fraction and purified GST bound 
proteins were analyzed by Western blotting using an anti-Gal antibody. The data revealed that 
the GST-MBD3 containing sample retained Gal-hp66α, Gal-hp66β and all single mutant forms 
(Fig.3.10A and 3.10B). The results indicated that mutation of the SUMO modification sites does 
not influence MBD3 binding to either hp66α or hp66β.  
 
3.2.6 Mutation of the N-terminal SUMO modification site impaired RbAp46  binding to 
hp66β, but not hp66α in vivo 
 
Other components of the Mi-2/NuRD complex, the RbAp46 and RbAp48 proteins, have been 
shown to function as histone escort proteins in various histone-related complexes (Loyola and 
Almouzni, 2004). The binding of RbAp46 to hp66α or hp66β and to the respective mutant 
forms were examined. The results demonstrated that GST-RbAp46 containing sample retains 
wild type Gal-hp66α or Gal-hp66β and most of the mutant forms Gal-hp66α or Gal-hp66β, 
whereas only partially retains Gal-hp66βK33R, which is major SUMO modification site of 
hp66β (Fig.3.11A and 3.11B). The results suggested that the interaction of RbAp46 with hp66β  
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requires an intact SUMOylation site K33 of hp66β. 
 
          
 
 
          
 
3.2.7 RbAp48 binding to hp66α and hp66β was independent of the SUMO 
modification sites 
 
pCMV-GST + – + – – – 
pCMV-GST-MBD3 – + – + + + 
Gal + + – – – – 
Gal-hp66β – – + + – – 
Gal-hp66β-K33R – – – – + – 
Gal-hp66β-K454R – – – – – + 
αGST 
αGal 
purified
input
Fig.3.10 Mutation of the SUMO modification site does not inhibit MBD3 binding to hp66β in 
vivo. HEK293 cells were harvested 48h after transfection with various combinations of DNA 
constructs as indicated above the figure. Nuclear protein fractions were prepared and purified using 
glutathione Sepharose beads. Bound proteins (purified) were analyzed by Western blot using an
anti-Gal antibody as compared to input, which was analyzed with the anti-GST antibody as well.  
B 
pCMV-GST + – + – – – – – 
pCMV-GST-MBD3 – + – + + + + + 
Gal + + – – – – – – 
Gal-hp66α – – + + – – – – 
Gal-hp66α-K30R – – – – + – – – 
Gal-hp66α-K149R – – – – – + – – 
Gal-hp66α-K451R – – – – – – + – 
Gal-hp66α-K487R – – – – – – – + 
αGST 
αGal 
purified
input 
Fig.3.10 Mutation of the SUMO modification sites does not affect MBD3 binding to hp66α in 
vivo. HEK293 cells were harvested 48h after transfection with various combinations of DNA 
constructs as indicated above the figure. Nuclear protein fractions were prepared and purified using 
glutathione Sepharose beads. Bound proteins (purified) were analyzed by Western blotting using an
anti-Gal antibody as compared to input, which was analyzed with the anti-GST antibody as well.  
A 
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Similar experiment was performed as shown in above work with expressing vector pCMV-GST-
RbAp48. All of the hp66α and hp66β mutant forms showed RbAp48 binding similar to the wild 
type hp66 proteins (Fig.3.12A and 3.12B). Thus the related RbAp46/RbAp48 proteins and the  
related hp66α/hp66β proteins are highly specific in protein/protein interaction.  
pCMV-GST + – + – – – 
pCMV-GST-RbAp46 – + – + + + 
Gal + + – – – – 
Gal-hp66β – – + + – – 
Gal-hp66β-K33R – – – – + – 
Gal-hp66β-K454R – – – – – + 
αGST 
αGal 
purified
input
Fig. 3.11 Mutation of the N-terminal SUMO modification site impairs RbAp46 binding to
hp66β in vivo. HEK293 cells were harvested 48h after transfection with various combinations of 
DNA constructs, as indicated above the figure. Nuclear extracts were prepared and GST-RbAp46 
were purified using glutathione Sepharose beads. Bound proteins (purified) were analyzed by 
Western blotting using an anti-Gal antibody as compared to input, which was analyzed with the 
anti-GST antibody as well. 
B
pCMV-GST + – + – – – – – 
pCMV-GST-RbAp46 – + – + + + + + 
Gal + + – – – – – – 
Gal-hp66α – – + + – – – – 
Gal-hp66α-K30R – – – – + – – – 
Gal-hp66α-K149R – – – – – + – – 
Gal-hp66α-K451R – – – – – – + – 
Gal-hp66α-K487R – – – – – – – + 
αGST 
αGal 
purified
input 
Fig.3.11 Mutation of the SUMO modification site does not affect RbAp46 binding to hp66α in 
vivo. HEK293 cells were harvested 48h after transfection with various combinations of DNA 
constructs, as indicated above the figure. Nuclear extracts were prepared and GST-RbAp46 were 
purified using glutathione Sepharose beads. Bound proteins (purified) were analyzed by Western 
blotting using an anti-Gal antibody as compared to input, which was analyzed with the anti-GST 
antibody as well. 
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3.3  Purification of hp66 protein complexes 
 
3.3.1 Strategies for purification of the hp66 proteins complexes 
 
Several lines of evidence demonstrated that hp66 proteins are components of the MeCP1  
pCMV-GST + – + – – – 
pCMV-GST-RbAp48 – + – + + + 
Gal + + – – – – 
Gal-hp66β – – + + – – 
Gal-hp66β-K33R – – – – + – 
Gal-hp66β-K454R – – – – – + 
αGST 
αGal 
purified
input
Fig.3.12 Mutation of SUMO modification site does not inhibit RbAp48 binding to hp66β in 
vivo. HEK293 cells were harvested 48h after transfection with various combinations of DNA 
constructs as indicated above the figure. Nuclear protein fractions were prepared and purified using 
glutathione Sepharose beads. Bound proteins (purified) were analyzed by Western blotting using an
anti-Gal antibody as compared to input, which was analyzed with the anti-GST antibody as well.  
B 
pCMV-GST + – + – – – – – 
pCMV-GST-RbAp48 – + – + + + + + 
Gal + + – – – – – – 
Gal-hp66α – – + + – – – – 
Gal-hp66α-K30R – – – – + – – – 
Gal-hp66α-K149R – – – – – + – – 
Gal-hp66α-K451R – – – – – – + – 
Gal-hp66α-K487R – – – – – – – + 
αGST 
αGal 
purified
input 
Fig.3.12 Mutation of the SUMO modification site does not influence RbAp48 binding to
hp66α in vivo. HEK293 cells were harvested 48h after transfection with various combinations of 
DNA constructs as indicated above the figure. Nuclear protein fractions were prepared and purified
using glutathione Sepharose beads. Bound proteins (purified) were analyzed by Western blotting
using an anti-Gal antibody as compared to input, which was analyzed with the anti-GST antibody 
as well.  
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complex, the MBD2/NuRD complex, the MBD3/NuRD complex, as well as the MTA1/MTA2 
formed complexes (Feng et al., 2002; Feng and Zhang, 2001; Le Guezennec et al., 2006; Yao and 
Yang, 2003). To gain better insight into the protein composition of the hp66 proteins complexes, 
further work is required to investigate whether hp66 proteins might be within same complex or 
different complexes. Since there was no hp66 antibody for immunoprecipitation commercially 
available, another approach was adopted by establishing stable cell lines expressing hp66 
proteins. As a prerequisite step for purification, I established a two-step purification method with 
epitope-tagged hp66 constructs based on recently developed tandem affinity purification (TAP) 
method with modifications (Rigaut et al., 1999). This method allows affinity purification with 
fusion of a tag, usually a peptide, or a small protein, to the target protein. The TAP method has 
been used successfully to purify protein complexes in yeast and mammalian cells (Gavin et al., 
2002; Westermarck et al., 2002). Nevertheless, this method has some potential disadvantages. 
For example, protein A epitope is rather big and might interfere with protein interaction surfaces 
in a protein complex. In order to avoid these potential problem, in this study, hp66 paralogs were 
fused to two tags, one is FLAG tag, the other is calmodulin binding peptide (CBP), which allow 
 
        
Whole cell extract
 Mono Q 
0.1M KCl
1M KCl
0.4-0.5M
Superose 6 
0.6-2.0MDa
M2 affinity 
the hp66 complexes 
Fig.3.13 Schematic representation of the steps used to purify the hp66 containing 
complexes. See details in text. The horizontal and diagonal lines indicate stepwise and gradient 
elution, respectively.  
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high affinity for both FLAG beads and calmodulin resin. In the prelimary experiment, the 
calmodulin resin was not able to capture the CBP tagged proteins. Therefore, further approach 
chosen for purification was ion-exchange chromatography and gel filtration chromatography, 
which could identified the possible hp66 proteins complexes at certain range of fractions. After 
each chromatographic separation, I monitored column fractions for the hp66 protein complexes 
by Western blotting using FLAG antibody. Only the peak fractions containing FLAG-hp66 
proteins from each column were used for subsequent chromatographic step. At last, these 
potential fractions were purified with FLAG M2 antibody directly conjugated to agarose resin, 
and the beads were eluted with FLAG peptide. The elute fractions were fractionated by SDS-
PAGE followed by silver staining or Western blotting using antibodies against the known 
components of the NuRD complex. The purification step is outlined in Fig.3.13. 
 
3.3.2 Establishment of stable cell lines expressing hp66 proteins 
 
The stable cell lines were established as described above (section 2.2.4.4). Finally, the stable cell 
colonies were identified by RT-PCR using specific primers and by Western blotting using FLAG 
antibody. These clones were first identifed on mRNA expression level. Total RNA was isolated 
from each clone, and was converted into cDNA by using reverse transcription (see section 2.2.3). 
Then several specific primers were designed for identification of stable cell clones which stably 
integrate double tagged fusion constructs (Fig.3.14). In the case of control stable cell lines, 
FLAG-CBP primer was designed, which ranges from FLAG tag to CBP tag. For  stable cell lines 
which stably integrate double tagged hp66 constructs, two pairs of primers were designed, one is 
FLAG primer which detects N-terminal part of double tagged hp66, the other is CBP primer 
which is able to amplify C-terminal part of double tagged hp66. To avoid false positive from 
transfected DNA, total RNA was first digested with DNase, then reverse transcription was 
performed. During the PCR reaction with specific primers, two templates were utilized, one was 
total RNA after digestion with DNase, the other was cDNA after reverse transcription. The 
results showed that one band with expected size was occurred after reverse transcription, whereas 
no band was observed without reverse transcription and the control HEK293 cells. Based on 
these findings, several clones were identified such as clone 54 (control stable cell line), cone 29 
(stably integrated pcDNA3-FLAG-hp66α-CBP), and clone 87 (stably integrated pcDNA3-
FLAG-hp66β-CBP). To further confirm these clones, these clones were detected by Western 
blotting with FLAG antibody. Moreover, these constructs were overexpressed in HEK293 cells  
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as positive control. The nuclear extract was prepared from these clones, and separated with SDS-
PAGE. Similar band was detected in both stable cell lines clone 29 and clone 87 and HEK293 
cells with overexpressed hp66 proteins, but not in control stable cell line clone 54 and in control 
HEK293 cells by using FLAG antibody. Taken together, several stable cell lines were 
successfully established for future purification procedure.  
         
 
3.3.3 Ion-exchange chromatography 
 
Whole cell extract of stable cell lines was prepared, concentrated, and loaded on Mono Q 
column, which is a strong anion-exchanger. The typical chromatogram from Mono Q ion-
exchange chromatography is shown in Fig.3.15A. The individual fractions were collected with 
salt gradient from 100mM KCl to 1M KCl. Western blotting analysis of proteins from 
individual fractions showed that the majority of FLAG-hp66α protein elutes with a broad range 
from fraction 14 to fraction 26, while the majority of FLAG-hp66β protein elutes with a range 
from fraction 16 to fraction 30. However, there is no signal detected in the case of control 
stable cell line clone 54 which stably integrates pcDNA3-FLAG-CBP (Fig.3.15B). These  
pcDNA3-FLAG-CBP 
Reverse transription (RT) PCR 
RT                   −       + 
FLAG CBP FLAG CBP hp66α/hp66β 
pcDNA3-FLAG-hp66α/hp66β-CBP 
FLAG primers CBP primers FLAG-CBP primers 
M    Ctrl         C54      M  Ctrl    C29         C87   
−     +     −     +
Ctrl   C29       C87      M  
−     +     −     + 
Western blotting 
Ctrl           1            C29             C54         2         C87 
Fig.3.14 Identification of stable cell lines by using RT-PCR and Western blotting.
Explanation: see text. Abbreviations: M: Marker; Ctrl: control HEK293 cell; C54: clone 54 
(stably integrated pcDNA3-FLAG-CBP); C29: clone 29 (stably integrated pcDNA3-FLAG-
hp66α-CBP); C87: clone 87 (stably integrated pcDNA3-FLAG-hp66β-CBP); 1: pcDNA3-
FLAG-hp66α-CBP (overexpression);  2: pcDNA3-FLAG-hp66β-CBP (overexpression). 
αFLAG 86 
62 
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Fig.3.15A The elution profile of Mono Q column ion-exchange chromatography. 
Absorbance of elute fraction monitored at UV 280nm (red line) and the collected fractions (blue 
sticks) are shown. 
fractions   14                       26
input      16       18       20         22      24        26        28      30 
clone 87 (pcDNA3-FLAG-hp66β-CBP) 
clone 29 (pcDNA3-FLAG-hp66α-CBP)
input        14        16      18       20        22       24       26         28      fractions 
α FLAG 
fractions 
α FLAG 
Fig.3.15B Western blotting analysis of the Mono Q fractions using aniti-FLAG antibody.
Individual fractions from ion-exchange chromatography were separated by SDS-PAGE and 
analysed by Western blotting directed against FLAG antibody on the left of the figure. Input 
denotes the sample used in the ion-exchange purification procedure. Fractions were pooled for 
analysis on a subsequent gel filtration.  
clone 54 (pcDNA3-FLAG-CBP) 
input       14      16        18        20         22      24        26        28      30 fractions 
α FLAG 
70
55
70
55
70
55
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fractions containing FLAG-hp66 protiens elute mainly at estimated 0.4M-0.5M KCl. Finally, 
those fractions containing FLAG-hp66 proteins from ion-exchange chromatography were 
pooled, concentrated, and passed through Superose 6 column. 
 
3.3.4 Gel filtration (size exclusion chromatography) 
 
Prior to start gel filtration, I made a standard curve by separation of a mixture of alcohol 
dehydrogenase (150KDa), apoferritin (443KDa), thyroglobulin (669KDa) on a Superose 6 
column (Fig.3.16A). Based on this standard curve, the Vo of this column is 7.0ml, the Ve of 
alcohol dehydrogenase, apoferritin, thyroglobulin is 14.8ml, 12.8ml, and 11.4ml, separately. 
Molecular weight of unknown proteins is determined by comparing the ratio of Ve/Vo for the 
protein to the Ve/Vo of protein standards of known molecular weight.  
 
         
Those fractions containing FLAG-hp66 proteins from ion-exchange chromatography were 
pooled, concentrated, and applied to a Superose 6 column. The fractions (0.5ml) were collected 
for further analysis. In case of clone 29 which stably integrates pcDNA3-FLAG-hp66α-CBP, 
Fig.3.16A Calibration curve obtained with standard proteins on Superose 6 column.   
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the elution profile of FLAG-hp66α containing fractions derived from gel filtration was shown 
in Fig.3.16B. Two major peaks were observed, one peak is appeared at fraction 16 with an 
estimated size of 1.8MDa, the other peak is occured at fraction 32 which corresponds to a 
molecular mass of 148KDa.  
 
 
Western blotting analysis of  proteins from individual fractions revealed that the majority of 
FLAG-hp66α protein elutes with a broad profile encompassing from fraction 16 to fraction 26, 
and separtates into two peaks, one peak is first detected at fraction 16, very close to the void 
volume, which could be an indicative of protein aggregation, with an estimated molecular 
weight of 1.8MDa, and then the other peak was occurred at fraction 22 which corresponds to a 
molecular weight of 763KDa. The results demonstrated that hp66α protein probably resides in 
two different size of protein complexes, one is about 1.8MDa, the other is 763KDa.  
Furthermore, the specific band was observed again at fraction 32which might be hp66α dimers 
with a theoretical molecular weight of 148KDa (Fig.3.16C).  
In another independent experiment, eukaryotic expressing GST-hp66 paralogs were 
cotransfected with Gal-hp66 proteins into HEK293 cells. Nuclear extract was prepared and 
incubated with glutathione beads. The bound proteins were detected with Gal antibody. The 
results obviously showed that GST-hp66α retained Gal-hp66α and Gal-hp66β, and vice versa  
Fig.3.16B The elute profile of fractions dereived from a Superose 6 column in the case of 
clone 29.  Absorbance of elute fraction monitored at UV 280nm (red line) and the collected 
fractions (blue sticks) are shown.  
1 10 20 30 40 fractions 
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(Fig.3.16D). The data suggested that both hp66 paralogs interact each other and do not exist as 
a free form but a dimer in vivo.  
          
 
 
 
        
 
It is known that hp66α is a component of the NuRD complex. To determine whether the 
subunits of the NuRD complex cofractionate with hp66α, individual fractions containing 
FLAG-hp66α from gel filtration were separated by SDS-PAGE and analyzed by Western 
blotting using antibodies directed against the known components of the NuRD complex such as 
HDAC1/HDAC2, RbAp46/RbAp48, MBD2/MBD3, Mi-2, PRMT5, as well as Sin3A  
α FLAG 1600KD 489KD 
α FLAG 
13   14   15   16   17   18   19   20  input 21     22   23   24   25    26   27   28  input 
1.8MDa 763KDa 
fractions     29   30    31    32     33    34     35   36 
148KDa 
  37    38    39    40    41    42    43    44 
fractions 
70
55
70
55
pCMV-GST + – – – – 
pCMV-GST-hp66α – + + – – 
pCMV-GST-hp66β – – – + + 
Gal-hp66α + + – – + 
Gal-hp66β – – + + – 
 
αGal 
Fig.3.16D Both hp66 paralogs interact each other and form a dimmer. HEK293 cells were 
harvested 48h after transfection with various combinations of DNA constructs, as indicated above the 
figure. Nuclear extract was prepared and GST-hp66 proteins were purified using glutathione 
Sepharose beads. Bound proteins  were analyzed by Western blotting using an anti-Gal antibody  
Gal-hp66α 
Gal-hp66β 
Fig.3.16C Western blotting analysis of the fractions from Superose 6 columm of clone 29 with 
FLAG antibody. Individual fractions from gel filtration were separated by SDS-PAGE and 
analysed by Western blotting directed against FLAG antibody shown on the left side of the figure. 
Input denotes the sample used in the gel filtration purification procedure. The arrows at the top 
denote the elution positions of calibration proteins of known molecular weights. 
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(Fig.3.16E). The results revealed that, as expected, most of the known components 
cofractionate with FLAG-hp66α in a similar profile of fractions. In detail, these known 
subunits of the NuRD complex start to occur at fraction 16, then co-elute in an overlapping set 
of high-molecular weight fractions of FLAG-hp66α, as approximately 1.8MDa complex. 
furthermore, these known subunits and hp66α are present in fractions of low-molecular weight 
which forms another possible complex. FLAG-hp66α and members of the NuRD complex 
        
α FLAG 1600KD 489KD 
α Mi-2 
13   14   15   16   17   18   19   20  input 21    22   23   24   25    26   27   28  input 
1.8MDa 763KDa 
fractions 
α HDAC1 
α HDAC2 
α RbAp48 
α MBD2 
α Sin3A 
α RbAp46 
70
55
α PRMT5 
α MBD3 
Fig.3.16E Western blotting analysis of the fractions from Superose 6 columm of clone 29 with 
antibodies against the know components of the NuRD complex and Sin3A.  Individual fractions from 
gel filtration were fractionated by SDS-PAGE and detected by Western blotting using antibodies directed 
against proteins to the left of the figure. Input denotes the sample used in the gel filtration purification 
procedure. The arrows at the top denote the elution positions of calibration proteins of known molecular 
weights. 
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display similar elution profiles, indicating that the FLAG-hp66α-NuRD association is stable 
over multiple steps of purification. In particular, all detected proteins are present in fractions 17, 
18 of the possible high molecular weight complex and most fractions of the likely low high 
molecular weight complex. These complexes are likely mixutre of many different complexes. 
Surprisingly, MBD2, which is the component of the MeCP1 complex or the MBD2/NuRD 
complex, doesn’t cofractionate with FLAG-hp66α. It is assumed that either amout of MBD2 
may not be sufficient for detecting by Western blotting, or interaction of MBD2 with hp66α is 
not stable enough. Interestingly, mSin3A, which is a subuit of the Sin3A/HDAC complex, also 
coelutes with fractions of two different molecular mass of FLAG-hp66α containing complexes, 
indicating that mSin3A may be recruited to histone deacetylases core which coexists with the 
NuRD complex. Taken together, hp66α stably associates with the NuRD complex. 
 
As to another stable cell line clone 87 which stably integrates pcDNA3-FLAG-hp66β-CBP, the 
elution profile of FLAG-hp66β containing fractions derived from gel filtration showed three 
main peaks, first peak is located at fraction 14 which is void volume (7ml), the second peak is 
located at fraction 24 which indicates a molecular mass of 600KDa, and a third peak is loacated 
at fraction 32  which stands for a molecular mass of 148KDa (Fig.3.16F).  
 
Individual fractions from gel filtration were then fractionated on SDS-PAGE and detected by 
Western blotting with FLAG antibody. As shown in Fig.3.16G, two different peak fractions 
containing the majority of FLAG-hp66β protein were detected in a broad range from fraction 
16 to fraction 26, one is at fraction 16 which corresponds to molecular weight of 1.8MDa, and 
the other is at fraction 24 which indicates molecular weight of 600KDa. The results suggested 
that hp66β appears to form two different sizes of protein complexes, one is about 1.8MDa, the 
other is 600KDa.  Moreover, the specific band again was found at fraction 32 which indicates 
the molecular weight of 148KDa, which corresponds to theoretical dimers of hp66β protein. 
Previously, hp66β was identified as a component of the MeCP1 complex or the NuRD complex.  
To confirm the association of hp66β with the NuRD complex and to get insight into the 
members of the hp66β-containing complex, individual fractions from gel filtration were further 
analyzed by Western blotting using antibodies directed against the known components of the 
NuRD complex same to above experiments (Fig.3.16H). Again, MBD2 doesn’t coelute with 
FLAG-p66β protein after gel filtration, indicating that interation of hp66β with MBD2 might 
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not be stable after several purification steps, although it was detected in the following 
purification step and mammalian GST pulldown experiment (see below). Nevertheless, most of 
the known components such as HDAC1/HDAC2, RbAp46/RbAp48, MBD3, Mi-2, PRMT5 of 
the NuRD complex cofractionate with FLAG-hp66β at the possible high/low molecular mass  
α FLAG 1600KD 489KD 
α FLAG 
13   14   15   16   17   18   19   20  input 21     22   23   24   25    26   27   28  input 
1.8MDa 600KDa 
Fig.3.16G Western blotting analysis of the fractions from Superose 6 columm of clone 87 with 
FLAG antibody.  Individual fractions from gel filtration were separated by SDS-PAGE and analyzed by 
Western blotting directed against FLAG antibody indicated on the left side of the panel. Input denotes the 
sample used in the gel filtration  purification procedure. The arrows at the top denote the elution positions 
of calibration proteins of known molecular weights. 
fractions           29   30    31    32     33    34     35   36 
148KDa
  37    38    39    40    41    42    43    44
fractions 
70
55
70
55
Fig.3.16F The elute profile of fractions dereived from a Superose 6 column in the case of clone 
87.  Absorbance of elute fraction monitored at UV 280nm (red line) and the collected fractions (blue 
sticks) are shown.  
1 10 20 40 30fractions 
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complexes similar to elution profile of FLAG-hp66β. As shown in Fig.16C, these components 
start to appear at the high molecular weight fractions, then these known subunits and FLAG- 
hp66β are detected at the low-molecular weight fractions. The data indicated that FLAG-hp66β 
coexists with the NuRD complex after multiple steps of purification. Again, all detected 
proteins are present in fractions 19, 20 of the possible high molecular weight complex and most 
fractions of the likely low high molecular weight complex. Furterhmore, Sin3A, a component 
of the Sin3A/HDAC complex, also cofracionates with fractions of the possible high/low- 
moledular weight complexes containing FLAG-hp66β, indicated that Sin3A may be recruited 
 
α FLAG 1600KD
α Mi-2 
13   14   15   16   17   18   19   20  input 21     22   23   24   25    26   27   28  input 
1.8MDa 600KDa 
fractions 
α HDAC1 
α HDAC2 
α RbAp48 
α MBD3 
α Sin3A 
α RbAp46 
70
55
α PRMT5 
α MBD2 
Fig.3.16H Western blotting analysis of the fractions from Superose 6 columm of clone 87 antibodies 
against Sin3A and the known subunits of the NuRD complex. Individual fractions from gel filtration 
were fractionated by SDS-PAGE and detected by Western blotting. The antibodies used are indicated the 
left side of the panel. Input denotes the sample used in the gel filtration purification procedure. The arrows 
at the top denote the elution positions of calibration proteins of known molecular weights. 
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to histone deacetylases which share with the NuRD complex.  
 
Next, to examine whether possible hp66 proteins complexes stably bind to FLAG M2 agarose 
beads, individual fractions such as fraction 8, fraction 16, and fraction 24 from gel filtration 
were incubated with FLAG M2 beads. After stringent washing of beads, the bound proteins 
were separated by boiling in SDS sample buffer, and then loaded on 10% SDS-PAGE. Western 
blotting analysis was used to detect the possible association of several known subunits of the 
NuRD complex. Most of the known components such as HDAC1/HDAC2, RbAp46/RbAp48, 
MBD3, Mi-2 of the NuRD complex as well as MBD2 are clearly retained with FLAG-hp66 
proteins at the possible high and low molecular mass complexes, suggesting that they are bona 
fide subunits of the NuRD complex (Fig.3.16I). Recently, arginine methyltransferase PRMT5 
was identified as specific subunit of the MBD2/NuRD but not the MBD3/NuRD complex (Le 
Guezennec et al., 2006). In this study, PRMT5 also binds to FLAG hp66 proteins. Furterhmore, 
mSin3A, a component of the Sin3A/HDAC complex, is not retained with FLAG-hp66 proteins, 
indicating that mSin3A may not be component of the hp66 proteins containing complexes. The 
data suggested that the possible hp66 complexes are stably bind to beads after stringent 
washing, which indicated the further elution step by using FLAG peptide is practical.   
 
After extensive washing, proteins were eluted from the beads with FLAG peptide and were 
separated on SDS-PAGE followed by Western blotting against with different antibodies or 
silver staining. The results revealed that the known components of the NuRD complex as well 
as MBD2 and PRMT5 are associated with hp66 paralogs. In addition, I observed that hp66α 
and hp66β are not mutually exclusive, which is consistent with above findings. (Fig.3.16J). So 
far, it seems that hp66 paralogs within same complex containing HDAC1/HDAC2, 
RbAp46/RbAp48, MBD2/MBD3, Mi-2, PRMT5 as well as hp66α/hp66β, however, the fact is 
that hp66 paralogs containing distinct complexes remain to be further investigated.  
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α MBD3 
α HDAC1 
α HDAC2 
α MBD2 
α RbAp46 
α RbAp48 
α FLAG 
Fig.3.16I hp66 proteins associate with the components of the NuRD complex on FLAG 
agarose beads. Individual fractions 8, 16, and 24 from gel filtration were incubated with FLAG 
M2 beads. After washing of the beads, the bound proteins were separated by boiling in SDS 
sample buffer and loaded on 10% SDS-PAGE. The interacting proteins were analyzed by 
Western blotting using antibodies against mSin3A, MBD2, PRMT5 and the known components 
of the NuRD complex. 
16 24 241688 
clone 29 clone 87
α PRMT5 
α mSin3A 
fractions
α Mi-2 
70 
55 
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α MBD3 
α HDAC1 
α HDAC2 
α MBD2 
α RbAp46 
α RbAp48 
α FLAG 
Fig.3.16J hp66 proteins associate with the components of the NuRD complex on elution 
with FLAG peptide. Individual fractions 8, 16, and 24 from gel filtration were incubated with 
FLAG M2 beads. After washing of the beads, the bound proteins were eluted with FLAG 
peptide and fractionated on 10% SDS-PAGE. The interacting proteins were analyzed by 
Western blotting using antibodies against MBD2, PRMT5 and the known components of the
NuRD complex. 
16 24 241688 
clone 29 clone 87
α PRMT5  
fractions
α Mi-2 
α p66β α p66α 
70 
55 
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3.3.5 hp66 proteins associate with the components of the NuRD complex 
 
The subunits of the NuRD complex binding to hp66 proteins were further determined by 
conducting mammalian GST pulldown experiments with transfection of mammalian expressing 
GST proteins or GST fusions of hp66 proteins into HEK293 cells. Western blotting analysis 
was used to determine the possible association of several endogenous proteins with GST-hp66 
proteins. The proteins specifically retained by GST-hp66 resins are Mi-2, HDAC1/HDAC2, 
MBD2/MBD3, RbAp46/RbAp48, PRMT5 which are the known components of the NuRD 
complex (Fig.3.17). The interaction of hp66 proteins with MBD2/MBD3, HDAC1/HDAC2, 
RbAp46/RbAp48, Mi-2 as well as PRMT5 indicated that hp66 proteins are associated with the 
MBD2/NuRD and the MBD3/NuRD complex. In addition, mSin3A is not retained with GST 
fusion hp66 paralogs, indicating that mSin3A is not associated with the hp66 proteins 
containing complexes. 
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Fig.3.17 hp66 proteins associate with the components of the NuRD complex. GST proteins 
or GST fusions of hp66 proteins were expressed in HEK293 cells. Forty-eight hours after 
transfection, nuclear extract was prepared and incubated with glutathione beads. After washing 
of the beads, the bound proteins were separated on 10% SDS-PAGE. The interacting proteins 
were analyzed by Western blotting using antibodies against mSin3A, MBD2, PRMT5 and the 
known components of the NuRD complex. 
GST-hp66α/β 
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4 DISCUSSION 
 
Methylation of cytosine at the carbon 5 position of CpG dinucleotides is an epigenetic 
modification that is implicated in transcriptional silencing. It has long been known that histone 
deacetylation is a major mechanism in DNA methylation-mediated transcriptional repression 
(Bird and Wolffe, 1999). In general, acetylated histone tails correlate with active gene 
transcription and an open chromatin conformation, whereas deacetylated histone tails correlate 
with inactive gene transcription and a closed chromatin conformation (Wu and Grunstein, 
2000). It has been proposed that the bridge between DNA methylation and histone 
deacetylation are methyl-CpG binding domain (MBD) proteins that are components of multi-
protein repressor complexes such as Mi-2/NuRD (Wu and Grunstein, 2000). The MBD3 
protein is an integral component of the multi-subunit protein complex Mi-2/NuRD, that 
contains nucleosomal remodeling activity as well as histone deacetylases that affect chromatin 
conformation resulting in gene silencing (Wade et al., 1999; Xue et al., 1998). While MBD3 of 
the Mi-2/NuRD complex can not be directly recruited to methylated DNA, interaction with 
MBD2, which has an intrinsic affinity for methylated DNA, targets Mi-2/NuRD to methyl-CpG 
(Boeke et al., 2000; Hendrich and Bird, 1998). This MBD2 containing Mi-2/NuRD complex 
has also been called MeCP1 (Feng and Zhang, 2001; Ng et al., 1999). It seems that there is an 
overlap for MBD2 and MBD3 binding sites (Ballestar and Wolffe, 2001; Le Guezennec et al., 
2006), whereas complex purification revealed the existence of distinct MBD2/NuRD and 
MBD3/NuRD complex (Le Guezennec et al., 2006). 
Two highly related human p66 proteins, referred to as hp66α and hp66β, have been shown to 
interact with MBD2 and with MBD3 and to enhance MBD2-mediated transcriptional 
repression. Both interact with histone tails and reside within the MBD2/NuRD and 
MBD3/NuRD complexes (Brackertz et al., 2002; Brackertz et al., 2006; Feng et al., 2002; Le 
Guezennec et al., 2006). Both hp66 proteins colocalize with MBD2 in a speckled nuclear 
pattern. A comparison between different species revealed two conserved regions, CR1 and CR2. 
CR1 of hp66β is required for interaction with MBD2, MBD3, MTA2, HDAC1, HDAC2, 
RbAp46 and RbAp48, whereas CR2 was reported to target hp66 and MBD3 to specific nuclear 
loci and to mediate histone tail interaction (Brackertz et al., 2006; Feng et al., 2002). 
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4.1 Transcriptional repression of hp66α and hp66β 
 
4.1.1 Both hp66α and hp66β differ in transcriptional repression and in their repression 
domains   
 
Both hp66α and hp66β are two closely related proteins with similar CR1 and CR2. The 
sequence similarity as well as their ubiquitous expression suggest that they have similar 
properties and exert similar functions (Brackertz et al., 2002). In this study we asked whether 
both hp66 proteins are functionally equivalent or whether each may have unique molecular 
features. Here I show that the transcriptional repression of hp66α is much stronger than that of 
hp66β based on analysis of protein expression level (see section 3.1.1). These finding show for 
the first time different functional properties of both related proteins. 
In addition, I demonstrated that hp66α contains two major repression domains, the C-terminus 
including CR2 and the N-terminus including CR1, whereas in hp66β only the N-terminal 
domain including CR1 is functionally equivalent to hp66α (see section 3.1.2), a finding which 
is consistent with previous study (Feng et al., 2002). I propose that combined domains may act 
in synergy to mediate the transcriptional repression activity of hp66α.  
Since hp66 proteins has been shown to be part of the NuRD complex, which harbor HDAC1 
and HDAC2 (Feng et al., 2002; Le Guezennec et al., 2006), I tested hp66 paralogs mediated 
transcriptional repression in the presence of the HDAC-inhibitor TSA. As expected, inhibition 
of histone deacetylases by TSA relieves the transcriptional repression of both hp66 proteins, 
suggesting that one or both hp66 paralogs recruit a protein complex containing HDAC activity. 
By comparing hp66α with hp66β, no qualitative difference in TSA sensitivity was observed. In 
particular, the transcriptional repression activity of C-terminus of hp66α and N-terminus of 
hp66β are partially abolished in the presence of TSA, indicating that both major repression 
domains are at least partially acting of hp66 protein paralogs through histone deacetylation. 
 
4.1.2  Functional interplay between MBD2 and hp66α 
 
Previous data provided evidence that both hp66α and hp66β are interaction partners of MBD2,  
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and are capable of enhancing MBD2-mediated transcriptional repression (Brackertz et al., 2002; 
Brackertz et al., 2006; Feng et al., 2002). In this work, I identified a SUMOylation consensus 
site at position K149, but not SUMO modification site of hp66α, is within CR1, which is not 
present in hp66β. Further investigation revealed that the interaction between MBD2 with 
hp66α requires an intact site K149 amino acid within hp66α. The mutant hp66αK149R protein 
is unable to enhance MBD2-mediated transcriptional repression (see section 3.1.4). 
Furthermore, I observed that the mutant hp66αK149R fused to EGFP results in overall loss of 
the typical speckle pattern but rather displays a diffuse nuclear localization (see section 3.1.5), 
indicating that nuclear distribution of hp66α may depend on hp66-interaction with MBD2. 
Thus the interaction between MBD2 and hp66α is essential for both, the functional 
enhancement of MBD2-mediated transcriptional repression and the nuclear localization of 
hp66α. This interaction is dependent on the integrity of the specific site at K149 of hp66α. 
However, according to the experimental observation from MBD2 knockout MEF cells 
(Brackertz et al., 2006) and knockdown of endogenous MBD2 with RNAi (see section 3.1.4), it 
seems that MBD2 is not essential for the transcriptional repression by either hp66α or hp66β, 
and thus does not function as a downstream factor for hp66 paralogs-mediated transcriptional 
repression.  
 
4.1.3  Concluding remarks and perspectives on transcriptional repression 
 
Human p66α and p66β are two potent transcriptional repressors that interact with the MBD2 
and MBD3. In the current work, hp66-mediated transcriptional repression is partially 
dependent on HDAC activity. Analysis of the molecular mechanisms mediating transcriptional 
repression resulted in the identification of two major repression domains in hp66α, and one in 
hp66β. Moreover, amino acid K149 of hp66α, which is a SUMO consensus site, is responsible 
for functional interaction with MBD2 (Fig.4.4). In contrast, MBD2 seems to be dispensable for 
hp66-mediated transcriptional repression. Future experiment should be addressed to the 
biological functions of hp66 for instance by creating a hp66 null mice. Can the Mi-2/NuRD 
complex be targeted to methylated DNA in hp66-/- mice? Is the MBD3- MBD2 interaction 
upregulated in hp66-/- mice? An attempt to identify target genes of hp66 proteins would be 
helpful, thereby to further investigate the subsequent consequences of hp66 action and 
strengthen the understanding on functions of hp66 proteins. 
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4.2 SUMO modification of both hp66α and hp66β 
 
4.2.1 Both hp66α and hp66β are substrates for SUMO modification 
 
Post-translational modification of transcription factors is a mechanism widely used to achieve 
regulation of gene expression. Over the past 10 years, SUMOylation has been shown to be a 
reversibly modification of many target proteins identified as regulators of gene expression 
including transcription factors, cofactors and regulators of the chromatin structure. Some of the 
target proteins by SUMO are shown in Fig.4.1.  
        
In the present study, different lines of evidence support the idea that both hp66α and hp66β can 
be SUMOylated in vivo. On one hand, SUMO-modified hp66α or hp66β was detected when  
Fig.4.1 Some SUMO-modified substrates grouped by function/localization. Many SUMO-
modified proteins function in regulation of transcription, chromatin structure, maintenance of the 
genome, and signal transduction. All proteins are of mammalian origin unless specifically 
indicated. (y) Yeast; (d) Drosophila; (Dd) Dictyostelium. Modified after (Gill, 2004). 
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FLAG-SUMO-1 and HA-Ubc9 was overexpressed. On the other hand, blocking the 
SUMOylation pathway with the SUMO mutant SUMO1G97A or with dominant negative Ubc9 
(DN-Ubc9) prevents the generation of SUMOylated hp66α and hp66β. Detailed inspection and 
mutational analysis revealed another difference between hp66α and hp66β in respect to 
SUMOylation. For hp66α I identified two SUMO modification sites (K30 and K487). Mutation 
of either site reduced SUMOylation of hp66α to undetectable levels. This suggests that both 
sites synergize in SUMO modification. In contrast, hp66β harbors only a single SUMO 
modification site (K33). Despite the presence of two SUMO sites in hp66α and a single site in 
hp66β, migration of the SUMOylated wild type forms seems to be similar, suggesting that only 
a single site is modified at a time. Moreover, PIAS1, a E3 ligase, is able to enhance the 
efficiency of SUMO modification on target substrates in vivo (Jackson, 2001; Kahyo et al., 
2001). In the case of hp66α, bi-SUMOylated form of hp66α is observed in the presence of 
PIAS1 protein, further suggesting two major SUMO modification sites in hp66α. However, in 
the case of hp66β, mono-SUMOylated form is occurring by co-expressing PIAS1 protein, 
strengthing the finding of only one major SUMO modification site in hp66β (see section 3.1.1). 
In conclusion, both hp66 protein paralogs are true substrates for SUMO modification. 
 
4.2.2 The SUMO pathway directly regulates transcriptional repression activity of hp66 
paralogs 
 
SUMOylation of transcription factors has been reported to have different effects on 
transcriptional activity in diverse pathways. Emerging evidence indicates that SUMOylation 
negatively regulates the transcriptional activity of several transcriptional factors such as C-Myb, 
AR, Elk-1, Sp3 (Bies et al., 2002; Nishida and Yasuda, 2002; Ross et al., 2002; Sapetschnig et 
al., 2002; Yang et al., 2003; Yang and Sharrocks, 2004). In line with these data, overexpression 
of FLAG-SUMO-1 and HA-Ubc9 enhance the transcriptional repression activity of both hp66α 
or hp66β. Moreover, blocking the SUMOylation pathway with SUMO1G97A or with DN-
Ubc9 impairs transcriptional repression of hp66 paralogs. In addition, mutations of the SUMO 
modification sites in hp66α and hp66β result in a reduction of transcriptional repression 
compared to wild type hp66α and hp66β. Taken together, the SUMO modification sites of  
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hp66α and hp66β are required for maximal repression. But, how does SUMO modification 
regulate the transcriptional repression of hp66α and hp66β. Based on our experimental 
observation, there are several possible mechanisms to explain how SUMO modification has 
such a large impact on both hp66 proteins-mediated transcriptional repression.   
First, I and others demonstrated that SUMO-1 itself exhibits intrinsic transcriptional repressive 
properties (Ross et al., 2002; Yang et al., 2003). This finding raises the possibility that SUMO-
1 conjugation of target proteins could mediate at least in parts of the transcriptional repression 
activity of target proteins. How this repression is achieved is unknown to this state. One 
mechanistical possibility is the recruitment of corepressors which contain SUMO-interacting 
motifs(Hecker et al., 2006; Song et al., 2004).  
Second, in some cases, a SUMOylation consensus motif is located within a repression domain. 
It was recently found that several unrelated proteins, for instance Elk-1 and Sp3, contain such 
an inhibitory domain responsible for the repressive function of the transcriptional factor 
(Sapetschnig et al., 2002; Yang et al., 2003). In addition, mutation of the critical lysine residue 
within a repression domain dramatically enhances the transcriptional activity of such proteins, 
indicating that SUMOylation is indeed involved in repression function. In this work, I 
demonstrated that the C-terminal region of hp66α and the N-terminal part of hp66β are major 
repression domain of hp66α and hp66β, respectively. Most importantly, K487, which is the 
major SUMO modification site of hp66α, is located within the C-terminal repression domain of 
hp66α, while K33, which is the major SUMO modification site of hp66β, is located within the 
N-terminal repression domain of hp66β. Moreover, mutation of both SUMO modification sites 
strongly abrogate the transcriptional repression compared to wild type p66α and p66β. Thus, I 
propose that SUMO modification may form complexes with Ubc9 and SUMO on repression 
domains and thereby creates scaffolds for the assembly of HDAC containing repression 
complexes, and thereby results in a repressive chromatin state.  
Third, another model has been presented that might explain the transcriptional repression 
function of SUMO in a different way. This model proposes that SUMOylated transcription 
factors are targeted to the repressive environment of specific subnuclear domains, as 
documented for the promyelocztic leukemia (PML) nuclear body. PML itself as well as other 
components of the PML bodies are SUMOylated (Hay, 2005). SUMO conjugation of these  
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proteins is required for recruitment of HDAC1 or heterochromatin protein 1 into the nuclear 
bodies (Ishov et al., 1999; Lallemand-Breitenbach et al., 2001; Zhong et al., 2000). In addition, 
SUMOylation or inhibition of SUMO conjugation results in a redistribution of nuclear 
components within the nucleus. All these findings demonstrated that localization of such target 
proteins to nuclear bodies by SUMO modification lead to create a local repressive environment 
within nuclear bodies. This type of SUMO function does not seem to play a role in the context 
of hp66 proteins. hp66 colocalizes with MBD2 and MBD3 in nuclear speckles (Brackertz et al., 
2002; Feng et al., 2002), that are clearly different from PML bodies and that are found at 
replication foci (Tatematsu et al., 2000). Furthermore, mutation of the SUMO modification 
sites in hp66α or hp66β does not lead to a redistribution in comparison to wild type hp66.  
Fourth, additional mechanism for SUMO function is exemplified by p300 and by Elk-1. In both 
cases SUMOylation allows HDAC binding and mediates transcriptional repression by histone 
deacetylation (Girdwood et al., 2003; Yang et al., 2003). Recently, lines of evidence revealed 
that HDACs play an essential role in SUMOylation-mediated transcriptional repression (Gill, 
2005). It has been reported that HDACs are able to enhance the efficiency of SUMO 
modification of some substrates. Furthermore, several HDACs have been reported to be 
substrates for SUMOylation. SUMO-modification of HDAC1 is found to increase both 
deacetylase activity and transcriptional repression activity (Cheng et al., 2004; David et al., 
2002). This is reminiscent of the situation I find with hp66. Mutation of the SUMO 
modification site (K30) abolishes the interaction between HDAC1 and hp66α, and leads to a 
loss of TSA sensitivity. This suggests that SUMOylation of this site is required for the 
interaction. In the case of hp66β, I observed that mutation of the N-terminal SUMO 
modification site (hp66βK33) abolishes the interaction between hp66β and RbAp46, which is 
also a component of the Mi-2/NuRD complex. This mutation lead to TSA insensitivity 
probably caused by the loss of RbAp46 binding, which itself may be bound to HDACs. It is 
well known that lysine residues can be modified by acetylation and SUMOylation. Thus, I 
assumed that enzymatic removal of acetyl groups on SUMO modification sites by HDAC1 
could increase susceptibility of target consensus lysine for SUMO modification. In addition, 
previous study showed that both hp66 paralogs interact with hitone tails, whereas acetylation of 
histone tails by the histone acetyltransferases p300 or PCAF abrogates the association with the 
hp66 proteins (Brackertz et al., 2006).  Taken together, these findings suggest that SUMO- 
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modified hp66 proteins repress transcription by recruitment of HDACs. The consequence are 
the efficiency of SUMO modification and the deacetylation of core histones, which in turn 
create a transcriptional repressive chromatin environment and allow the assembly a stable Mi-
2/NuRD complex. In conclusion, crosstalk between deacetylation and SUMOylation might be 
important for regulation of gene expression (Fig.4.2).  
        
Although, the above explanations have been proposed for SUMO-mediated transcriptional 
repression of hp66 proteins, I clearly realized two apparently conflicting observations during 
SUMO-mediated transcriptional repression, that was recently termed as “SUMO enigma”. This 
finding describes that in most systems analyzed the proportion of a particular protein found to 
be SUMOylated is rather small. Indeed, only a small proportion of hp66 proteins appears to be 
modified by SUMO at the steady state. However, under these conditions SUMO modification 
is required for maximal repression of hp66 paralogs and mutation of the target lysine residues 
used for SUMO modification relieves transcriptional repression. A plausible model that 
accommodates these observations is depicted in Fig.4.3. In this model newly synthesized hp66 
paralogs are rapidly SUMOylated and incorporated into a Mi-2/NuRD repression complex in a 
SUMO-dependent manner. The SUMO peptide could be removed in the presence of 
constitutively active SUMO specific proteases, but hp66 proteins are retained in the Mi-
2/NuRD repression complex in a SUMO-independent manner. Under normal circumstances a 
relatively slow dissociation of the stable repression complex could release sufficient quantities  
Ac 
hp66α/β 
K 
hp66α/β 
SUMO 
hp66α/β × 
HDAC1 
HDAC1 
HDAC1 Mi-2/NuRD 
deacetylated histones 
Fig.4.2 Functional interplay between SUMO and HDACs in hp66-mediated transcriptional 
repression.  See text for details. 
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of unmodified hp66 proteins to allow basal transcription. Thus, in this model, SUMO is 
required for the initiation of transcriptional repression, but not for the maintenance of 
transcriptional repression. Colocalization of enzymes implicated in SUMO conjugation and 
deconjugation within the cell nucleus (Zhang et al., 2002), suggesting that SUMO modification 
is a highly dynamic process with substrates undergoing rapid SUMO modification followed by 
equally rapid deconjugation.     
    
A possible mechanism which explains that SUMO-modified hp66 paralogs incorporate into 
Mi-2/NuRD repression complex is that SUMO-modified hp66 proteins may recruit chaperonins 
such as HDAC1 or RbAp46 that assemble the modified hp66 proteins into a stable Mi-2/NuRD 
complex. Once formed, SUMO can be removed, leaving the once modified hp66 proteins 
retained with the repressed state in the Mi-2/NuRD repression complex. This model is also 
consistent with experimental observations where expression of SUMO1G97A mutant or 
dominant negative Ubc9 relieves SUMO-mediated transcriptional repression of hp66 proteins.  
hp66α/β hp66α/β 
SUMO 
SUMO 
 hp66α/β 
SUMO 
Mi-2/NuRD 
complex 
SUMO 
 hp66α/β 
Mi-2/NuRD 
complex 
hp66α/β 
Active state Repressed state 
SUMOylation 
(FAST) 
constitutive 
deSUMOylation 
SUMO-independent 
retention in 
repression complex 
SUMO-dependent  
incorporation into 
repression complex 
(FAST) 
release from  
repression complex 
(SLOW) 
Fig.4.3 Model for transcriptional repression of hp66 proteins by SUMO modification.  See 
text for details.  Modified after (Girdwood et al., 2004).  
  
 
Discussion                                                                                                                    
 
Moreover, mutation of SUMO acceptor lysines of p66 paralogs also results in reduction of 
SUMO-dependent transcriptional repression of hp66 proteins. These observations revealed that 
the initial SUMO modification of hp66 proteins would be blocked by SUMO1 mutant, 
catalytically inactive Ubc9 mutation or by mutation of the target lysine residues of hp66 
proteins. As a consequence, hp66 proteins could not be incorporated into Mi-2/NuRD 
repression complex and would thus fail to be transcriptionally repressed. It has been shown that 
SUMO modification of transcription factors have diverse functional consequences and can both 
activate and repress transcripton. This model could fit to many different situations. Thus, 
SUMO modification of transcription factors could recruit chaperonins to assembly or 
disassembly a wide variety of multiprotein complexes, which in turn switch transcription 
factors between different states to regulate transcription. If SUMOylation is indeed only 
required during a transient phase of complex formation, the amount of protein that needs to be 
modified at any given time point would then only be a small fraction of the total amount of this 
protein present in the cell. 
 
4.2.3 Concluding remarks and perspectives on SUMOylation 
 
In the current work, I provided evidence that both hp66α and hp66β are modified by SUMO in 
vivo, hp66α at two sites (K30 and K487) and hp66β at one site (K33). The Mi-2/NuRD 
components MBD3, RbAp46, RbAp48 and HDAC1 were found to bind to both hp66α and 
hp66β in vivo. Most of the interactions were not affected by the SUMO site mutations in hp66α 
or hp66β, with two exceptions. HDAC1 binding to hp66α was lost in the case of a hp66αK30R 
mutant and RbAp46 binding was reduced in the case of a hp66βK33R mutant (Fig.4.4). These 
results suggest that interactions within the Mi-2/NuRD complex as well as optimal repression 
are mediated by SUMOylation. SUMO modification is a dynamic, reversible process, which 
might explain that only a small proportion of modified proteins can be detected under 
physiological conditions. It is also possible that the bona fide effects of SUMO modification is 
different from what is found with an overexpression system. Analyzing the stable cell lines 
which stably integrated mutants impaired in SUMOylation of hp66 proteins, or transgenic mice, 
which express these mutants, will likely provide more findings considering the function of 
endogenous hp66 proteins, for instance, interactions with associated proteins such as HDAC1,  
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and the effect of SUMO-modified hp66 proteins in living animals. Since SUMO modification 
of hp66 proteins is implicated in recruitment of the NuRD complex through interaction with 
HDAC1 or RbAp46, it would be also worth to try whether SUMO modification of hp66 
proteins could alter the protein composition of the Mi-2/NuRD complex. Moreover, it is also 
interesting to know whether a knockdown of components of the NuRD complex could 
influence the function of SUMO-modified hp66 proteins.    
         
 
4.3  Complex formation of hp66α and hp66β 
 
4.3.1 hp66α/NuRD complex and hp66β/NuRD complex: distinct or same? 
 
The vertebrate Mi-2/NuRD complex is a multisubunit complex containing nucleosome 
remodeling and histone deacetylase activity (Tong et al., 1998; Tyler and Kadonaga, 1999; 
Wade et al., 1998; Xue et al., 1998; Zhang et al., 1998). The histone deacetylases HDAC1 and 
HDAC2 and the histone-binding proteins RbAp46 and RbAp48 form a core complex which is 
shared between the Mi-2/NuRD complex and the Sin3-histone deacetylase complex (Guschin 
et al., 2000; Le Guezennec et al., 2006; Yao and Yang, 2003). It has been reported that Mi-2, 
MTA1/2 and MBD3 are present in the Mi-2/NuRD complex. Although MBD3 is not able to  
CR1 CR2
CR1 CR2
hp66α 
hp66β 
repressive domains 
195 225 340 480 593 1651 
SUMO K33 
RbAp46 
1 144 178 205 340 480 633 
SUMO K30 
HDAC1 
SUMO K487 
Fig.4.4 The major repression domains, relevant amino acid positions, and SUMO modification 
sites of hp66α and hp66β. SUMO modification sites affecting interaction with HDAC1 and 
RbAp46, as well as the CR1 and CR2 regions that are conserved between different species 
(Brackertz et al., 2002; Feng et al., 2002), are indicated. 
K149
MBD2 
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recognize the methylated DNA, the Mi-2/NuRD complex can be targeted to methylated DNA 
through an interaction with MBD2. Thus, the Mi-2/NuRD complex associated with MBD2 
form the so-called “MeCP1 complex”, which provides an important link between DNA 
methylation and histone deacetylation (Feng et al., 2002; Feng and Zhang, 2001). It has been 
described that the  MeCP1 complex contains 10 major polypeptides including MBD2, all seven 
subunits of Mi-2/NuRD complex, and possibly hp66β (p66/p68) (Fig.4.5). I also identified a 
novel protein, hp66α, which is highly related to hp66β. A recent study clearly demonstrated 
that hp66α and hp66β are components of the MBD2/NuRD complex and the MBD3/NuRD 
complex (Le Guezennec et al., 2006). In fact, it seems that different known subunit may form 
unique complexes.  
       
Both hp66α and hp66β proteins are highly related, and have similar properties and exert similar 
functions. In addition, previous data and results presumed in this work revealed that both hp66 
proteins are involved in distinct molecular functions. It has been shown that several subunits of 
the Mi-2/NuRD complex are found in pairs, nevertheless, these duplicated subunits form 
different complexes. Since hp66α and hp66β are highly related, I further investigated whether 
both hp66 proteins are within the same complex or form distinct complexes. To purify the hp66 
proteins containing complexes, stable cell lines expressing hp66 proteins were established. The  
Mi-2/NuRD complex 
MBD3
RbAp48 
HDAC2 HDAC1 
hp66β
MTA1/2 Mi-2 
RbAp46
mCpG mCpG 
MBD2
MeCP1 complex 
Fig.4.5 Model of the MeCP1-NuRD complex.  The complex consists of the indicated proteins. 
Recruitment of the MeCP1-NuRD complex to CpG-methylated DNA occurs via interaction of the 
NuRD complex with MBD2, mediated by direct binding of MBD3 or hp66β. 
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cell extract was precleared with ion-exchange chromatography, and those fractions containing 
FLAG-hp66 proteins were eluted mainly at estimated 0.4-0.5M KCl. To determine the size of 
both hp66 proteins containing complexes, the pooled fraction were passed through gel filtration 
chromatography. Interestingly, the results revealed two different molecular mass on both hp66 
complexes, 1.8MDa and 600-700KDa, respectively, indicating that both hp66 proteins may 
form distinct complexes with different compositions. As expected, the known subunits of the 
Mi-2/NuRD complex as well as Sin3A are associated with hp66 proteins, suggesting that these 
proteins may be components of hp66 proteins complexes. However, the data also demonstrate 
that there is no significant difference between the high molecular weight and the low molecular 
weight fractions containing hp66 proteins. I assumed that there are additional subunits in the 
high molecular weight complex. Further purification with FLAG M2 beads revealed that the 
known components of the Mi-2/NuRD complex as well as MBD2 and PRMT5 are associated 
with hp66 proteins on both beads and elution fraction with FLAG peptide. Although MBD2 is 
not associated with the fractions from gel filtration chromatography, I argue that the amount of 
MBD2 may not be sufficient for detection by Western blotting. It is also interesting that 
PRMT5 was previously identified as a component of the MBD2/NuRD complex, but not of the 
MBD3/NuRD complex, which is retained with hp66 proteins, indicating that PRMT5 may be 
one of unknown subunit of the hp66 complexes. In contrast, Sin3A, which is a subunit of the 
Sin3A/HDAC complex, coelutes with FLAG-hp66 proteins after gel filtration chromatography. 
However, Sin3A is not retained with hp66 proteins after purification with FLAG beads, 
indicating that Sin3A is not a component of the hp66 proteins complexes. Taken together, so 
far, our results from the initial protein complex purifications suggest that both hp66α and 
hp66β may form similar complexes, these are probably not be mutually exclusive. In other 
words, both hp66α and hp66β may be within the same complex. 
 
4.3.2 Concluding remarks and perspectives on complex formation 
 
A number of evidence have revealed that different components of the Mi-2/NuRD complex 
may constitute specific Mi-2/NuRD complex. Our results summarized here leads us to propose 
a new model of the Mi-2/NuRD complex, which further uncovers the link between DNA 
methylation and transcriptional repression. Recent evidence clearly showed that MBD2 and 
MBD3 form distinct complex, that the MBD2/NuRD complex contains additionally PRMT5,  
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and the MBD2/NuRD complex and the MBD3/NuRD complex are mutally exclusive (Fig.4.6). 
Based on our observation, the MBD2-NuRD complex is recruited to CpG methylated DNA 
through interaction with MBD2, achieved by hp66α/hp66β-MBD2 and PRMT5-MBD2 
interaction, whereas the MBD3-NuRD complex is targeted to methyl-CpG sites via interaction 
with MBD2, mediated by two different interactions: MBD3-MBD2 and hp66α/hp66β-MBD2. 
There is another possible mechanism that MBD3/NuRD complex can be recruited to 
unmethylated DNA by transcription factors such as CTIP2, FOG-1 (Hong et al., 2005; Topark-
Ngarm et al., 2006). The different enzymatic activities may act synergistically to regulate 
transcriptional repression within the hp66-NuRD complex: deacetylation of nucleosomes by 
HDAC1/HDAC2 surrounding the target gene in combination with chromatin remodeling 
activity by the ATPase Mi-2, or the addition of transcriptional repressive arginine methyl marks 
in the histone H3 and H4 tails by the associated PRMT5 (Pal et al., 2004), which in turn leads 
to closed chromatin structure and gene silencing. As described to date, both hp66α and hp66β 
may be within the same complex containing HDAC1/HDAC2, MBD2/MBD3, 
RbAp46/RbAp48, hp66α/hp66β, Mi-2 and PRMT5, which may in fact be the mixture of the 
hp66-MBD2-NuRD complex and the hp66-MBD3-NuRD complex.  
 
 
MBD2/NuRD complex 
RbAp48 
HDAC2 HDAC1 
MTA1/2 Mi-2 
RbAp46 
mCpG mCpG 
MBD2 
hp66β 
 
hp66α 
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MBD3/NuRD complex 
RbAp48 
HDAC2 HDAC1
MTA1/2 Mi-2 
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mCpG mCpG 
MBD2
 
hp66β
 
hp66α
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Fig.4.6 Model of the hp66-MBD2-NuRD and the hp66-MBD3-NuRD complexws.  The 
complex consists of the indicated proteins. Recruitment of the hp66-MBD2-NuRD complex to 
CpG-methylated DNA occurs via interaction of the NuRD complex with MBD2 mediated by 
direct binding of hp66 paralogs or PRMT5, whereas recruitment of the hp66-MBD3-NuRD 
complex to CpG-methylated DNA mediated by direct binding of MBD3, or  hp66 paralogs with 
MBD2. MBD3/NuRD complex can also be recruited to unmethylated DNA by transcription 
factors such as FOG-1. 
transcription 
factors (FOG-1)
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Nevertheless, the story of complex purification is not sufficient to draw a conclusion. Since a 
high molecular weight complex is observed, I assumed that there are additional components 
which are not identified within the hp66-NuRD complex to date. The future experiment is to 
identify these unknown subunits with mass spectrometry, and these results will further reveal 
the complete hp66-NuRD complex. 
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Plasmids 
 
pAB-Gal94-hp66α1-205. 
This vector was generated by in-frame insertion of the EcoRI/HindIII fragment from pSG5-
hp66α into the pAB-Gal94 linker opened with SalI/HindIII. 
 
pAB-Gal94-hp66α205-345. 
This vector was created by subclonting the HindIII/NotI fragment from pSG5-hp66α and in-
frame ligation into the pAB-Gal94 linker digested with Cfr9I. 
 
pAB-Gal94-hp66α205-475. 
This vector was cloned by excision of the HindIII/Eco47III fragment out of pSG5-hp66α into 
the pAB-Gal94 linker cut with Eco47III. 
 
pAB-Gal94-hp66α345-475. 
This vector was created by in-frame insertion of the NotI/Eco47III fragment from pSG5-hp66α 
into the pAB-Gal94 linker opened with SalI/Eco47III. 
 
pAB-Gal94-hp66α345-633. 
This vector was generated by in-frame ligation of the NotI/BglII fragment from pSG5-hp66α 
into the pAB-Gal94 linker cut with SalI/BamHI. 
 
pAB-Gal94-hp66α475-633. 
This vector was constructed by cutting the Eco47III/BglII fragment from pSG5-hp66α and in-
frame insertion into the pAB-Gal94 linker digested with Eco47III/BamHI. 
 
pAB-Gal94-hp66αK30R. 
This vector was created via mutagenesis PCR with the sense primers 5'- 
GTGGAGAGCAAGAAAAT AAGAATGGAGAGAGGATTGTTG -3' and antisense primers 
5'- CAACAATCCTCTCTCCATTCT TATTTTCTTGCTCTCCAC -3' on pAB-Gal94-hp66α by 
using the QuikChange site-directed mutagenesis kit according to the manufacturer's instructions.  
 
pAB-Gal94-hp66αK149R. 
This vector was generated via mutagenesis PCR with the sense primers 5'-GGATGATCAAGC  
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AGCTGAGGGAAGAATTGAGGTTAG-3' and antisense primers 5'-CTAACCTCAATTC 
TTCCCTCAGCT GCTTGATCATCC-3' on pAB-Gal94-hp66α by using the QuikChange site-
directed mutagenesis kit.  
 
pAB-Gal94-hp66αK451R. 
This vector was made via mutagenesis PCR with the sense primers 5'- GAAGAAGGCGCT 
CAGGGTGGAGCACACC-3' and antisense primers 5'- GGTGTGCTCCACCCTGAGCGCC 
TTCTTC -3' on pAB-Gal94-hp66α by using the QuikChange site-directed mutagenesis kit.  
 
pAB-Gal94-hp66αK487R. 
This vector was generated via mutagenesis PCR with the sense primers 5'- CCTGCACAGGC 
CAGGGCCGAGCCCACC -3' and antisense primers 5'- GGTGGGCTCGGCCCTGGCCTGT 
GCAGG -3' on pAB-Gal94-hp66α by using the QuikChange site-directed mutagenesis kit.  
 
pAB-Gal94-hp66αK30RK149R. 
This vector was created via mutagenesis PCR with the K149R mutagenesis primers on pAB-
Gal94-hp66αK30R by using the QuikChange site-directed mutagenesis kit.  
 
pAB-Gal94-hp66αK30RK451R. 
This vector was made via mutagenesis PCR with the K451R mutagenesis primers on pAB-
Gal94-hp66αK30R by using the QuikChange site-directed mutagenesis kit.  
 
pAB-Gal94-hp66αK149RK451R. 
This vector was created via mutagenesis PCR with the K451R mutagenesis primers on pAB-
Gal94-hp66αK149R by using the QuikChange site-directed mutagenesis kit.  
 
pAB-Gal94-hp66αK451RK487R. 
This vector was generated via mutagenesis PCR with the K487R mutagenesis primers on pAB-
Gal94-hp66αK451R by using the QuikChange site-directed mutagenesis kit.  
 
pAB-Gal94-hp66αK30RK149RK451R. 
This vector was made via mutagenesis PCR with the K451R mutagenesis primers on pAB-
Gal94-hp66αK30RK149R by using the QuikChange site-directed mutagenesis kit.  
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pAB-Gal94-hp66αK30RK149RK451RK487R. 
This vector was constructed by ligation of the NotI/BamHI fragment from pAB-Gal94-
hp66αK451RK487R into the pAB-Gal94-hp66αK30RK149R digested with NotI/BamHI. 
 
pAB-Gal94-hp66β1-225. 
This vector was created by in-frame ligation of the EcoRI/HindIII fragment out of pSG5-hp66β  
into the pAB-Gal94 linker opened with Eco47III/HindIII. 
 
pAB-Gal94-hp66β225-349. 
This vector was generated by excision of the HindIII/NotI fragment from pSG5-hp66β into the 
pAB-Gal94 linker cut with Cfr9I. 
 
pAB-Gal94-hp66β225-479. 
This vector was cloned by cutting HindIII/Eco47III fragment from pSG5-hp66β and in-frame 
insertion into the pAB-Gal94 linker digested with Eco47III. 
 
pAB-Gal94-hp66β349-479. 
This vector was created by subcloning the NotI/Eco47III fragment from pSG5-hp66β into the 
pAB-Gal94 linker cut with SalI/Eco47III. 
 
pAB-Gal94-hp66β349-593. 
This vector was generated by in-frame insertion of the NotI/BamHI fragment from pSG5-hp66β 
into the pAB-Gal94 linker opened with SalI/BamHI. 
 
pAB-Gal94-hp66β479-593. 
This vector was constructed by excision of the Eco47III/BamHI fragment out of pSG5-hp66β 
and in-frame ligation into the pAB-Gal94 linker digested with Eco47III/BamHI. 
 
pAB-Gal94-hp66βK33R. 
This vector was generated via mutagenesis PCR with the sense primers 5'-GGCAAAGCGAC 
TCAGAATGGAGGGGCATG -3' and antisense primers 5'- CATGCCCCTCCATTCTGAGT 
CGCTTTGCC -3' on pAB-Gal94-hp66β by using the QuikChange site-directed mutagenesis kit.  
 
pAB-Gal94-hp66βK454R. 
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This vector was created via mutagenesis PCR with the sense primers 5'- CCAGAAAAAGGCT 
CTAAGAGCTGAACACACCAACC -3' and antisense primers 5'- GGTTGGTGTGTTCAG 
CTCTTAGAGCCTTTTTCTGG -3' on pAB-Gal94-hp66β by using the QuikChange site-
directed mutagenesis kit.  
 
pAB-Gal94-hp66βK33RK454R. 
This vector was made via mutagenesis PCR with the K454R mutagenesis primers on pAB-
Gal94-hp66βK33R by using the QuikChange site-directed mutagenesis kit.  
 
pEGFPC2-hp66αK30R.   
The EGFP fusions of hp66αK30R was generated by subcloning the SalI/BamHI fragment of 
pAB-Gal94-hp66αK30R followed by insertion into pEGFP-hp66α opened with SalI/BamHI. 
 
pEGFPC2-hp66αK149R.      
The EGFP fusions of hp66αK149R was constructed by excision of the SalI/BamHI fragment 
out of pAB-Gal94-hp66αK149R and insertion into pEGFP-hp66α digested with SalI/BamHI. 
 
pEGFPC2-hp66αK487R. 
The EGFP fusions of hp66αK487R was created by ligation of the SalI/BamHI fragment of 
pAB-Gal-p66αK487R into pEGFP-p66α opened with SalI/BamHI. 
 
pEGFPC2-hp66βK33R.     
The EGFP fusions of hp66βK33R was generated by insertion of the SalI/BamHI fragment of 
pAB-Gal94-hp66βK33R into pEGFP-hp66β digested with SalI/BamHI. 
 
pEGFPC2-hp66βK454R. 
The EGFP fusions of hp66βK454R was made by cutting the SalI/BamHI fragment of pAB-
Gal94-hp66βK454R followed by insertion into pEGFP-hp66β cut with SalI/BamHI.                               
 
pSG5-hp66α mutants for cloning of deletion constructs.  
pSG5-hp66αHindIIImut at position aa205 was created by using sense primer:5’-CATTCCTG 
CTGGCAAGCTTTCACTCCAGACCTCTTC-3’ and antisense primer: 5’-GAAGAGGTCTG 
GAGTGAAA GCTTGCCAGCAGGAATG-3’. pSG5-hp66αEco47IIImut at position aa475 was 
generated by using sense primer: 5’-GAGATTGAGCAGCGCTTGCTGCAGCAGGGCACG- 
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3’ and antisense primer: 5’-CGTGCCCTGCTGCAGCAAGCGCTGCTCAATCTC-3’. pSG5-
hp66αEco47IIIdel, the naturally occurring Eco47III site at position aa14 was deleted via using 
sense primer: 5’-GGAGTCAGA AACGAGCCCTTGAACGGGACCC-3’ and antisense primer: 
5’-GGGTCCCGTTCAAGGGCTC GTTTCTGACTCC-3’. 
 
pSG5-hp66β mutants for cloning of deletion constructs. 
pSG5-hp66βNotImut at position aa349 was generated via using sense primer: 5’-GCCAACTCA 
CAGGCGGCCGCCAAATTGGCTC-3’ and antisense primer: 5’-GAGCCAATTTGGCGGC 
CGCCTGTGAGTTGGC-3’. pSG5-hp66βEco47IIImut at position aa479 was created by using 
sense primer:5’-AGGAAATTGAACAGCGCTTACAGCAGCAGGCAGC-3’ and antisense 
primer: 5’-GCTGCCTGC TGCTGTAAGCGCTGTTCAATTTCCT-3’. 
 
pSG5-hp66αK149R. 
This vector was created by ligation of the SalI/BamHI fragment from pAB-Gal94-hp66αK149R 
into pSG5-hp66β digested with SalI/BamHI. 
 
pcDNA3-FLAG-hp66αmut/hp66βmut-CBP. 
This vector were generated with PCR from pBK-CMV-FLAG-hp66α/hp66ß-CBP. The PCR 
products were digested with BamHI/XbaI and ligated into pcDNA3-FLAG-hp66α.  
 
pcDNA3-FLAG-CBP. 
Control plasmid pcDNA3-FLAG-CBP was constructed with PCR from pBS1479, and cut with 
BamHI/XbaI and ligated into pcDNA3-FLAG-hp66α. 
 
pBK-CMV-FLAG. 
This vector was generated by digesting the annealed double strand oligos, (sense strand: 
CTAGAGCCACCATGGACTACAAGGACGACGATGACAAGGCTAGCGAATTCGCTCG
AGGGGATCCGAT, antisense strand: ATCGGATCCCCTCGAGCGAATTCGCTAGCCTTG 
TCATCGTCGTCCTTGTAGTCCATGGTGGCT) with SpeI/SmaI and inserted into pBK-CMV 
vector. 
 
pBK-CMV-FLAG-hp66αmut/hp66βmut-CBP. 
 
pBK-CMV-FLAG-hp66α/hp66ß-CBP was amplified by PCR from pSG5-hp66α/hp66β, 
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respectively. Products were then digested with EcoRI, EcoRI/XhoI and ligated into pBK-CMV-
FLAG-CBP, respectively.  
 
pBK-CMV-FLAG-CBP. 
CBP(calmodulin binding peptide) was amplified by PCR from pBS1479 vector (Euroscarf), cut 
with XhoI/BamHI and inserted into pBK-CMV-FLAG. 
 
pSilencer hMBD2     
This vector was generated by annealing oligos 5’-GATCCGGGTAAACCAGACTTGAATTT 
CAAGAG AATTCAAGTCTGGTTTACCCTTTTTTGGAAA-3’ and 5’-AGCTT TTCCAAA 
AAAGGGTAAAC CAGACTTGAATTCTCTTGAAATTCAAGTCTG GTTTACCCG-3’  and 
ligating the product into pSilencer 2.1-U6 neo digested with BamHI/HindIII. 
 
pN3-FLAG-SUMO1G97A 
This vector was generated via mutagenesis PCR with the sense primers 5'-CAGGAACAAA 
CGGGGGCTCATTCAACAGTTTAG-3' and antisense primers 5'- CTAAACTGTTGAATGA 
GCCCCCGTTTGTTCCTG-3' on pN3-FLAG-SUMO1 by using the QuikChange site-directed 
mutagenesis kit.  
 
pcDNA3-HA-Dominant negative Ubc9 (DN-Ubc9). 
This vector was generated via mutagenesis PCR with the sense primers 5'- CTTCGGGG 
ACAGTGTCCCTGTCCATCTTAGAG-3' and antisense primers 5'- CTCTAAGATGGACA 
GGGACACTGTCCCCGAAG -3' on pcDNA3-HA-Ubc9 by using the QuikChange site-
directed mutagenesis kit.  
 
pCMV-GST-hp66α. 
This eukaryotic expression vectors was generated by cutting the BglII/BamHI fragment of 
pEGFP-C1-hp66α and insertion into pCMV-GST cut with SalI/NotI. 
 
pCMV-GST-hp66β. 
This eukaryotic expression vectors was cloned by ligation of the BglII/BamHI fragment of 
pEGFP-C1-hp66β into pCMV-GST digested with SalI/NotI. 
 
pCMV-GST-MBD3. 
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This eukaryotic expression vectors was constructed by subcloning the BamHI/SalI fragment of 
c-Myc-MBD3 into pCMV-GST cut with BamHI/SalI. 
 
pCMV-GST-HDAC1. 
The eukaryotic expression vectors pCMV-GST-HDAC1 was cloned by cutting the BamHI/SalI 
fragments of pcDNA3-HDAC1 and insertion into pCMV-GST digested with BamHI/SalI. 
 
pCMV-GST-RbAp46. 
This vector was generated by in-frame ligation of the NcoI/BamHI fragment of RbAp46 into 
pCMV-GST opened with BamHI/XhoI. 
 
pCMV-GST-RbAp48. 
This vector was created by in-frame insertion of the NcoI/XhoI fragment of RbAp48 pCMV-
GST cut with BamHI/NotI. 
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Abbreviations 
 
% percent 
ºC centigrade 
A adenosine 
α anti 
Amp ampicillin 
APS ammonium persulfate 
ATP adenosine triphosphate 
bp base pairs 
BSA bovine serum albumin 
C cytosine 
CaCl2 calcium chloride 
CaPO4 calcium phosphate 
CBP calmodulin binding peptide 
cm centimeter 
CpG, CpGs cytosine guanine dinucleotide 
CR1, CR2 conserved region 1, 2 
CsCl caesium chloride 
CTAB cetyl trimethyl ammonium bromide  
C-terminus carboxyl-terminus 
DBD DNA Binding Domain 
ddH2O double distilled water 
dNTP deoxynucleotide triphosphate 
DMEM Dulbecco’s modified Eagle’s medium 
DMSO dimethylformamide 
DNA deoxyribonucleic acid 
DTT dithiothreitol 
E.coli Escherichia coli 
ECL enhanced chemoluminescence 
EDTA ethylenediamine tetraacetic acid 
et al. Et alli (=and others) 
FCS fetal calf serum 
Fig Figure 
g gram 
g acceleration of gravity 
G guanosine 
Gal94 N-terminal 1-94 amino acids of yeast Gal4 activator  
GFP green fluorescent protein  
EGFP enhanced green fluorescent protein  
G3PDH / GAPDH Glycerinaldehyd-3-phosphat Dehydrogenase 
GST glutathione-S-transferase  
HATs histone acetyltransferases 
HBS HEPES-buffered saline 
HDAC histondeacetylase 
HEPES n-2-Hydroxyethylpiperazine 
HRP horseradish peroxidase 
k kilo (103) 
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K lysine 
kDa kilodalton 
l liter 
LacZ β-galactosidase 
LB Medium Luria Bertani Medium 
ml milliliter (10-3 liter) 
M molar; mol/l 
mg milligram 
µl microliter (10-6 liter) 
MBD methyl CpG binding domain 
MBPs methyl CpG binding proteins 
MeCP1 methyl CpG binding protein complex 1 
MeCP2 methyl CpG binding protein 2 
Mi-2 dermatomyositis specific antigen 
mRNA messenger RNA 
MTA metastasis associated protein 
MW molecular weight 
ng nanogram (10-9 gram) 
NaCl sodium chloride 
NaAc sodium acetate 
NaOH sodium hydroxide 
NEM                                         N-ethylmaleimide  
NP-40 Nonidet P-40 
N-terminus amino-terminus 
NuRD complex nucleosome remodeling and deacetylase complex 
OD600 (OD420) optical density at 600 nm (420 nm) 
ONPG ortho-Nitrophenyl β-D-galactopyranoside 
ORF open reading frame 
pmol picomolar (10-12 molar) 
PBS phosphate buffered saline 
PAGE polyacrylamide gel electrophoresis 
PCR polymerase chain reaction 
PIAS protein inhibitor of activated STAT 
PIC protein inhibitor cocktail 
PMSF phenylmethylsulfonyl fluoride 
PVDF polyvinzlidene difluoride 
R arginine 
RbAp46/48 retinoblastoma protein (Rb) associated protein 46/48 
RLU relative light unit 
RNA ribonucleic acid 
RNase ribonuclease 
RNasin ribonuclease inhibitor 
RNAi RNA interference  
rpm revolutions per minute 
RT room temperature 
RT reverse transcription 
SDS sodium dodecyl sulfate 
SUMO small ubiquitin related modifier 
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T thymine 
TAE Tris-Acetate-EDTA buffer 
TB-Medium Terrific-Broth-Medium 
TE Tris-EDTA buffer 
TEMED n,n,n’,n’-Tetramethylethylenediamine 
Tm melting temperature 
Tris Tris-hydroxymethylaminomethane 
TSA trichostatin A 
Tween 20 polyoxyethylenesorbiten monolaurate 
U units 
UAS activating upstream sequence 
Ubc9 ubiquitin conjugating enzyme 9units 
UV ultraviolet 
V volt 
vol volume  
v /v volume pencentage 
wt wild type 
w/v weight pencentage 
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